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ABSTRACT 
The increasing demand for “greener” products in chemical and biochemical processes 
made enzymatic or chemo-enzymatic cascades a very popular approach. Combining 
different reactions in one pot without intermediate purification steps represents 
numerous advantages compared to the classic approach. In a classic organic synthesis, 
longer operation time is needed and lower yields are typically reached. In addition, the 
elimination of work up steps in between reactions significantly reduces the amount of 
waste improving the environmental impact of a given process. The use of chemo-
enzymatic cascades is particularly suitable for pharmaceutical processes where very 
specific diastereoisomers need to be synthesised. The priority is typically given to 
selectivity over high volumetric productivity. Furthermore, combination of chemical and 
enzymatic catalysts allows to access the complete set of reactions available for organic 
synthesis. However, several challenges arise as often the reaction conditions are 
incompatible and require extensive optimization. 
In this thesis, the establishment of a chemo-enzymatic cascade for the synthesis of 
enantiopure aliphatic amino or azido alcohols starting from achiral non-terminal alkenes 
is presented. Optically active amino alcohols are an important class of compounds that 
find applications mostly in pharmaceutical products, as well as agrochemicals and the 
cosmetic or food industry. The new synthetic route was assembled using either two 
enzymes and one chemical catalyst or two chemical catalysts and one enzyme to enable 
the synthesis of both opposite amino alcohol enantiomers starting from prochiral alkenes. 
This was achieved by using either an enzymatic or a chemical epoxidation in the first 
step to selectively synthesise opposite enantiomers. The second step involved an 
enzymatic epoxide ring opening to control the regioselectivity of the nucleophilic attack. 
Finally, the resulting azido alcohol was chemically reduced affording enantiopure 
(2S,3R)-2-amino-3-hydroxyhexane, (2S,3R)-2-amino-3-hydroxyheptane, (2R,3S)-2-
amino-3-hydroxyhexane and (2R,3S)-2-amino-3-hydroxyheptane. During this project, 
suitable catalysts for each step have been selected and optimal conditions for each step 
could be identified. For the combination of the different steps in a cascade, fine tuning of 
the reaction conditions was required to afford sufficient isolated yields and enantiopurity. 
Additionally, the catalytic scope of HHDHs was further expanded by in depth 
characterization of the regio- and enantioselectivity of a set of 22 HHDHs, representing 
all phylogenetic subtypes, in the epoxide ring opening of racemic, vicinally di-substituted 
trans-epoxides. 
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1. Introduction 
1.1 White biotechnology 
The use of biotechnology dates backwards to 6000 BC,[1] long before the existence of 
enzymes was even discovered. The use of yeast in fermentations to make bread, wine 
and cheese or to brew beer can be considered a biotechnological method. The name 
‘enzyme’ is derived from ancient Greek and means “in-yeast” (en= in, zyme= leaven).[2] 
To this day, food and beverages technology represents a major portion of the total 
industrial enzyme market.[3] Enzyme’s global market value is set to grow about 7% per 
year to reach a value of approximatively $ 6.2 billion (market value per year) in 2020.[1]  
Currently, the application of enzymes in other industrial processes is limited compared 
to the many application of classic chemical reactions (Figure 1). So far, most of the 
enzymes that meet industrial criteria belong to the class of hydrolases (e.g. amylases, 
proteases, cellulases and lipases), although processes involving other enzyme classes 
can be found.[4] One reason for this may be that enzymes evolved in cellular environment 
where substrate concentrations are far from the typical industrial requirements. 
Therefore, not many native enzymes could outperform the available chemical catalysts. 
In the last couple of decades, with the development of sophisticated technologies for 
DNA manipulation more examples of industrial applications of enzymes are emerging. 
These technologies made possible to engineer proteins to match certain process 
specifications. Bornscheuer el at. described the development of enzymatic catalysts as 
waves.[5] The first wave was characterised by the use of homogenized animal tissues or 
plant extract known to perform a certain reaction. At this point, the responsible enzymes 
able to catalyse the reaction were unknown. Around the 1980s, the newly discovered 
molecular technologies allowed the isolation and recombinant production of enzymes of 
interest, it was the beginning of the second wave. A decade later, the establishment of 
advanced DNA manipulation techniques to introduce mutations and improve enzymes 
for a specific function dictated the beginning of the third wave.[5] This strategy allowed a 
more efficient improvement of enzymes and is now commonly addressed as “directed 
evolution”.[6,7] 
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Figure 1. Fields where enzymes are applied. 
 
Recently, the importance of the third wave was recognized with the Nobel Prize in 
Chemistry won by Frances Arnold, George Smith and Sir Gregory Paul Winter for their 
work on directed evolution of enzymes and for phage display of peptides and antibodies, 
respectively. According to Bornscheuer, we are currently on the edge of the fourth 
wave.[6] This new period will be characterized by the exponential development of 
computer technology. It is already evident that the progress made on algorithms for 
machine learning and big data analysis is huge. Therefore, in the close future it is likely 
that sequence-function relations, the tertiary structure of proteins and even correct 
mutations to improve a certain characteristic could be predicted with extremely high 
accuracy. Additionally, stringent laws on environment preservation may be indirectly 
responsible for the recent boost in the development of enzyme-based processes. 
Enzymes generally work at milder reaction conditions using renewable materials 
(preferably) and often they allow the elimination of toxic components. All these 
characteristics make enzymes very suitable candidates for the Green Chemistry 
guidelines. However, normally intense enzyme and process engineering are required to 
develop an enzyme-catalysed industrial process. 
1.1.1 Biocatalysis 
Biocatalysis is generally defined as the use of free enzymes or whole cells in catalytic 
conversions. This kind of reactions can be further classified in two types: the first and 
oldest known type involves the use of growing cells and a carbon source. The carbon 
source is needed to ensure cellular growth as, in this case, the cellular metabolism is 
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exploited to produce proteins, primary or secondary metabolites or to convert a certain 
substrate. This type is also commonly referred to as fermentation. The second type 
involves the use of isolated enzymes, cell-free extract or resting cells for the conversion 
of desired substrates. In this case, catalyst production and substrate conversion are 
carried out in different stages. Fermentation was a known process for many centuries as 
mentioned previously, however, biocatalysis was not taken seriously until the 1980s 
where DNA technology developed exponentially. Additionally, stricter legislation for 
commercial drugs has indirectly influenced the development of biocatalysis. These laws 
required to test the activity of isomers of chiral drugs separately forcing chemists to look 
for alternative catalysts for asymmetric synthesis (e.g. enzymes). Thus, the use of 
enzymes in catalysis started to be more popular and the publication of Zaks and Klibanov 
in 1984 can be considered the first milestone.[8] They demonstrated that some enzymes, 
lipases in their case, could work well in organic solvents and at elevated temperatures. 
This represented a groundbreaking discovery as it was widely accepted that enzymes 
could only work in water. Hence, organic chemists suddenly had a whole range of new 
catalysts in their hands as an alternative to classic chemical catalysts. As mentioned 
earlier, directed evolution contributed heavily to the adoption of enzymes in industrial 
processes. Before this technology, it was necessary to adjust the conditions of a given 
process to the required optimal conditions of a given biocatalyst. With the advent of DNA 
manipulation techniques and high throughput screening, it was possible to do the exact 
opposite. Nowadays, industrial enzymes are almost entirely evolved in vitro and further 
formulated to fit the requirements of the process. This significantly lowers the investment 
for their integration in pre-existing technologies as enzymatic reactions can be run in 
multipurpose batch reactors. Currently, enzymes are mostly applied in the production of 
fine chemicals and pharmaceuticals where normally high productivities can be sacrificed 
as, in contrast to bulk chemicals production, the market of fine chemicals favours high 
regio- and/or enantioselectivity. These are both fundamental characteristics when 
designing a new drug.[9,10] According to Turner, the use of biocatalytic reactions will 
continue its growth giving the increasing number of available enzyme catalysts.[11] Turner 
used biocatalytic steps in many novel synthetic pathways for the production of interesting 
and complex molecules.[11,12]  
1.2 Enzymatic and chemo-enzymatic cascade reactions 
One of the advantages of enzymes is that they generally work under similar conditions 
as the result of millions of years of evolution under similar selective pressure. After all, in 
the cytosol of any living organism, thousands of enzymes work in combination with each 
other forming the whole metabolism of a given cell. Thus, the integration or combination 
of different enzymatic reactions requires limited tweaking of reaction conditions. This 
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enables the construction of synthetically interesting pathways for the production of 
chemicals of high molecular complexity.[13] Furthermore, the combination of different 
reactions in one step represents numerous advantages compared to the classic 
approach as it typically shortens the operation time, reduces the waste and improves the 
overall yields (Figure 2).[14] Indirectly, it enables better handling of harmful or unstable 
intermediates produced in certain chemical processes, as they are directly converted by 
the next catalyst of the cascade.[15]  
 
 
Figure 2. Schematic representation of the advantages of cascades over the classic syntheses. In the 
cascade approach, all steps are carried out without intermediate purification steps. 
 
In the last years, the use of cascade reactions has become very popular and different 
classifications can be found. Four main designs can be defined depending on how the 
steps are running during the reaction course.[15] I) The most intuitive case is represented 
by the production of a single compound through multiple catalytic steps starting from a 
single substrate (Figure 3, A). II) The second type is widely applied and typically 
characterises enzymes that require a cofactor for their function. This cascade is defined 
as orthogonal as the main reaction is coupled with a secondary reaction to regenerate 
the cofactor (Figure 3, C). III) The third kind of cascade reaction is very similar to the 
second type, where two enzymes convert distinct substrates to produce different 
products. In this case, the reactions are also linked by opposite cofactor usage although 
both products are going to be isolated as they are of high value, whereas in the type II 
cascade, the co-substrate and co-product are discarded (Figure 3, B). IV) Finally, the 
fourth type, generally used for deracemization, can be considered a cyclic cascade 
where the enzyme only converts one of the enantiomers to an intermediate that is 
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converted back to the original mixture until only the non-reactive substrate enantiomer 
remains[15] (Figure 3, D).  
 
 
Figure 3. Four main types of cascade reactions (adapted from Ricca et al.[15]). 
 
The different cascade designs can be combined to form new kinds and therefore the 
classification is not absolute. Moreover, cascades do not need to be strictly enzymatic 
or chemical. Instead, the synthetic chemist can pick from either enzymatic or chemical 
catalysts to assemble new synthetic routes. These two types of catalysts, in fact, were 
never exclusive but complementary to each other. The first example of a chemo-
enzymatic cascade can be dated back to 1980 when a glucose isomerase was combined 
with platinum on carbon. The use of glucose isomerase was the key to achieve a fast 
interconversion of glucose to fructose while limiting the formation of the side product D-
glucitol. As a result, the combination of these two catalysts could improve the D-mannitol 
yield from 25% to 46% (Scheme 1).[16]  
6 
 
 
Scheme 1. General scheme of the first chemo-enzymatic cascade where a glucose isomerase and 
platinum on carbon were combined to improve efficiency over a purely chemical process (Adapted from 
Makkee et al. [16]). 
 
A decade later, cascade strategies gained more attention as they allowed overcoming 
the theoretical maximum yield of 50% in classic kinetic resolutions of racemates. This 
was achieved by combining a lipase with a palladium-catalysed racemisation resulting in 
a so-called dynamic kinetic resolution.[17,18] Lipase and palladium could perform the 
corresponding reactions simultaneously as no compatibility issues were observed.  
In a more recent chemo-enzymatic cascade a palladium-catalysed Suzuki-cross 
coupling was combined with an alcohol dehydrogenase-catalysed reduction (Scheme 2). 
This time, the reactants of the first step were incompatible with the enzyme used in the 
second step.[19] The strategy used to solve observed compatibility issues was to run the 
steps sequentially, the so-called one pot two steps strategy. In the first step, a palladium 
complex is used to catalyse the Suzuki-cross coupling reaction and, once all the reagents 
are consumed, the (S)-selective alcohol dehydrogenase from Rhodococcus sp. is added 
to perform the dehydrogenation together with isopropanol for cofactor regeneration 
(Scheme 2).[19] 
 
 
Scheme 2. Concept of the chemo-enzymatic cascade to combine Suzuki-cross coupling reaction with a 
biocatalytic reduction (adapted from Burda et al. [19]). 
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While enzymes typically work well together, the combination of chemical and enzymatic 
catalysts is not trivial. Often compatibility is achieved via extensive adjustment of reaction 
conditions as well as careful selection of reagents to suit all catalysts. One popular way 
to overcome incompatibility is compartmentalization to physically separate the catalysts 
and possibly the reaction conditions.[14] Despite the predictable difficulties, the design 
and set up of chemo-enzymatic cascades is becoming a popular approach to tackle the 
synthetic challenges that arise when a complex molecule needs to be synthesised.  
 
1.3 Chiral azido and amino alcohols 
The chemistry of compounds containing an azido group has caught the attention of 
organic chemists already in the previous century and they are still important building 
blocks for the synthesis of amino alcohols. Furthermore, they are key intermediates in 
the synthesis of carbohydrates and nucleosides.[20,21] Azido alcohols are generally 
synthesised by azidolysis of epoxides in aqueous alcohol systems. This type of reaction, 
however, requires high temperatures and long reaction times and no chemo- or 
stereoselectivity is observed.[21] Few chemical catalysts were designed to catalyse an 
enantioselective epoxide ring opening, however, their molecular complexity and price 
are major limitations.[22,23] In contrast, halohydrin dehalogenases (HHDHs)[24] and 
epoxide hydrolases[25] can perform regio- and enantioselective epoxide ring opening 
reactions and especially HHDHs can use sodium azide to produce azido alcohols in a 
selective way (Section 1.5).[26,27] 
Amino alcohols are very important building blocks as well and they can be found in a 
number of natural compounds and drugs.[28] They are often used as chiral intermediates 
or chiral auxiliaries in organic synthesis. Furthermore, the simple manipulation of the 
hydroxyl- or amino-group can lead to a variety of other compounds.[29]  
The synthesis of chiral amino alcohols starting from chiral amino acids is a common and 
simple synthetic route as only the reduction of the carboxylic group is required. Whereas 
a less common synthetic strategy is the intensive manipulation of carbohydrates that 
leads to amino alcohols.[30]  
Most examples for the synthesis of chiral amino alcohol deal with terminal amino alcohols 
for which only one stereocenter needs to be controlled. In one example (Cascade A, 
Scheme 3), the cascade was composed by a styrene monooxygenase in the first step 
for the enantioselective epoxidation. The configuration of the hydroxyl group of 
phenylethanolamine and derivatives is controlled in the first reaction and the remaining 
steps are required to insert the terminal amino group. In particular, the styrene oxide is 
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hydrolysed by an epoxide hydrolase, consequently the terminal hydroxyl group is 
oxidised by an alcohol dehydrogenase. Finally, the amino group is inserted using a 
transaminase.[31] The approach is very interesting; however, reducing the steps could 
result in a more attractive process from an economic point of view as three steps out of 
four are used to insert the amino group.  
Alternatively, phenylethanolamine could be synthesised starting from 2-chloro-1-
phenylethanol (Cascade B, Scheme 3) reducing the number of steps to three compared 
to cascade A.[32] In this case, the halogen is removed via azidolysis and the stereocenter 
is controlled by reducing the keto-group in the second step using a selective ADH. Lastly, 
the azide is reduce to amino group and, as for cascade A, a terminal amino alcohol is 
produced. If a non-terminal halo ketone would be used, the configuration of the 
stereocenter where the amino group is attached would be predetermined by the chirality 
of the carbon-halide bond. Cascade C shows an example of the synthesis of a non-
terminal amino alcohol starting from hydroxypyruvate and glycolaldehyde. Here both 
stereocenters are controlled during the reaction. In the first step, the transketolase 
controls the configuration of the carbon atom to which the hydroxyl group is attached and 
subsequently, a transaminase generates the second chiral centre.[33] Due to their natural 
function, transketolases can only be used for the synthesis of carbohydrate-like 
compounds, hence unfunctionalised compounds such as aliphatic alkenes would not be 
converted.[33,34] 
 
Scheme 3. Different cascade examples for the biocatalytic synthesis of chiral amino alcohols (adapted from 
Wu et al. (A),[31] Schrittwieser et al. (B),[32] and Ingram et al. (C)[33]). 
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1.4 Asymmetric epoxidations 
1.4.1 Chemical catalysts 
Several chemical catalysts have been developed to catalyse asymmetric epoxidations 
and the most notable example is certainly the Sharpless epoxidation. Sharpless, for the 
first time, could produce a chemical catalyst for the epoxidation of allylic alcohols that 
could reach up to 90% enantiomeric excess (Scheme 4).[35] His strategy was to use a 
chiral environment around the actual catalytic moiety, the transition metal (Mo, Ti or V). 
This discovery highlighted the importance of surrounding the catalytic metal with a chiral 
ligand to improve the enantioselectivity of the reaction. However, the first generation 
ligand was not optimized and had a low turnover number. Additionally, it was very 
specific for allylic alcohols while not performing well with homoallylic alcohols.[36,37] 
Several optimizations have been performed to improve the stability and 
enantioselectivity of the catalyst by changing the ligand, the transition metal and the 
oxygen donor. Nonetheless, the Sharpless epoxidation is very specific for allylic alcohols 
as the substrate’s hydroxyl group is used as a pivot point.[38,39] 
 
Scheme 4. General scheme of the first Sharpless epoxidation example (adapted from Katsuki and 
Sharpless[35]). 
 
Salen complexes represent a different class of catalysts for the asymmetric synthesis of 
epoxides. In this case, Jacobsen and Katsuki paved the ground for what is now known 
as Jacobsen-Katsuki epoxidation.[40] The enantioselectivity in this reaction is controlled 
via a chiral environment as well but the epoxidation requires only simple oxidation agents 
such as PhIO, NaClO, H2O2 or Oxone® compared to titanium tetraisopropoxide required 
in the Sharpless epoxidation.[41] The synthesis of the chiral salen ligand is performed by 
condensation of diamines with salicylaldehyde derivatives allowing a substrate specific 
tuning of the substituents.[42] Originally, the salen complex was used to coordinate 
manganese (III) (Scheme 5), but in the later development chromium, cobalt, palladium, 
nickel and ruthenium were also applied.[38,43] The major limitation of this class of catalysts 
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is the fact that they show high selectivity mostly towards cis-di-substituted olefins[44], 
however, examples for epoxidation of tri- and tetrasubstituted olefins (eg. 1,1-
diphenylpropene) are also reported to show good performances, whereas selectivity 
towards trans-olefins was found to be low.[45,46]  
 
Scheme 5. General scheme of the first example for epoxidation of unfunctionalised olefins catalysed by 
(salen)manganese complexes (adapted from Jacobsen et al.[40]). 
 
An additional method for asymmetric epoxidation is the use of dioxiranes. These moieties 
can be directly added to the reaction mixture, however, the most common method is the 
in situ synthesis using KHSO5 (Oxone) and ketones. The first example was reported in 
1984 where the epoxidation of (E)-β-methylstyrene and 1-methylcyclohexene was 
carried out with modest enantioselectivity (16-35% ee).[47] The most important example 
of the use of dioxiranes in asymmetric epoxidations, however, is the Shi epoxidation 
firstly reported in 1996.[48] In this case, the dioxirane is generated from a fructose-derived 
ketone which allows the reaction to proceed at mild conditions reaching extremely high 
enantioselectivity (Scheme 6). Moreover, the chiral centres in this catalyst are closer to 
the active ketone moiety ensuring a better stereoselectivity compared to other scaffolds 
holding keto groups. Additionally, the carbohydrate-derived scaffold is a rigid structure 
which is preferable to enhance enantioselectivity.[38] This fructose-derived ketone (Shi 
diketal epoxidation catalyst) shows optimal performances with trans-unfunctionalised 
olefins and poor selectivity with cis-olefins, in contrast to the Jacobsen catalysts 
((salen)manganese complexes).[48,49] The major disadvantage of this catalyst is that it 
can undergo auto-Baeyer-Villiger oxidation producing acetone. The dioxirane can then 
be generated from the keto-group of acetone to carry out the same oxidation cycle but 
with no stereoselectivity (A, Scheme 6). This was partially solved by running the reaction 
at low temperatures and pH above 11 to prevent catalyst decomposition. Later, an 
acetate analogue of the original catalyst was synthesized. The acetate, with its higher 
electron withdrawing effect, could reduce the auto-oxidation making the catalyst more 
stable (B, Scheme 6).[50]  
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Scheme 6. A) General scheme of the epoxidation using the Shi epoxidation diketal catalyst and 
degradation pathway. (adapted from Shi et al[48]). B) Acetate analogue of the Shi epoxidation diketal 
catalyst.   
 
1.4.2 Enzyme Catalysts for chiral epoxidations 
Despite the available chemical catalysts for asymmetric epoxidation mentioned before, 
controlling stereo- and regio-selectivity in some alkenes is still challenging and in most 
cases, toxic metals and reagents need to be used.[51] Nature has evolved a few oxidative 
enzymes to perform asymmetric epoxidations on olefins using molecular oxygen. The 
most popular are monooxygenases, oxidases and peroxygenases.[52–54] Among these, 
cytochrome P450 monooxygenases (CYP450) carry a heme-iron prosthetic group for 
oxygen activation (Scheme 7).[55,56] Cytochrome P450s became very popular for their 
ability to hydroxylate non-activated carbon atoms with extremely high regio- and 
stereospecificity.[57] Being the main xenobiotic metabolizing enzymes in the human body, 
CYP450 research is often associated with studies on their interactions with drugs and 
other xenobiotics in vitro.[58,59] Lately, the advances of protein engineering and process 
engineering enabled also the application of these enzymes in the production of fine 
chemicals, fragrances and in bioremediation.[57] One of the oldest industrial examples is 
the regio- and stereoselective hydroxylation of Reichstein S at 11β-position to 
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hydrocortisone using a CYP450 from Curvularia sp., which reached a production of 
approximatively 100 tons per year.[60]  
Peroxygenases are similar to cytochromes P450s as they share the same prosthetic 
group and they can catalyse a similar range of reactions. On the other hand, they take 
advantage of the hydrogen peroxide shunt (Scheme 7) making them independent from 
the electron transfer systems that characterise cytochromes P450s.[54,61] Through the 
peroxide shunt pathway, the catalytic cycle of the Iron in the heme is shortened as 
compound I if formed using oxidants (e.g. hydrogen peroxide) instead of O2 reducing the 
number of steps in the catalytic cycle. For approximatively 20 years, the 
chloroperoxidase from Caldariomyces fumago (CPO) was the only representative of this 
group of enzymes. Only recently, more peroxygenases applications have emerged due 
to their highly interesting chemistry.[62] The aromatic peroxygenase from Agrocybe 
aegerita (AaeAPO) is currently the more investigated and is at least twofold more active 
than CPO, furthermore it displays a broader substrate scope. Hence, it was classified as 
unspecific peroxygenases.[62] The major challenge in using peroxygenases in 
biocatalysis is the efficient hydrogen peroxide supply. On the one hand, hydrogen 
peroxide is essential for enzyme activity, on the other hand, high concentrations of this 
molecule cause irreversible degradation of the heme prosthetic group.[61,63] In the close 
future, it is possible that this class of enzymes could replace cytochrome P450s as they 
retain the same interesting chemistry but they use a simplified catalytic cycle.[64]  
 
Scheme 7. Catalytic cycle of cytochromes P450 monooxygenases. The two electrons coming from 
NAD(P)H are transferred separately to the iron ion by the electron transport chain (adapted from Hollmann 
at al.[54]). 
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Flavin-dependent monooxygenases are another interesting group of enzymes that can 
perform epoxidations. These enzymes contain a flavin-cofactor to activate molecular 
oxygen and perform oxidations. In this reaction mechanism, the oxygen is activated 
before the substrate binds forming the reactive peroxyflavin.[65] Once it reaches the active 
site, the substrate is oxidised, typically with high regio- and stereoselectivity.[66] Next to 
epoxidations, they can catalyse hydroxylations, Baeyer-Villiger oxidations and 
sulfoxidations depending on the shape of the active site and exposed amino acid side 
chains.[65] 
 
Scheme 8. Catalytic cycle of flavin-dependent monooxygenases. flavinRED and flavinOX represent the 
reduced or oxidised state of the flavin-cofactor, respectively (adapted from Fraaije et al.[56,65]). 
 
Among flavin-dependent monooxygenases, Baeyer Villiger monooxygenases 
(BVMOs),[67] and styrene monooxygenases[68,69] are probably the most known together 
with flavin monooxygenases (FMOs). FMOs are a sub-class of flavin-dependent 
monooxygenases that carry a covalently bound cofactor.[70] BVMOs are probably the 
most familiar in organic chemistry as few multi-kg scale applications are already available 
(generally using whole cells).[71,72] The best known BVMO is cyclohexanone 
monooxygenase (CHMO) from Acinetobacter calcoaceticus which proved to have a wide 
substrate scope and high regio- and stereoselectivity.[71,73] 
Styrene monooxygenases are getting increasing attention for their extremely high 
stereoselectivity in the epoxidation on unactivated C=C bonds. More specifically, the 
substrate scope is generally limited to vinyl aromatic compounds with few 
exceptions.[68,74] The styrene monooxygenase from Pseudomonas sp. VLB 120 is 
14 
 
probably the most characterised.[75–78] This enzyme could produce up to 388 g of styrene 
oxide in a biphasic system.[76] Interestingly, all known enzymes produce preferentially 
the (S)- or (S,S)-epoxide enantiomer despite several styrene monooxygenases from 
different sources have been characterized.[74,79–81] This, very likely, represents a 
temporary limitation and screening of more natural sources and/or engineering of 
existing enzymes should allow improvements of the substrate scope of these enzymes.  
Generally, styrene monooxygenases are composed of two subunits: the flavin-
dependent catalytic subunit (StyA) and the flavin oxidoreductase (StyB) (Scheme 9), but 
there are examples of self-sufficient styrene monooxygenases with the two subunits 
fused together.[82] A recently characterised styrene monooxygenase from Rhodococcus 
sp. ST-10 was found to be able to convert short-chain aliphatic alkenes with good 
performance.[83] Toda et al. have shown that StyB from Rhodococcus sp. ST-10 is strictly 
dependent on NADH and no activity could be measured with NADPH, whereas it could 
accept both FAD and FMN. On the other hand, StyA from Rhodococcus sp. ST-10 
exclusively accepted FAD for catalytic activity. Unfortunately, this enzyme displays 
substrate and product inhibition exhibiting the highest activity at only 2.5 mM styrene 
concentrations and when < 5 mM styrene oxide is present.[83] The inhibitory effect of 
substrate and product could be reduced by using a two-phase system with a second 
organic phase as found by Panke et al. using the styrene monooxygenase from 
Pseudomonas sp. VLB 120.[84] A second organic phase acts as substrate and product 
sink decreasing the toxicity for the biocatalyst. 
 
Scheme 9. General reaction scheme for alkene epoxidation catalysed by styrene monooxygenases with 
optional cofactor regeneration system (adapted from Toda et al.[85]).  
 
1.4.3 Cofactor regeneration strategies 
Generally, enzymes that can activate molecular oxygen (e.g. monooxygenases) must 
rely on the availability of NAD(P)H to provide electrons needed for the catalytic 
mechanism; with the exception of peroxygenases that directly use hydrogen peroxide for 
substrate oxidation.  
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Adding NAD(P)H in stoichiometric amounts would result in an extremely expensive 
process, hence a few methods for in situ cofactor regeneration were set up. This allows 
using NAD(P)H in catalytical quantities.[53] 
There are two main strategies to regenerate cofactors: the first one relies on the 
expression host’s metabolism. This way, the cells provide NAD(P)H upon degradation of 
a cheap carbon such as glucose. A second strategy is to supply a cofactor regenerating 
enzyme that uses a sacrificial inexpensive cosubstrate that is oxidised to regenerate 
NAD(P)H (commonly used enzymes are listed in Table 1). 
Using the host cell’s metabolism is an easy method for in situ cofactor regeneration, as 
no coexpression of additional enzymes is required. However in some cases, the 
substrate or product can be toxic for the cells resulting in inefficient NAD(P)H supply. 
Here, using a cofactor regeneration enzyme would make the reaction independent from 
cellular metabolism. Furthermore, by not relying on cell’s metabolism, the enzyme 
catalysts can be applied as cell-free extract improving the reaction rate as some 
substrates cannot diffuse easily through the cellular membrane.  
Table 1. Common cofactor regeneration enzymes that are used in biocatalysis in combination with 
monooxygenases (adapted from Holtmann et al.[54]). 
Enzyme Cosubstrate Coproduct Cofactor Example 
FDH Formate CO2 NADH Churakova et al.[86] 
ADH Isopropanol Acetone NAD(P)H Schulz et al.[87] 
PDH Phosphite Phosphate NAD(P)H Watanabe et al.[88] 
G6PDH Glucose-6-phosphate 
Glucono-6-phosphate 
lactone 
NAD(P)H 
Rioz‐Martínez et 
al.[89] 
 
An additional strategy developed to tackle the high costs of the cofactors NADH and 
NADPH is to chemically synthesise and use cheaper analogues instead. In these 
cofactor mimics, the adenosine dinucleotide is exchanged with a shorter synthetic 
substituent. They are known since 1936,[90]  however, only recently they received more 
attention for applications in biocatalytic reactions. Their redox potential can be tuned to 
spontaneously reduce FAD[91] and being cheap, they can be used in stoichiometric 
amounts.[92] In one recent example by Paul et al., 1-benzyl-1,4-dihydronicotinamide 
(BNAH) was used as NAD(P)H mimic in the epoxidation of styrene catalysed by the 
styrene monooxygenase from Rhodococcus opacus 1CP. In this specific case, two 
enzymes (regeneration system and StyB, Scheme 9) could be omitted due to the use of 
BNAH to reduce the flavin needed by the catalytic subunit (StyA, Scheme 10).[91,92] 
Despite the clear advantages, real applications of cofactor mimics in biocatalysis are still 
scarce.  
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Scheme 10. In situ regeneration of FADH2 using the cofactor mimic BNAH. Used in stoichiometric amounts, 
BNAH substitutes for StyB and cofactor regeneration system in the epoxidation catalysed by the styrene 
monooxygenase (see Scheme 9, adapted from Paul et al.[91]).  
 
1.5 Epoxide ring opening 
Epoxide ring opening is a common reaction that has been used in organic synthesis for 
many years. However, the chemical reactivity of the epoxide ring is rather low and 
depends on the surrounding if more or less tension on the ring is present.[93,94] The 
chemical ring opening usually does not proceed with regio- or stereoselectivity and, if 
any, the selectivity is substrate-controlled. Satisfying regioselectivity was only reported 
for terminal or aromatic epoxides, whereas the ring opening of linear epoxides carrying 
similar substituents on both sides of the ring proceeds with poor selectivity.[95] Currently, 
most of the chemical catalysts that would allow regio- or enantioselective ring opening 
require a very challenging synthesis and showed high performances only with terminal 
or meso-epoxides.[22,96] 
On the other hand, a group of enzymes called halohydrin dehalogenases (HHDH, EC 
4.5.1.-) can catalyse the epoxide ring opening under mild conditions and with chemo-, 
regio- and enantioselectivity depending on the substrate. The natural function of HHDHs 
is actually the reversible dehalogenation of vicinal haloalcohols forming the 
corresponding epoxide.[26,97–99] The dehalogenation, a reversible reaction, can be 
exploited by providing different nucleophiles such as cyanide, azide, nitrite, cyanate, 
thiocyanate or formate to catalyse the irreversible epoxide ring opening (Scheme 
11).[24,100,101] 
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Scheme 11. Reaction scheme of reversible dehalogenation and irreversible epoxide ring opening catalysed 
by halohydrin dehalogenases.  
 
These enzymes are both structurally and mechanistically related to the short-chain 
dehydrogenase/reductase (SDR) superfamily. HHDHs assume a tertiary structure that 
resembles a Rossman fold and they show a quaternary structure of four subunits 
(homotetramer), these structural features are also typical of SDR-like enzymes. 
Furthermore, the Ser-Tyr-Arg catalytic triad in HHDHs has a similar function as for the 
Ser-Tyr-Lys catalytic triad in most SDR enzymes. The main difference is that HHDHs 
evolved a halide/nucleophile binding site instead of the nicotinamide cofactor binding site 
found in SDR enzymes.  
Recently, the number of available HHDH sequences was extended through database 
mining to 65.[102,103] These new HHDH sequences were identified in public databases, 
using a novel approach, by filtering out all SDR-like sequences that did not present the 
HHDHs catalytic triad motif (S-X12-Y-X3-R) and the nucleophile binding pocket motif (T-
X4-F/Y-X-G).[102] Noteworthy, the phylogenetic analysis of the newly discovered 
sequences revealed that most of them could not be classified in the existing phylogenetic 
groups (A, B and C) and four new subtypes were added (D to G).[102] A subset of 17 from 
each subtype were then isolated and extensively characterized to prove that they were 
true halohydrin dehalogenases.[104,105]  
The active site assumes a tunnel-like shape on most HHDHs and the shape is enzyme 
dependent and residues composing the tunnel are known to influence activity and 
selectivity, as demonstrated in HheC.[106–109] HheG, in contrast, shows an open cleft that 
possibly confers it the broad substrate scope.[105] In the dehalogenation reaction, the 
catalytic triad function is to abstract the proton of the hydroxyl group present in the 
substrate. In SDR enzymes, the negative charge left on the hydroxyl oxygen is 
transferred to the NAD(P)+ cofactor; in HHDHs the oxyanion, stabilised by the serine, 
performs a nucleophilic attack on the carbon where the halogen is present. As a 
consequence, the halogen is displaced leading to the epoxide formation (Scheme 
12).[110] Conversely, in the epoxide ring opening reaction, the halide (or one of the 
accepted nucleophiles) performs a nucleophilic attack on one of the carbons of the 
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epoxide ring leading to cleavage of the carbon-oxygen bond. The tyrosine donates a 
proton to the oxyanion leading to the formation of the halo-alcohol or other β-substituted 
alcohols (depending on the nucleophile).  
 
 
Scheme 12. General dehalogenation and epoxide ring opening reaction catalysed by the HHDHs. (Residue 
numbering according to HheC, adapted from Schallmey et al.[103]) 
 
Cyanide is possibly the most interesting nucleophile accepted by HHDHs as it allows the 
formation of a novel C-C bond, which is generally challenging in classic organic 
chemistry. The cyano-group can further be manipulated to access amino, amide, or 
carboxyl groups.[111,112] Azidolysis also represents an important reaction catalysed by 
halohydrin dehalogenases as it yields azido- and amino-alcohols (after a simple 
reduction of the azido group) that are important building blocks as described in section 
1.3. In a process developed by Codexis Inc. (Redwood City, CA, USA)[113] a highly 
engineered HheC mutant was applied in the synthesis of the statin precursor. In this 
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process, a HheC mutant performs in two steps the dehalogenation of ethyl (S)-4-chloro-
3-hydroxybutyrate to the intermedia epoxide and consequently, the epoxide ring opening 
using cyanide as nucleophile producing (R)-4-cyano-3-hydroxybutyrate.[114,115] 
Atorvastatin, also known as Lipitor, is a cholesterol-lowering drug which was the top-
selling prescription medication until 2010 with more than $7 billion worth in total 
revenue.[116]  
 
1.6 Hydrogenations 
The ability of certain transition metals to react with molecular hydrogen has been known 
for roughly a century. The presence of these catalysts proved to be essential to promote 
hydrogenation of certain substrates at high temperature.[117] The reactivity of the metals 
can be tuned by different additives or supports and in the years, several catalysts were 
produced to fit the kind of compounds to be hydrogenated.[118] These metals can be used 
as salts, that can dissolve in solution (homogeneous catalysts). However, 
heterogeneous catalysts offer more advantages especially when it comes to applicability. 
They are called ‘heterogeneous’ as the metal ions are immobilised on organic or 
inorganic (or a combination of both) supports and they do not dissolve in solution. The 
main advantage here is the fact that the supports bring the size of the catalyst to a 
macromolecular level enabling easy separation by filtration during work up.[118]    
The first industrial process, established in 1897, was based on a Nickel catalyst and 
since then a number of metals (Table 2) were applied on supports, as complex oxide 
systems or as Raney metal catalysts.[119]  
 
Table 2. Common hydrogenation reactions and the respective metal catalysts used (adapted from 
Navalikhina et al.[119]). 
Reaction Catalyst 
Hydrogenation of alkenes supported Ni, Cu, Pt, Pd, Ru, and Rh 
Hydrogenation of alkynes supported Ni, Pd, Ni-Pd, Co-Pd, and Cu-Pd 
Hydrogenation of aromatic 
hydrocarbons 
supported Ni, Pd, Rh, Pt, Co-Mo, Raney Ni 
Hydrorefining of motor 
fuels 
Ni, Ni-Mo, and Co-Mo on Al2O3 and diatomaceous earth 
Hydrogenation of carbonyl 
compounds 
skeletal and supported Ni and Co, compounds supported Pd, Rh, and Pt, 
and Cu-Cr-O, Cu on diatomaceous earth 
Hydrotreating 
(Hydrodesulfurisation) 
Ni-Mo, Ni-W, Co-Mo, Co-W, and Ru on Al2O3 and carbon, Mo and W 
carbides 
Hydrogenation of nitriles, 
azides 
supported Ni, Pd, and Pt 
Hydrogenation of 
(methanation) 
supported Ni, Cu, Co, Fe, Pt,  and Rh, Pt mesh, Mo and W carbides 
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Nowadays, heterogeneous palladium is one of the most used catalysts to perform 
hydrogenation of most reducible functionalities due to its high activity and easy 
handling.[120] Heterogeneous palladium on carbon (Pd/C) is possibly the most used 
hydrogenation catalyst and due to its high reactivity, shows low chemoselectivity. The 
reactivity and consequently chemoselectivity can be adjusted in two ways: by catalysts 
poisons (e.g. sulphur) or additives (e.g. lead acetate) that can tune the reactivity. The 
second way to improve chemoselectivity is by selecting the characteristic of the support 
(e.g. surface area or pore size).[120] Typically, palladium catalysed hydrogenations are 
performed in ethanol or methanol in an autoclave reactor under pressurised H2. Pd/C, 
thanks to its high reactivity, can be used in aqueous buffer as well with little to no activity 
loss. Recently, Schrittwieser et al. used lignin stabilised palladium nanoparticles to 
efficiently reduce 2-azido-1-aryl alcohols to 2-amino-1-aryl alcohols in phosphate buffer 
pH 9 under pressurised H2 (Scheme 13).[32] The reduction of azide to amine occurred in 
four hours reaching full conversion in this case the chirality of the molecules was 
determined by the alcohol dehydrogenase (ADH) catalysed reduction as the terminal 
carbon is not chiral (Scheme 13). In any case, the reduction of azides to amine does not 
involve chiral centres, hence the chirality should be already present in the substrate (e.g. 
synthesised via azidolysis of an enantiopure epoxide[121]).  
  
 
Scheme 13. Chemo-enzymatic cascade for the synthesis of enantiopure 1,2-amino alcohols using 
palladium catalysed azide hydrogenation (adapted from Schrittwieser et al.[32]). 
 
As mentioned previously, Pd/C is one of the most used hydrogenation catalysts, however 
when combined with enzymes few challenges can arise. It is known that carbon 
nanoparticles and nanotubes can interact with the hydrophobic patches of proteins 
causing destabilization of the protein’s tertiary structure. This results in the formation of 
a “corona” of unfolded peptides around the nanoparticles;[122] and, in the case of a Pd/C 
catalysed azide hydrogenation, the “corona” would act as a barrier between the substrate 
and the nanoparticles. Changing the support to one more “protein-friendly” is the more 
straightforward solution (e.g. lignin stabilised palladium nanoparticles[32]). An interesting 
strategy is to exploit the ability of ferritin to encapsulate the desired metal. Naturally, 
ferritin is used by organisms to safely store iron and use it when the intracellular iron 
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concentration is too low.[123] Thus, incubating ferritin in its apo-form with clusters of 
different metals including Pd would lead to the encapsulation of the metals inside the 
ferritin cage. Furthermore, Pd, for example, can be reduced to form nanoparticles of 
extremely uniform size inside the ferritin cage that act as a micro-reactor. This complex 
can then be used to perform hydrogenations without interfering with other protein or 
enzymes present in the reaction solution, as the nanoparticles are isolated by the ferritin 
cage; but at the same time, the substrate can freely diffuse inside the cage and be 
reduced[124] (Scheme 14). Palladium in ferritin has been successfully applied in analytical 
scale reactions, however, the long process to synthesise the Pd-ferritin nanoparticles 
has not yet found its way to industrial applications.[125]  
 
 
Scheme 14. Example reaction scheme using azido alcohols as substrate and palladium nanoparticles 
encapsulated in a ferritin cage. The ferritin cage would prevent adsorption of external proteins onto the metal 
nanoparticles whereas substrate and hydrogen can freely diffuse inside the Pd-ferritin complex and react. 
 
1.7 Protein engineering 
Wild-type enzymes normally work at submillimolar concentrations in their natural 
functions. For biocatalytical application, however, significantly higher substrate 
concentrations are required hence, often the natural activity of a certain enzyme is not 
fitting for direct practical application in biocatalytical and industrial processes. Most of 
the times, it is necessary to improve the enzyme’s activity and/or stability to fit the desired 
reaction conditions of a biocatalytic process.[5,126] Enzymes’ function and structure are 
the results of their sequence, hence manipulating its sequence leads to variants with 
different characteristics. Since the advent of molecular technologies to efficiently 
manipulate DNA, enzymes have been evolved to improve certain characteristics,[7] to 
develop unnatural reactions[127,128] or to match industrial requirements.[129] 
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Mimicking natural evolution, a given enzyme can be mutated and selected for the desired 
characteristic iteratively until satisfaction. There are two main ways for “in vitro” enzyme 
evolution: directed evolution and rational design. 
Directed evolution 
The definition of directed evolution was used for the first time around 1972 and in the 
first experiments, whole cells were subjected to artificial environments that would cause 
"adaptive" changes in a given enzyme (Figure 4, A).[130] Francis and Hansche evolved 
and acid phosphatase from Saccharomyces cerevisiae by constructing a selection 
environment in a chemostat to reduce the enzyme’s activity of about 70% (pH 6). Mutants 
with improved acid phosphatase activity at pH 6 would be positively enriched in the 
chemostat as β-glycerophosphate, metabolised by the enzyme, was provided as sole 
carbon source.[130] After 1000 generations of asexual reproduction, adaptive mutants 
were analysed to determine the new genetic and biochemical features. In the first part of 
the 1990s, Frances Arnold and Pim Stemmer improved this technique by using advanced 
molecular biology methods coupled with efficient screening methods to improve 
enzymes.[5] In directed evolution, only the enzyme’s DNA sequence is required as the 
mutations are randomly introduced throughout its sequence to generate large mutant 
libraries. The most popular way to do that is the use of error-prone PCR (epPCR).[131] 
Mutagenesis and screening or selection can then be iterated until the enzyme displays 
improved characteristics or acquired the wanted features. The major drawback is the 
need for a screening method using a fast and reliable assay to efficiently identify 
improved variants before starting with the next round of mutagenesis (Figure 4, B).[132]  
 
Figure 4. General representation of directed evolution using in vivo selection (A) or high-throughput 
screening (B) (adapted from Brakmann[133]). 
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Rational design 
Unlike directed evolution, rational design strongly relies on the availability of structural 
information on the enzyme and knowledge about the mechanism/function. The 
exponentially increasing number of protein structures generated by X-ray 
crystallography, NMR, and cryo-electron microscopy made this approach more and more 
accessible.[134] Using available molecular modelling tools (e.g. PyMol or Yasara), it has 
been possible to “rationally” select residues that may be responsible for substrate 
specificity or enantioselectivity. This is generally done by replacing the single residues 
with amino acids present in homologous sequences.[135] Hence, the number of mutants 
to analysed is significantly reduced and there is no need for an efficient screening 
method. 
Site-saturation mutagenesis (SSM), is a hybrid approach between random mutagenesis 
and rational design as selected positions are randomly replaced with all amino acids. 
Mutations are introduced on DNA level by replacing the codon coding for the specific 
amino acid with all possible codons (64 codons, 20 amino acids). SSM of a single site 
using an NNN-codon requires the screening of 192 random variants to achieve a 95% 
coverage considering an oversampling factor of three.[136] This number increases to 
12’288 if two positions are mutated at the same time. Hence, smart libraries have been 
developed to decrease the number of variants to screen but keeping the 95% coverage. 
Due to the redundancy of the genetic code, the number of codons introduced during 
mutagenesis can be reduced from 64 to 32 (NNK-strategy with K coding for G or T) and 
still covering all 20 amino acids. This way, it is possible to reduce the number of variants 
to screen to 32 or 3’072 for 1 or 2 mutated positions, respectively.[132] In a later approach, 
the number of introduced codons was further reduced to 12 (NDT codon) by eliminating 
the chemical redundancy of amino acid residues, but keeping representatives of 
aromatic, aliphatic, non-polar, polar, negatively and positively charged amino acid 
residues.[136] Statistically speaking, the NDT-codon strategy is by far more efficient than 
the NNK-strategy (based on the screening of 5000 clones), and mutagenesis on the 
epoxide hydrolase from Aspergillus niger proved its validity by producing a library with 
511 hits whereas the NNK-library only contained 38.[132,136] Furthermore, rational design 
allows a more in-depth characterization of the mutated position by testing different amino 
acids compared to random mutagenesis where generally a lower number of mutants can 
be explored at each position.[134]   
Computational approaches 
As mentioned above, the advent of DNA sequencing and manipulation has brought 
exceptional benefits to a number of fields like molecular and synthetic biology and 
biocatalysis. In parallel with molecular techniques, computational approaches 
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(bioinformatics) raised in popularity with the increasing availability of sequence data. In 
the past years, the sophistication of the algorithms has exponentially increased the ability 
to extract more and more useful information from this enormous amount of sequence 
data.[137] Moreover, a number of different algorithms have been developed to help to 
predict protein function based on the sequence and/or three-dimensional structure of a 
protein,[138,139] to predict mutations for improved stability[140] or enhanced substrate 
binding, or to completely change the substrate specificity of an enzyme.[141,142] The 
improved prediction efficiency significantly contributed to the growing success of these 
bioinformatics tools together with a user-friendly graphical interface. One of the most 
popular software packages for protein structure visualization, YASARA Structure,[143,144] 
has several built-in functions where a simple protein-ligand docking is only a few clicks 
away. Pymol, another famous software for protein structure visualization, has several 
plugins available that allow using bioinformatics methods without coding experience.[145] 
As mentioned previously, these bioinformatic tools can help to visualise the enzymes 
and select specific positions to mutate reducing the screening effort. Recently, a novel 
algorithm was implemented in the Rosetta software suite[146] here a new strategy was 
refined to predict mutations improving the interaction between proteins and small 
molecules. This new method, called “coupled moves”, takes into consideration the subtle 
rearrangements that can take place at the backbone level after a mutation.[147] Backbone 
rearrangements, side-chain conformational changes, amino acid mutations or ligand 
movements occur at the same time and the new calculated energy determines the 
probability of the mutation or conformational change (Figure 5). Once started, the 
algorithm changes residues selecting the amino acids that improve the binding energy 
with the ligand in a sort of Darwinian way mixed with a random acceptance-rejection rate, 
typical of the Metropolis-Monte Carlo algorithm.[148] This procedure is repeated for N 
times (determined by the user) and a list of accepted sequences is the output. This new 
approach could predict mutations improving protein-ligand interaction with a prediction 
efficiency up to 68% compared to the previous method with fixed backbone.[149] The 
method is very powerful although the enzyme’s reaction mechanism or a ligand-bound 
structure must be known as the new non-natural ligand is manually docked into the 
catalytic tunnel of the enzyme. The successful run must then be experimentally verified 
by generating the top scoring mutants and by checking their activity. This approach can 
also be combined with classic site-directed mutagenesis where the coupled moves 
method is used to identify target positions for SSM. If in the coupled moves output, a 
specific position appears to have high variability, it is very likely that mutations in that 
position will result in better protein-ligand interaction as other amino acids were accepted 
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more frequently than the wild type. Hence, a site where the wild type amino acid showed 
low frequency would likely be a potential target for SSM. 
An additional and important advantage is the possibility to include epistatic mutations. 
Epistasis is the phenomenon where the effect of a given mutation becomes relevant only 
after other changes have taken place and often they appear to be neutral or deleterious 
for the protein to evolve.[150,151] Epistatic effects are normally neglected in classical 
protein engineering strategies as only positive variants are selected in screening 
methods. With the coupled moves strategy, some random mutations may be accepted 
and be beneficial at a later stage as multiple residues are mutated at the same time. 
 
 
Figure 5. Flow-chart representation of the strategy used in the coupled moves algorithm implemented in the 
Rosetta software suite (taken from Ollikainen et al.[149]). 
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1.8 Aim of the project  
The main objective of this project was to develop a new chemo-enzymatic route for the 
synthesis of enantiopure vicinal amino alcohols starting from non-terminal alkenes. For 
this, two main cascades were envisaged for the synthesis of (2S,3R)- and (2R,3S)-2-
amino-3-hydroxyhexane as well as (2S,3R)- and (2R,3S)-2-amino-3-hydroxyheptane 
starting from achiral trans-2-hexene and trans-2-heptene, respectively. Additionally, a 
third cascade was aimed for converting cyclohexene to the corresponding chiral 2-
aminocyclohexan-1-ol. All cascades should combine the following three reaction steps: 
1) epoxidation of the alkene, 2) epoxide ring opening using azide as nucleophile and 3) 
hydrogenation of the resulting azido alcohol (Scheme 15). 
 
Scheme 15. General reaction scheme for the cascades starting either from non-terminal trans-alkenes for 
the synthesis of enantiopure acyclic amino alcohols or starting from cyclohexene for the synthesis of the 
corresponding cyclic amino alcohol. 
 
Starting from a non-terminal alkene, the final amino alcohol will carry two stereocenters. 
To control the configuration of both stereocenters in the final product, the aim was to 
combine an enantioselective epoxidation (step 1) of the acyclic alkenes with a 
regioselective epoxide ring opening (step 2) to afford single enantiomers of the 
corresponding azido alcohols. In contrast, starting from cyclohexene will only require an 
enantioselective ring opening of the corresponding cyclohexene oxide as the epoxide is 
not yet chiral (Scheme 15). The final hydrogenation step should then proceed with 
preservation of the enantiopurity. 
Hence, the first project objective was to identify suitable catalysts with desired selectivity 
for each reaction step by testing several available chemical and enzymatic catalysts. The 
subsequent project goal was to optimize each reaction step individually and to study 
possible compatibility issues in order to identify optimal conditions for the combination of 
the individual reaction steps in cascades. Finally, upscaling of the established cascades 
should be performed to isolate and characterize the formed products. 
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Additionally, for the cascade starting from cyclohexene, engineering of HheG was aimed 
for to improve its enantioselectivity using a new in silico method. This was necessary 
since HheG was the only HHDH able to convert cyclohexene oxide but displayed only 
moderate enantioselectivity in the ring opening of this epoxide using azide as 
nucleophile.  
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemical standards and substrates 
All chemicals were purchased from either Sigma Aldrich Chemie (Steinheim, Germany), 
AppliChem (Darmstadt, Germany), abcr GmbH (Karlsruhe, Germany), Acros Organics 
(Geel, Belgium) and Carl Roth (Karlsruhe, Germany) unless otherwise stated, taking 
care of ordering the highest quality available. 
Trans-2-hexene (1) and cyclohexene oxide were purchased from Acros Organics (Geel, 
Belgium), trans-2-heptene (2) was purchased from abcr GmbH (Karlsruhe, Germany). 
Trans-2-hexen-1-ol (3) was purchased from J&K Scientific bvba (Lommel, Belgium). 
Trans-3-heptene (5) and trans-β-methylstyrene (5) were purchased from TCI 
Deutschland GmbH (Eschborn, Germany). (S,S)-1-phenylpropylene oxide (25), (R,R)-1-
phenylpropylene oxide (25), Shi epoxidation diketal catalyst, (R,R)- and (S,S)-
Jacobsen's catalyst, formate dehydrogenase from Candida boidinii, apoferritin from 
horse spleen, heterogeneous Palladium catalysts kit I (2017), Pd/C, loading 10 wt%, 2-
chlorocyclohexanol, (1R,2R)- and (1S,2S)-2-aminocyclohexanol, hydrazine hydrate 
solution 78-82%, triethylsilane (TES) were purchased from Sigma Aldrich Chemie 
(Steinheim, Germany).  
Chemical synthesis of the substrate epoxides 
The respective racemic epoxides trans-2,3-epoxyhexane (21) and trans-2,3-
epoxyheptane (22) were synthesised using meta-chloroperbenzoic acid (m-CPBA) 
through a slightly modified protocol from Sharma et al.[152]  Epoxidations were carried out 
in CH2Cl2 (40 mL/g of alkene). m-CPBA (1.5 eq.) was added in small portions over 15 
min at RT. After 1 h at RT, the mixture was stirred on ice for 5 min and the white slurry 
was filtered. 5% w/v aq. Na2SO3 (40 mL/g alkene) was added and stirred at RT for 15 
min, then the phases were separated. The aqueous layer was extracted two times with 
CH2Cl2. The combined organic layers were washed with sat. aq. NaHCO3 (1×) and brine 
(1×), dried over MgSO4 and filtered before solvent removal by evaporation. The epoxides 
were purified by column chromatography using a mixture of cyclohexane/ethyl acetate, 
95:5. 
The racemic epoxides trans-4,5-epoxyhexanol (23), trans-3,4-epoxyheptane (24) and 
trans-1-phenylpropylene oxide (25) were synthesised mixing the respective alkene (3, 4 
and 5) to a final concentration of 200 mM in water with 30% acetonitrile and 10% of 
acetone. 3 eq. of oxone® was added portion wise over 4 hours. The pH was kept at 8 by 
adding NaHCO3 to the solution.[153] The reactions were followed by TLC and when no 
more substrate was visible the reaction mixture was extracted three times with tert-
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butylmethylether (TBME). The combined organic layers were washed with brine (1×), 
dried over Na2SO4 and filtered before solvent removal by evaporation. The epoxides 
were purified using column chromatography with cyclohexane/isopropanol (95:5) for 23, 
cyclohexane/ethyl/acetate (95:5) for 24 and (90:10) for 25. The synthesised epoxides 
were confirmed using NMR (300 MHz; diluted solution in CDCl3) and literature data.[154–
156]  
Chemical synthesis of authentic azido alcohol standards 
1 mmol of either trans-2,3-epoxyhexane (21) (100 mg) or trans-2,3-epoxyheptane (22) 
(114 mg) were mixed with 202 mg of NaN3 (3.1 eq.) and 166 mg of NH4Cl (3.1 eq.) in 3.5 
mL of methanol and refluxed until no more substrate was visible on TLC (5-6 h). The 
reaction mixture was then diluted in diethyl ether, washed with brine and the water phase 
was extracted twice with diethyl ether. The organic layers were combined and dried over 
Na2SO4. The crude extracts were purified by column chromatography with 
cyclohexane/diethyl ether (90:10) yielding 52% azido-hydroxyhexane (31) and 48% 
azido-hydroxyheptane (32).[157] 
Following a similar protocol the azido alcohols 33, 34 were synthesised by dissolving the 
respective epoxides in MeOH with 5% H2O to a final concentration of 200 mM, NaN3 (3.1 
eq.) and NH4Cl (3.1 eq.) was added and the reaction was stirred overnight at reflux. 
Methanol was evaporated, the crude extract was dissolved in tert-butylmethylether 
(TBME) and washed with the same volume of brine (1x) and the water phase was 
extracted three times with TBME. The combined organic layers were dried over Na2SO4 
and filtered before solvent removal by evaporation. 33 and 34 were purified by column 
chromatography with chloroform/acetone (95:5) and cyclohexane/ethyl acetate (95:5), 
respectively.  
Chemical synthesis of authentic amino alcohol standards 
The azido group hydrogenation protocol was adapted from a previously published 
method.[158] 200 mg of pure azido alcohol 31 or 32 (~60 mM) were dissolved in 20 mL 
methanol. Pd/C in larger quantities (40 mg) is pyrogenic. Therefore, it was pre-wetted 
with methanol before adding it to the mixture. The solution was magnetically stirred at 
500 rpm at room temperature and hydrazine was added dropwise for 2 h until a 
concentration of 150 mM was reached (2.5 equivalents). After ~4 h the reaction was 
filtered through Celite® to separate Pd/C and the solvent was removed with vacuum. 
Amino alcohols 41 and 42 were purified by column chromatography using a mixture of 
chloroform:methanol:ammonia (90:9:1). 
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2.1.2 Kits, equipment and software 
Table 3. Kits used in this study. 
Kit Supplier 
NucleoSpin® Gel and PCR Clean-up Kit Macherey-Nagel 
NucleoSpin® Plasmid Purification Kit Macherey-Nagel 
QIAquick® Gel Extraction Kit Quiagen 
Heterogeneous Palladium catalyst Kit I Sigma-Aldrich 
 
Table 4. Equipment used in this study. 
Equipment Supplier 
ÄKTA pure GE Healthcare 
HisTrapTM FF column Macherey-Nagel 
CARY 60 Bio UV-Vis spectrophotometer Agilent Technologies 
Helios UV / Vis Spectrophotometer Unicam 
Ultrospec 3000 UV/Visible Spectrophotometer Pharmacia Biotech 
Implen NanoPhotometer NP80 Touch Intas-Science-Imaging Instruments GmbH 
NanoDrop™ 1000 spectrophotometer peqlab 
Heraeus Fresco 21 Centrifuge Thermo Fisher Scientific 
Heraeus Fresco 17 Centrifuge Thermo Fisher Scientific 
Heraeus Pico 17 Centrifuge Thermo Fisher Scientific 
Heraeus Primo R Centrifuge Thermo Fisher Scientific 
Heraeus Multifuge X3R Centrifuge Thermo Fisher Scientific 
Mikro 185 Centrifuge Andreas Hettich GmbH & Co.KG 
PeqSTAR Thermocycler VWR Peqlab 
Gel Doc™ XR+ System Biorad 
ThermoMixer C Eppendorf 
Microx 4 PreSens Precision Sensing GmbH 
Profiling oxygen microsensor (needle type) PreSens Precision Sensing GmbH 
Vibra-Cell™ VCX130 Sonics & Materials, Inc. 
Bioflo 110 New Brunswick Scientific 
Laborota 4001 Heidolph Instruments GmbH & Co Kg 
SC 920 KNF Neuberger GmbH 
Speed Vac® SC 110 Savant 
Gel Doc™ XR+ System Biorad 
GC2010 plus gas chromatograph with AOC-20i-
injector and FID detector 
Shimadzu 
GC2014 gas chromatograph with AOC-20i-injector 
and FID detector 
Shimadzu 
Supreme 5ms column CS Chromatographie Service 
HYDRODEX γ-DiMOM column Macherey-Nagel 
Lipodex® E column Macherey-Nagel 
CP-Sil 5 CB Agilent Technologies, Inc 
BPX5 column SGE Analytical Science 
HYDRODEX β-3P column Macherey-Nagel 
Lipodex® G column Macherey-Nagel 
 
Table 5. Software used in this study. 
Software Supplier 
PyMOL  DeLano Scientific LLC. 
Rosetta 3.6 RosettaCommons 
UNICORN (5.31)  GE Healthcare 
ChemDraw Professional 15.1 Perkin Elmer 
Clone Manager (9.1)  Scientific & Educational Software 
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Serial Cloner 2.6 SerialBasic 
GCsolution (2.32.00)  Shimadzu 
GCMSsolutions (2.53)  Shimadzu 
LabSolution (5.51)  Shimadzu 
MestRenova 6.0 Mestrelab Research 
Origin 2017 OriginLab 
TopSpin 4.0.3 Bruker BioSpin GmbH 
PreSens measurements Studio 2 PreSens Precision Sensing GmbH 
RStudio 1.0.136 RStudio, Inc. 
  
2.1.3 Bacterial strains, plasmids and oligonucleotides 
The Escherichia coli DH5α strain (Invitrogen, Carlsbad, CA, USA) was used for plasmid 
amplification and DNA manipulation, while E. coli BL21 (DE3) (Novagen, EMD 
Biosciences, San Diego, CA, USA) and E. coli C43 (DE3) (Lucigen, Middleton, WI, USA) 
were used for heterologous expressions. 
The vector pMK-RQ containing the codon-optimized genes coding for styA and styB was 
ordered from Invitrogen (Thermo Fisher Scientific division, Wilmington, USA).  
The alcohol dehydrogenase from Lactobacillus kefir (LkADH) was present in pET21(+) 
vector and was used as it is from Enzymicals’ cofactor regeneration enzyme collections. 
The alcohol dehydrogenase from Leisfonia sp. S749 (LsADH) was ordered cloned in 
pCDF1Duet-1, while the gene coding for StyB was ordered cloned in pRSFDuet-1 
(Genescript, New Jersey, U.S.). 
The vectors pET28a(+)-cyp154C5, pET28a(+)-cyp154H1, pACYC-Duet1-camA-camB, 
pACYC-camA, pACYC-camB were readily available from previous projects.[159,160]  
The vector pET28a(+)-MsAct was present in the plasmid collection from a previous 
project.[161] 
All HHDH genes except hheA2, hheB2 and hheC were readily available in pET28a(+)-
based vectors.[102] Instead HheA2, HheB2 and HheC genes were present in pBAD 
vector, as described previously.[24,162] 
styAB subcloning in pETDuet and pRSFDuet-1 vector 
Synthetic styB gene was cut from the commercial plasmid using the endonucleases XhoI 
and NdeI (NEB). In parallel pETDuet vector was digested using the standard NEB 
protocol with the same restriction enzymes. Afterwards, the cut plasmid and styB were 
excised from 0.8% agarose gel and purified via the QIAquick® Gel Extraction Kit 
(Qiagen, Hilden, Germany). The ligation was carried out overnight at 26 °C using the T4 
ligase and a molar ratio of 1:3 (vector to insert). After transformation of chemically 
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competent E.coli DH5α, the successful insertion in the MSC-2 was verified by colony 
PCR using the protocol described below (Section 2.2.1). 
The gene coding for styA was directly adjacent to styB with only one restriction site in 
between. For viable cloning in the MSC-1 the restriction sites at both ends were modified 
via PCR using primers with modified ends. The 5’-end of styA was modified using 
Fw_StyA_NcoI, while the 3’-end was modified by using the primer Rv_StyA_BamHI. 
Hence, the restriction sites were exchanged from NdeI to NcoI at the 5´-end and from 
HindIII to BamHI at the 3’-end. The gene was amplified by PCR as described in section 
2.2.1 and was digested at 37 °C using NcoI and BamHI and purified using the 
NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel). In parallel, pETDuet-styB 
was digested with the same endonucleases and excised from the agarose gel as 
described above. The ligation was performed overnight using the standard protocol and 
a molar ratio of 1:3 (vector to insert). The successful insertion in the MSC-1 was then 
verified after transformation of chemically competent E.coli DH5α by colony PCR using 
the protocol described below. Finally, plasmid DNA was isolated with NucleoSpin 
Plasmid kit (Macherey Nagel, Düren, Germany) and digested using the endonucleases 
XhoI, NdeI, NcoI and BamHI to verify the presence of the two inserts. Additionally, an 
aliquot was sent for sequencing to Eurofins Genomics. 
The cloning of styA from pETDuet-styAB to pRSFDuet-1-styB was performed as 
described above. pETDuet-styAB and pRSFDuet-1-styB were digested at 37 °C using 
NcoI and HindIII. Open vector and gene of interest were purified using the QIAquick® 
Gel Extraction Kit (Qiagen, Hilden, Germany). The ligation was performed overnight 
using the standard protocol for T4 ligase and a ratio of 1:3 (vector to insert). The 
successful insertion in the MSC-1 was then verified by sequencing of the isolated 
plasmid DNA after transformation of chemically competent E.coli DH5α plasmid 
extraction and sequencing using GATC Biotech sequencing (Konstanz, Germany).   
Table 6. List of primers used for gene amplification and sequencing and relative lengths and melting 
temperatures 
Oligo’s name 
Sequence (5’ → 3’) Length 
(bp) 
Tm (°C) 
Fw_StyA_NcoI GGAGACCCATGGCCAAGAGCATCGCCATCGTC 32 58.6 
Rv_StyA_BamHI    AGGCCCGGATCCTTACACACCCGTACCTGCGAAC 34 59.3 
T7-fwd TAATACGACTCACTATAGGG 20 53.2 
T7-rev GCTAGTTATTGCTCAGCGG 19 56.7 
T7 term CTA GTT ATT GCT CAG CGG T 19 54.5 
ACYCDuetUP1 GGATCTCGACGCTCTCCCT 19 61.0 
DuetDOWN1 GATTATGCGGCCGTGTACAA 20 57.3 
petup ATGCGTCCGGCGTAGA 16 54.3 
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2.2 Methods 
2.2.1 Molecular and microbiological methods 
Cultivation and conservation of Escherichia coli 
Escherichia coli cells were cultivated in LB (5 g/L peptone, 10 g/L NaCl, 10 g/L yeast 
extract) or TB (4 mL/L glycerol, 12 g/L peptone, 24 g/L yeast extract, 0.17 M KH2PO4, 
0.74 M K2HPO4) medium supplemented with the respective antibiotics (Table 7) at 37 °C 
overnight. The antibiotic was added after sterilization of the medium by autoclave. Agar 
plates were prepared by adding agar-agar (1.2% w/v) to the medium before autoclaving. 
For long-term conservation of E. coli cells, 900 µL of an overnight culture were mixed 
with either 60 µL of DMSO or alternatively 500 µL of E. coli cells were mixed with 500 µL 
of a solution of 60% v/v glycerol and stored at -80 °C.  
 
Table 7. List of vectors and respective antibiotic used during this work. The strains used are described in 
section 2.3.1 
Vectors Antibiotics 
pMK-RQ-styAB Kanamycin (50 µg/mL) 
pETDuet-styB or pETDuet-styAB,    Ampicillin (100 µg/mL) 
pRSFDuet-1-styB or pRSFDuet-1-styAB  Kanamycin (50 µg/mL) 
pETDuet-styAB, pG-KJE8  
Ampicillin (100 µg/mL), Chloramphenicol (20 
μg/ml), Tetracycline (5 ng/m), Arabinose (0.5 
mg/m) 
pET21(+)-LkADH Ampicillin (100 µg/mL) 
pCDF1Duet-1-LsADH Spectinomycin (100 µg/mL) 
pRSFDuet-1-styAB, pET21(+)-LkADH  Kanamycin (50 µg/mL), Ampicillin (100 µg/mL) 
pRSFDuet-1-styAB, pCDF1Duet-1-LsADH 
Kanamycin (50 µg/mL), Spectinomycin (100 
µg/mL) 
pETDuet-styAB, pCDF1Duet-1-LsADH 
Ampicillin (100 µg/mL), Spectinomycin (100 
µg/mL) 
pET28a(+)-cyp154C5 or pET28a(+)-cyp154H1 Kanamycin (50 µg/mL) 
pACYC-camA or pACYC-camB or pACYC-Duet1-
camA-camB 
Chloramphenicol (25 μg/ml ) 
pET28a(+)-cyp154C5, pACYC-Duet1-camA-camB 
Kanamycin (50 µg/mL), Chloramphenicol (25 
μg/ml)  
pET28a(+)-cyp154H1, pACYC-Duet1-camA-camB 
Kanamycin (50 µg/mL), Chloramphenicol (25 
μg/ml)  
pET28a(+)-MsAct  Kanamycin (50 µg/mL) 
pET28a(+)-hhdh except hheA2, hheB2 and hheC  Kanamycin (50 µg/mL) 
pBAD-hheA2 or pBAD-hheB2 or pBAD-hheC  Ampicillin (100 µg/mL) 
 
Preparation of competent E. coli cells 
Depending on the genetic transformation efficiency wanted two different types of 
competent cells, chemically competent or electrocompetent, were used in this study. 
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Chemically competent cells preparation 
For the preparation of chemically competent cells of E. coli DH5α, Top10, BL21 (DE3) 
and C43 (DE3) 50 mL LB medium was inoculated with an overnight culture of the desired 
bacterium to an optical density at 600 nm (OD600) of 0.1. The culture was incubated at 
37 °C at 250 rpm until an OD600 between 0.4 and 0.6 was reached. After incubation on 
ice for 15 min cells were harvested by centrifugation (4000 rpm, 4 °C, and 30 min). The 
cell pellet was resuspended in 20 mL ice-cold RF1 buffer (30 mM KCH3CO2, 50 mM 
MnCl2, 100 mM RbCl2, 10 mM CaCl2, 15%(v/v) glycerol, pH 5.8) and incubated for 2 h 
on ice. Afterwards, the mixture was centrifuged and the resulting pellet was resuspended 
in 4 mL RF2 buffer (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% (v/v) glycerol, pH 
6.8) and in 200 μL aliquoted. Aliquots were shock frozen in liquid nitrogen and stored at 
-80 °C.[163] 
Electrocompetent cells preparation 
E. coli cells were cultivated and harvested as described above. The cell pellet was 
washed 3 times with 200 mL ice-cold sterile ddH2O followed by washing with ice-cold 
20% (v/v) glycerol/water solution and centrifugation. Finally, the cell pellet was 
resuspended in 2 mL ice-cold 10% (v/v) glycerol solution and 50 μL aliquots were 
prepared. Aliquots were shock frozen in liquid nitrogen and stored at -80 °C.[163] 
Transformation of E. coli 
Chemically competent E. coli cells were transformed by adding 50 to 100 ng of plasmid 
DNA to a cell aliquot. The cells were incubated for 20 min on ice and heat shock was 
performed for 90 s at 42°C. 600 µL of SOC medium (2 g/L KCl, 2 g/L NaCl, 5 g/L yeast 
extract, 10 g/L  tryptone, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added and 
cells were incubated for 1 h at 37 °C at 800 rpm for cell recovery and antibiotic resistance 
expression.  
Electrocompetent E. coli cells were transformed by adding 50 to 100 ng of plasmid DNA. 
The cells were thawed on ice, gently mixed and transferred in a pre-cooled 2 mm cuvette 
for electroporation. The electroshock was carried out using Electroporator 2510 
(Eppendorf AG, Hamburg, Germany) at 2500 V and 5 ms. 600 µL of SOC medium was 
readily added to the cuvette and the mixture was transferred to a 1.5 mL reaction tube 
to incubate for 1 h at 37°C at 800 rpm. 
At last, the transformed cells were plated on LB agar plates containing the desired 
selection marker (antibiotic, Table 7). 
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Standard protocol for agarose gel electrophoresis 
Agarose gel electrophoresis was generally used for plasmid visualization and vector 
insert separation after restriction enzyme’s digestion. Agarose (0.8 or 1% w/v) was 
dissolved in TAE buffer (40 mM Tris-HCl, 2 mM acetic acid, 1 mM EDTA, pH 8.5) and 
the gel was formed via microwave oven. DNA samples were mixed with 6x loading dye 
(New England Biolabs, Frankfurt, Germany) and typically 10-20 µL were loaded on the 
gel together with 1 kb ladder (NEB) to reference the size of the DNA fragments. The 
separation based on molecular weight using an electric current of 100 V. TAE buffer was 
used as running buffer as well. The gels were stained for 15 in a water bath containing 
ethidium bromide and visualized under UV light. The DNA concentration of samples was 
determined using a NanoDrop™ 1000 spectrophotometer.[164] 
Polymerase chain reaction (PCR) 
The polymerase chain reaction is an extremely versatile laboratory technique that allows 
amplifying a selected DNA sequence.[165,166] Depending on the oligonucleotides (primers) 
used to drive the amplification different results can be obtained. In this work, the PCR 
was applied to selectively modify the restriction sites at both ends of the gene coding for 
StyA, to verify if the ligation was successful (colony PCR) or to introduce mutations in 
hheG gene via site-directed mutagenesis. 
Gene of interest amplification and selective restriction site modification 
20-100 ng template DNA was added to a solution containing 1 U Phusion© polymerase 
(New England Biolabs, Frankfurt, Germany), 5% (v/v) 5x Phusion HF buffer, 200 µM 
dNTPs. The target DNA sequence is then selectively amplified using designed forward 
and reverse primers to a final concentration of 0.5 µM, finally the volume was adjusted 
to 50 µL with ddH2O. The gene of interest was amplified according to the temperature 
profile in Table 8. 
Table 8. Settings used in the thermocycler for the PCR. 
Step Temperature (°C) Time (min)  Cycles 
1 98 30 s 1 
2 98 10 s 
25 - 35 3 Tm primer -5°C  30 s 
4 72 30 s per kb 
5 72 10  min 1 
 
The DNA fragments of interest were separated via agarose gel electrophoresis, excised 
from agarose gels and purified using QIAquick® Gel Extraction Kit prior to further 
experiments. 
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Colony PCR 
Colony PCR is a powerful tool to quickly determine if a ligation was successful. After E. 
coli DH5α was transformed with the ligation product, individual colonies were picked from 
a LB-agar plate, dissolved in 20 µL ddH2O and transferred on a fresh LB-agar plate. The 
mixture was heated for 2 min at 98 °C and 2 µL of the cell suspension were used for the 
amplification. The sample was mixed with DreamTaq Green DNA Polymerase (0.5 µL), 
10X DreamTaq Green Buffer, 5 µM forward and reverse primer and ddH2O to a final 
volume of 50 µL. The gene of interest was amplified according to the temperature profile 
in Table 9. After amplification, the mix was directly loaded on the agarose gel and the 
results directly visualized after electrophoresis.  
Table 9. Temperature profile used in the thermocycler for colony PCR. 
Step Temperature (°C) Time (min)  Cycles 
1 94 5 1 
2 94 1 
30 3 primer Tm-5°C 0.5 
4 72 1 
5 72 3 1 
 
QuickChange PCR method 
The site-directed mutagenesis was performed by Janine Mayer (Master thesis, 2017) to 
analyse the mutations suggested by the in silico mutagenesis done with the coupled 
moves method (Section 3.3.3). 100 ng of parental vector DNA and 125 ng of the 
respective forward and reverse primer were added to a 25 µL aliquot of the PCR 
Mastermix and the volume was adjusted to 50 µL with ddH2O. The temperature profile 
used for the amplification is shown in Table 10.  
Table 10. Temperature profile used in the thermocycler for the QuickChange PCR protocol. 
Step Temperature (°C) Time (min)  Cycles 
1 95 2 1 
2 95 0.5 
30 3 55 1 
4 68 1 min/kb 
 
The template vector DNA was digested overnight using 1 µL of DpnI and incubation at 
37 °C. Afterwards, chemically competent E. coli DH5α cells were transformed with 5 μL 
of the PCR mixture and plated on LB agar plates The plasmid DNA was isolated, from 5 
mL of liquid culture, the amino acid exchange was confirmed by sequencing (Eurofins 
Genomics). More rounds were performed to generate multiple mutations in the same 
vector. 
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2.2.2 Biochemical methods 
Recombinant protein expression in E. coli 
Flask cultivations for protein expression 
Heterologous protein expression was generally done in 400 mL TB media (2 L flask) with 
the respective selection markers shown in Table 7. A colony from the desired LB-agar 
place was picked to inoculate 5 mL of LB media for the overnight culture. The ON-culture 
was then used to inoculate 50 ml TB media pre-culture (250 mL flask) to allow the cells 
to adapt to the new medium. The cells were grown at 37 °C at 200 rpm until they reached 
OD600 of approx. 2-4. The main culture (400 mL) was then inoculated with a volume to 
have a starting OD600 of 0.1. The cells were grown at 37 °C at 200 rpm until they reached 
OD600 of 0.8-1.2, afterwards the desired amount of Isopropyl-β-D-thiogalactopyranoside 
(IPTG) was supplemented as inducer and the temperature was lowered to the required 
expression temperature. The induction was performed overnight except whereas protein 
production in E. coli C43 (DE3) required 48 h. Optimal temperatures and IPTG 
concentrations for the different combinations of strain and expression vector used are 
shown in Table 11. After the expression time, the cells were harvested by centrifugation 
at 4000 rpm for 30 min at 4 °C, cell pellets were washed and stored at -20 °C until further 
experiments. Alternatively, cells pellets were resuspended in 50 mM potassium 
phosphate buffer pH 7.5 to a concentration of 0.60 g/mL and cell disruption was 
performed via sonication (6 cycles of 30 s at an amplitude of 50%, with 30 s pause on 
ice between cycles). Cellular debris was removed by centrifuging the cellular lysate at 
10,000 rpm for 30 min at 4 °C. Glycerol to a final concentration of 20% was added to the 
cell-free extract to a final concentration of 75 mg/ml ca. and stored at -20 °C. 
Table 11. Expression conditions used for the different strains and heterologous proteins. *Additional 0.5 mM 
of δ-amino levulinic acid (δ-ala) and 0.1 % v/v of trace element solution (0.50 g/L of CaCl2∙2H2O, 0.18 g/L of 
ZnSO4∙7H2O, 0.10 g/L of MnSO4∙H2O, 20.10 g/L of Na2-EDTA, 16.70 g/L of FeCl3∙6H2O, 0.16 g/L of 
CuSO4∙5H2O and 0.18 g/L of CoCl2.6H2O) 
Strain Vectors 
Temperature 
(°C) 
IPTG (mM) 
E. coli BL21 (DE3) pETDuet-styAB, 20 °C 0.2 or 0.5 mM 
E. coli C43 (DE3) pETDuet-styAB, 25 or 30 °C 0.2 or 0.5 mM 
E. coli BL21 (DE3) pETDuet-styAB, pG-KJE8 20 °C 0.2 or 0.5 mM 
E. coli C43 (DE3) pETDuet-styAB, pG-KJE8 25 or 30 °C 0.2 or 0.5 mM 
E. coli BL21 (DE3) pRSFDuet-1-styAB 20 °C 0.2 mM 
E. coli BL21 (DE3) pET21(+)-LkADH 20 °C 0.2 mM 
E. coli BL21 (DE3) pCDF1Duet-1-LsADH 20 °C 0.2 mM 
E. coli BL21 (DE3) pRSFDuet-1-styAB, pET21(+)-LkADH 20 °C 0.2 mM 
E. coli BL21 (DE3) pRSFDuet-1-styAB, pCDF1Duet-1-LsADH 20 °C 0.2 mM 
E. coli BL21 (DE3) pETDuet-styAB, pCDF1Duet-1-LsADH 20 °C 0.2 mM 
E. coli C43 (DE3) 
pET28a(+)-cyp154C5 or pET28a(+)-
cyp154H1 
30 °C 0.8 mM* 
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E. coli C43 (DE3) 
pACYC-camA or pACYC_camB or pACYC-
Duet1-camA-camB 
30 °C 0.8 mM* 
E. coli C43 (DE3) 
pET28a(+)-cyp154C5, pACYC-Duet1-camA-
camB 
30 °C 0.8 mM* 
E. coli C43 (DE3) 
pET28a(+)-cyp154H1, pACYC-Duet1-camA-
camB 
30 °C 0.8 mM* 
E. coli BL21 (DE3) pET28a(+)-MsAct 20 °C 0.2 mM 
E. coli BL21 (DE3) pET28a(+)-HheE 20 °C 0.2 mM 
E. coli BL21 (DE3) pET28a(+)-HheE5 20 °C 0.2 mM 
E. coli BL21 (DE3) pET28a(+)-hhdh Previous results[167] 
E. coli TOP10 pBAD-hhdh Previous results[24,162] 
 
Cultivation of E. coli at 2 L bioreactor scale 
Production of the biocatalyst selected for the cascade was also tested at a larger scale. 
E. coli BL21 (DE3) cells harbouring either pETDuet-styAB and pCDFDuet-1-LsADH or 
pET28a(+)-HheE or pET28a(+)-HheE5 were grown overnight in 5 mL LB medium with 
the appropriate selection marker at 37 °C and 150 rpm. To ensure enough biomass for 
inoculation at the larger scale a 200 mL pre-culture in TB medium was inoculated with 
the 5 mL overnight culture. When the OD600 reached ~2-3, finally the 2 L bioreactor 
(Bioflow 110, New Brunswick Scientific) containing 1.8 L of TB medium was inoculated 
taking care to adjust the starting OD600 to 0.1. The pH was set to 7.0 and titrated during 
the cellular growth with either 5 M KOH or 1 M H3PO4 solutions. Compressed air was 
provided with a 1.5 L/min flow and the dissolved oxygen was controlled via pO2 sensor 
and set to be at least 30%. The stirring speed was set to be variable depending on the 
dissolved oxygen values from 300 to 800 rpm. Finally, excessive foam formation was 
controlled with the commercial Antifoam 204 from Sigma Aldrich Chemie (Steinheim, 
Germany). Protein expression was started when the OD600 reached a value of approx. 
0.8-1.2 with 0.2 mM IPTG as inducer and the temperature was lowered to 20 °C. 
Samples at different time points were taken to measure the cellular density and enzyme 
activity (for StyAB) and after 16-22 h the cells were harvested by centrifugation (4000 
rpm, 30 min, and 4 °C). Cell pellets were washed with 50 mM potassium phosphate 
buffer pH 7.5, the cellular suspension was centrifuged again and pellets were stored at -
20 °C until further use. 
SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
commonly used technique that allows protein separation by applying an electric field. 
SDS is used to denaturate and to homogenize the number of charges around the protein 
resulting in separation based on the molecular weight.[168] For the typical separation 12% 
(v/v) acrylamide gels were used (composition in Table 12). To assess the protein 
expression, the cellular suspensions were normalized by adjusting the concentration to 
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OD600 ~10 in 1 mL in 50 mM potassium phosphate buffer pH 7.5. The samples were 
lysed by sonication (2 cycles of 30 seconds pulse with each 45 seconds pause, 50% of 
amplitude). After centrifugation at 13.300 rpm for 10 minutes, 30 μL of supernatant were 
mixed with 10 μL of loading dye (50 mM Tris HCl pH 6.8, 10 % (v/v) glycerol, 4 % (w/v) 
SDS, 0.03 % (w/v) bromophenol blue and 15 mg/mL DTT) and incubated at 95°C for 5 
min. The remaining pellet was resuspended in 1 mL of 50 mM potassium phosphate 
buffer pH 7.5. Afterwards, 30 μL of the solution were mixed with 10 μL of loading dye 
and treated as mentioned previously. In all cases, 12 μL samples were loaded and gels 
were run at 80 V for 10 min to allow the protein sample to align during the stacking gel, 
followed by another 60 min ca. at 120 V for separation. 
Table 12. Composition of the two gels that composes a 12% Tris-glycine SDS-PAGE gel 
Component Stacking gel (6% acrylamide) Resolving gel (12% acrylamide) 
ddH2O 1.5 mL 2.25 mL 
Acrylamide (40%) 375 μL 1.5 mL 
1,5 M Tris-HCl (pH 8.8) 0.4 % 
SDS 
- 1.25 mL 
1 M Tris-HCl (pH 6.8) 0.4 % SDS 625 μL - 
10 % APS 25 μL 50 μL 
TEMED 2.5 μL 5 μL 
 
Purification of His-tagged proteins 
The expression of proteins with a C or N-terminal hexahistidine tag from the pET28a(+) 
based expression vector system, allows the facile protein purification by immobilized 
metal affinity chromatography (IMAC) using a 5 mL HisTrap HP column and Äkta FPLC 
system (GE Healthcare, Freiburg, Germany). Cells pellets, prepared as described 
previously, were resuspended in the equilibration buffer (50 mM Tris∙SO4, 500 mM 
Na2SO4, 25 mM imidazole, pH 7.9) containing 1 mg/mL lysozyme and 100 µM 
phenylmethylsulfonylfluoride (PMSF) as protease inhibitor to a final concentration of 0.50 
mg/mL. Cell disruption was performed by sonication (6 cycles of 30 s at an amplitude of 
50%, with 30 s pause on ice between cycles) and cell-free extract (CFE) was produced 
by centrifuging the cellular lysate at 10000 rpm for 30 min at 4 °C. Further, CFE was 
filtered through a 0.45 μm cellulose acetate membrane filter prior loading it on an 
equilibrated column (5x column volumes (cv) of equilibration buffer). The filtered CFE 
was loaded with a flow rate of 2 mL/min and the non-specifically bound proteins were 
eluted by washing the column with 5 cv of equilibration buffer with a flow rate of 5 mL/min. 
The His-tagged protein was eluted with an imidazole concentration gradient from 25 to 
500 mM realized by mixing the equilibration buffer with elution buffer (50 mM Tris∙SO4, 
500 mM Na2SO4, 500 mM imidazole, pH 7.9) in different percentages over 100 mL with 
a flow rate of 2 mL. Fractions of 2 mL were collected and the elution of the target protein 
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was followed by the intensity of the UV signal at 280 nm. 30 µL samples of elution 
fractions were analysed by SDS-PAGE to determine the purity. Fractions with lowest 
impurity content were pooled together and concentrated via ultrafiltration (Amicon Ultra-
15 Centrifugal Filter with 10 kDa cut-off, Merck Millipore, Darmstadt, Germany). PD-10-
columns (GE Healthcare) were used to change the buffer from elution to storage buffer 
(TE buffer: 10 mM Tris∙SO4, pH 7.9, 4 mM EDTA) containing 10% (v/v) glycerol. The 
protein concentration was calculated with the extinction coefficient of the purified protein 
and the absorption at 280 nm measured with the NanoDrop™ 1000 Spectrophotometer. 
100 µL aliquots were stored at -20 °C until further use. Cytochrome P450 
monooxygenases concentration was determined by CO-difference spectroscopy 
calculating the maximum absorbance of CO-bound at 450 nm (ε450=91 mM-1 cm-1).[169] 
Purification of non-his-tagged proteins 
PdR and Pdx from P. putida were both expressed without an affinity tag and therefore 
the two proteins were purified in two steps. 
Ion exchange chromatography 
The first step was in common for both proteins and the cell-free extracts were prepared 
as described before, with the exception that the equilibration buffer was different (50 mM 
potassium phosphate buffer pH 7.5). Using a 120 mL Q-Sepharose FF ion exchange 
column equilibrated with the equilibration buffer PdR or Pdx were loaded with a flow of 6 
mL/min. Proteins were eluted using a 1 L gradient from 0 to 500 mM KCl in 50 mM 
potassium phosphate buffer pH 7.5 with a flow of 6 mL/min. PdR and Pdx eluted at 
approx. 350 and 300 mM of the gradient, respectively. It was possible to follow the 
separation of PdR and Pdx by their colour as PdR has a typical yellow colour given by 
FAD cofactor. Whereas Pdx possesses the typical brown colour of proteins containing 
an iron-sulphur cluster. Elution fractions containing PdR (45 kDa) were concentrated by 
ultrafiltration (Amicon Ultra-15 Centrifugal Filter with 30 kDa cut-off, Merck Millipore, 
Darmstadt, Germany) and submitted to the next purification step. The fractions 
containing Pdx (11 kDa) were pooled together and further purified by ultrafiltration 
(Amicon Ultra-15 Centrifugal Filter with 30 kDa cut-off, Merck Millipore, Darmstadt, 
Germany). Hence, larger proteins can be removed and the flow through containing 
purified Pdx was concentrated using a 10 kDa cut-off Amicon centrifugal filter. Desalting 
and storage were carried out as described previously.  
Hydrophobic interaction chromatography 
The concentrated PdR fractions obtained by ion exchange chromatography were 
dissolved in 20 mL 50 mM potassium phosphate buffer pH 7.5 containing 1.5 M KCl and 
loaded on a 50 mL Phenyl-Sepharose FF hydrophobic interaction column equilibrated 
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with the same buffer. The elution was started with a gradient from 1.5 to 0 M of KCl in 
500 mL with a linear flow of 6 mL/min. PdR eluted approximately at 1.12 M KCl (15% of 
the gradient), the best purity fractions containing PdR were pooled together 
concentrated, desalted and stored as described previously. The concentration of pure 
PdR was determined at 454 nm (ε455=10.0 mM-1 cm-1) while the concentration of Pdx at 
455 nm (ε455=10.4 mM-1 cm-1). The electron transfer components (ETC) Pdx and PdR 
(ration 3:16) was determined by monitoring the increase in absorbance at 550 nm of 
reduced cytochrome c (ε450=19.1 mM-1 cm-1).[170] 
Enzyme assays 
Styrene monooxygenase 
The activity of whole cells or cell-free extracts harbouring the styrene monooxygenase 
was measured via trans-2,3-epoxyheptane (22) formation from the substrate trans-2-
heptene (2.5 mM) (2) by adjusting a previously published protocol.[78] Whole cells (60 g/L 
wet cell weight) or cell-free extract (2.3 g/L) were resuspended in 50 mM potassium 
phosphate buffer pH 7.5 to a final volume of 1 mL. In the case of whole cells, glucose 
was added to a final concentration of 10 mM and the cells were incubated at 30 °C, with 
magnetic stirring at 400 rpm for 3 min to allow the metabolism to start. While cell-free 
extract typically contained LsADH and therefore the cofactor regeneration was 
performed using the isopropanol derived from the substrate stock solution. In both cases 
substrate (2) was added to a final concentration of 3.5 mM from a 50 mM stock solution 
in isopropanol and the reactions were incubated at 30 °C, with magnetic stirring at 400 
rpm for 5 min. After 5 min reaction, a 400 µL sample was transferred to a 1.5 mL reaction 
tube stored on ice. Immediately, 400 µL of TBME containing 0.1% (v/v) dodecane as an 
internal standard was added and the sample was mixed using a vortex for 1 min. After 
phase separation by centrifugation the organic phase was dried over anhydrous sodium 
sulphate and submitted to gas chromatography for analysis. One unit of enzyme activity 
was determined as product formation with a rate of µmol/min. Each experiment was 
carried out in duplicate. 
Halohydrin dehalogenases 
The activity of halohydrin dehalogenases was determined directly using cell-free extract 
with a colourimetric assay measuring the pH variation caused by the dehalogenation 
reaction carried out by the enzymes (Scheme 16). The cell-free extract solution was 
prepared in HEN buffer (2 mM Hepes, 0.5 mM EDTA, 10 mM, Na2SO4, pH 8.2) to a final 
total protein content of 10 mg/ml and the pH was carefully adjusted to 8.2. Typically, 15 
µL of the phenol red solution (1 mg/mL in 20% ethanol) were dissolved in 925 µL HEN 
buffer and incubated at 30 °C and 600 rpm for 5 min. Afterwards, 10 µL of the substrate 
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solution (1M 1,3-dichloro-2-propanol in DMSO) were added to the solution and 50 µL of 
the enzyme solution were added. The cuvette was immediately inserted in the 
spectrophotometer and the decrease in absorbance at 560 nm was monitored for 1 min. 
1 U of enzyme activity is defined as the amount of enzyme necessary to generate 1 
µmol/min of H+ from dehalogenation at 30 °C. The change of concentration of H+ is 
calculated using a calibration curve where HCl (10 mM stock solution in ddH2O) is added 
at different concentrations (0-1 mM). The calibration curve must be rejected if the square 
of the Pearson coefficient (R2) is lower than 0.98. All experiments were performed at 
least in triplicate due to the high standard deviation of this assay. 
 
Scheme 16. Reaction scheme of the colourimetric assay used to measure the HHDH activity. 
Enzyme kinetics 
The kinetics parameters for HheE and HheE5 were determined by fitting the 
experimental data with either the Michaelis-Menten equation (1)[171] or the Hill’s equation 
(2) to include cooperative bindings in the fitting.[172,173] Reaction rates (V) at different 
substrate or NaN3 concentrations ([S]) were measured in order to determine 
KM/K50(substrate concentration at which the reaction rate is at half-maximum), Vmax 
(maximum rate at a given enzyme concentration). 
𝑉 =
𝑉𝑚𝑎𝑥 ∙ [𝑆]
𝐾𝑚 + [𝑆]
               (1)               𝑉 =
𝑉𝑚𝑎𝑥 ∙ [𝑆]
𝑛
(𝐾50)𝑛 + [𝑆]𝑛
               (2) 
The kinetic parameters relative to HheE and trans-2,3-epoxyhexane (1) were calculated 
by keeping the enzyme and sodium azide concentrations constant and varying the 
substrate concentration. Initial reaction rates were calculated at 5, 10, 25, 50, 100, 150 
and 200 mM of 1, keeping HheE concentration at 300 µg/mL and NaN3 at 50 mM.  
The kinetic parameters relative to HheE and trans-2,3-epoxyheptane (2) were calculated 
as described above using different substrate concentrations (10, 20, 50, 100, 150 and 
200 mM). 
8. p 7.
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To determine the kinetic values for sodium azide for HheE, trans-2,3-epoxyhexane (1) 
concentration was kept constant at 50 mM and the reaction rate was calculated at 5, 10, 
20, 50 and 150 mM of NaN3.  
In a similar way, HheE5’s kinetic data was obtained for trans-2,3-epoxyheptane (2) 
where the concentration was varied from 5,10, 20, 50, 80, 100 to 120 mM. As described 
above for HheE, HheE5 concentration was kept at 150 µg/mL and NaN3 concentration 
at 50 mM.  
Similarly, the kinetic values for sodium azide were determined by keeping constant trans-
2,3-epoxyheptane (2) concentration at 50 mM and varying sodium azide concentration 
(10, 20, 50, 100, 120, 150 and 200 mM).  
All reactions were performed in 1.2 mL at 25 °C and samples were taken at 60, 65, 75 
and 90 min as no product was formed in the first hour. The samples were prepared and 
analysed in GC using the protocol described below. 
2.2.3 Analytical methods 
Sample preparation  
Typically an extraction with an organic solvent is required when reactions are performed 
in aqueous buffer as GC columns are very sensible to the presence of water. For this, 
generally a 400 µL sample from the aqueous phase was mixed with 400 µL of TBME or 
ethyl acetate containing 0.1% (v/v) dodecane as an internal standard and mixed by 
vortexing for 1 min. The organic phase was separated by centrifugation, dried over 
anhydrous sodium sulphate or magnesium sulphate and submitted to the analysis by 
gas chromatography. 
Analysis in gas chromatography 
Samples for gas chromatography were prepared as described above and conversions 
of substrate into the corresponding products were determined by achiral GC based on 
relative peak areas. Ratios of regioisomers 31a/b, 33a/b and 34a/b were calculated 
based on peak areas derived from chiral GC. Calculation of the ratios of 32a/b and 35a/b 
regioisomers was based on peak areas derived from achiral GC. Enantiomeric excesses 
(ee) of azido alcohol products 31, 32 and 35 were determined using chiral GC and 
according to literature.[174]  
Non-commercially available products were detected and confirmed using gas 
chromatography coupled with mass spectrometry (GC-MS) and NMR (see below). A 
summary of the detailed information of the different temperature programs and columns 
can be found in Table 13-15. 
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Table 13. GC programs used for the analysis of the listed compounds using the columns listed carried out 
at TU Braunschweig. 
Compound Temperature profile 
RT 
(min) 
Column 
trans-2-hexene (1) 
50 °C // 10 °C/min // 70 °C // 50 
°C/min // 300 °C 
3.6 
Achiral: Optima 
5s 
trans-2,3-epoxyhexane (21) 8.4 
3-azido-2-hydroxyhexane 
(31b)  
11.8 
2-azido-3-hydroxyhexane  
(31a) 
11.8 
trans-2-heptene (2) 
70 °C, 2 min // 50 °C/min // 125 °C, 3 
min // 50 °C/min // 300 °C 
2.1 
trans-2,3-epoxyheptane (22) 3 
trans-4,5-epoxyhexanol (23) 3.9 
trans-3,4-epoxyheptane (24) 5.6 
3-azido-2-hydroxyheptane 
(32b)  
6 
2-azido-3-hydroxyheptane  
(32a) 
6.1 
3,4-azidoheptanol (34a and 
34b)   
6.3 
azidohexanediol (33a and 33b) 7.3 
cyclohexene 100°C, 3min// 50°C/min // 200°C// 
20°C/min// 300°C 
2.4 
cyclohexene oxide 3.3 
trans-1-phenylpropylene oxide 
(25) 
80 °C, 1 min // 10 °C/min // 160 °C // 
20 °C/min // 200 °C 
6.8 
1-azido-1-phenylpropan-2-ol 
(35b) 
10.3 
2-azido-1-phenylpropan-1-ol 
(35a)     
10.4 
trans-(2S,3S)-epoxyhexane 
(21) 30 °C // 2 °C/min// 50 °C // 10 °C/min// 
200 °C 
8 
Chiral: 
HYDRODEX γ-
DiMOM  
trans-(2R,3R)-epoxyhexane 
(21) 
8.3 
trans-(2S,3S)-epoxyheptane 
(22) 40 °C // 1 °C/min// 50 °C // 10 °C/min 
// 200 °C 
12.1 
trans-(2R,3R)-epoxyheptane 
(22) 
12.2 
(2S,3R)-2-azido-3-
hydroxyhexane (31a) 
70 °C, 20 min // 10 °C/min // 200 °C 
25.6 
Chiral: Lipodex E 
(2R,3S)-2-azido-3-
hydroxyhexane(31a) 
25.8 
(3R,2S)-3-azido-2-
hydroxyhexane (31b) 
26.3 
(3S,2R)-3-azido-2-
hydroxyhexane (31b) 
26.6 
(2S,3R)-2-azido-3-
hydroxyheptane (32a) 
85 °C // 0.5 °C/min // 95 °C // 10 
°C/min // 200 °C 
17.5 
(2R,3S)-2-azido-3-
hydroxyheptane(32a) 
17.9 
(3R,2S)-3-azido-2-
hydroxyheptane (32b) 
19.6 
(3S,2R)-3-azido-2-
hydroxyheptane (32b) 
20.7 
4-azidohexane-1,5-diol (34a) 
85 °C, 10 min // 5 °C/min // 170 °C, 5 
min // 10 °C/min // 200 °C 
24.3 
4-azidohexane-1,5-diol (34a)  24.6 
5-azidohexane-1,4-diol (34b)  25.1 
5-azidohexane-1,4--diol (34b) 25.2 
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3-azido-4-hydroxyheptane 
(33a) 
80 °C, 10 min // 2 °C/min // 110 °C, 5 
min // 10 °C/min // 200 °C 
22.1 
4-azido-3-hydroxyheptane 
(33b) 
22.1 
4-azido-3-hydroxyheptane 
(33b) 
22.8 
(1S)-azido-1-phenylpropan-
(2R)-ol (35b) 
110 °C, 10 min // 10 °C/min // 165 °C, 
10 min // 5 °C/min // 170 °C, 10 min // 
5 °C/min  // 205 °C 
15.6 
(1R)-azido-1-phenylpropan-
(2S)-ol (35b) 
15.8 
(2R)-azido-1-phenylpropan-
(1S)-ol (35a) 
17.08 
(2S)-azido-1-phenylpropan-
(1R)-ol (35a) 
17.15 
 
Table 14. GC programs used for the analysis of the listed compounds using the columns listed carried out 
at TU Delft. 
Compound Temperature profile RT (min) Column 
trans-2-hexene (1) 
50 °C, 6 min // 30 °C/min // 115 °C, 1 
min // 30 °C/min // 155 °C, 1min // 30 
°C/min // 325 °C 
3.4 
Achiral:CP-sil 5  
trans-2,3-epoxyhexane (21) 5.9 
2-amino-3-hydroxyhexane  (41a) 8.3 
2-azido-3-hydroxyhexane  (31a) 9.6 
trans-2-heptene (1) 
60 °C, 5 min // 30 °C/min // 140 °C, 2 
min// 30 °C/min // 325 °C 
2.9 
trans-2,3-epoxyheptane (22) 3.2 
2-amino-3-hydroxyheptane  (42a) 7.8 
2-azido-3-hydroxyheptane  (32a) 8.8 
 
Table 15. GC programs used for the analysis of the listed compounds using the columns listed carried out 
at Enzymicals. 
Compound Temperature profile RT (min) Column 
trans-2-hexene (1) 
40 °C, 3 min // 20 °C/min// 90 °C 
// 20 °C /min // 180 °C, 2 min 
3 
Achiral: 
BPX5 
trans-2,3-epoxyhexane (21) 4.7 
2-amino-3-hydroxyhexane  (41a) 9.7 
3-amino-2-hydroxyhexane (41b)  9.9 
3-azido-2-hydroxyhexane (31b)  11.3 
2-azido-3-hydroxyhexane  (31a) 11.3 
trans-2-heptene (2) 
70 °C, 3 min // 15 °C/min // 135 
°C, 3 min // 20 °C/min // 180 °C, 
2 min 
2.5 
trans-2,3-epoxyheptane (22) 4.9 
2-amino-3-hydroxyheptane  (42a) 7.4 
3-amino-2-hydroxyheptane (42b)  7.5 
3-azido-2-hydroxyheptane (32b)  10.1 
2-azido-3-hydroxyheptane  (32a) 10.4 
trans-(2S,3S)-epoxyhexane (21) 40 °C, 12 min // 20 °C min-1 // 
180 °C  
11.3 
Chiral: 
HYDRODEX 
β-3p 
trans-(2R,3R)-epoxyhexane (21) 11.9 
trans-(2S,3S)-epoxyheptane (22) 50 °C, 5 min //  2.5 °C min-1 // 60 
°C, 10 min // 20 °C min-1 // 180 
°C 
15.2 
trans-(2R,3R)-epoxyheptane (22) 15.4 
(2S,3R)-2-azido-3-hydroxyhexane (31a) 
70 °C, 20 min // 10 °C min-1 // 
200 °C 
26.6 
Chiral: 
Lipodex G 
(2R,3S)-2-azido-3-hydroxyhexane(31a) 26.7 
(3R,2S)-3-azido-2-hydroxyhexane (31b) 27.1 
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(3S,2R)-3-azido-2-hydroxyhexane (31b) 27.1 
(2S,3R)-2-azido-3-hydroxyheptane (32a) 
85 °C // 0.5 °C min-1 // 95 °C // 
10 °C min-1 // 200 °C 
28.3 
(2R,3S)-2-azido-3-hydroxyheptane(32a) 28.5 
(3R,2S)-3-azido-2-hydroxyheptane (32b) 29.07 
(3S,2R)-3-azido-2-hydroxyheptane (32b) 29.1 
 
GC-MS analysis 
GC-MS analysis of the compounds was performed on a Shimadzu GCMS-QP2010SE 
equipped with a ZB-5MS GUARDIAN column (Phenomenex) or BPX5 and helium as 
carrier gas. 
TLC stains 
Epoxides were stained with Ceric Phosphomolybdic acid stain. The staining solution was 
prepared by mixing 2g Ce(SO4)2 and 5g Phosphomolybdic acid (H3PMo12O40) in 200 ml 
ddH2O and 16 ml cc. H2SO4 which was added at last. The mixture was slightly heated 
up to obtain a clear yellow solution. For visualization, the dry TLC plate was dipped into 
the staining solution and heated using a heat pistol until the characteristic blue spots 
became visible. 
Visualization of azido alcohols and alkenes (not volatile) was carried out using a 
potassium permanganate stain. The stain was prepared by mixing 2.4 g of KMnO4 with 
16 g K2CO3 in 240 ml ddH2O, at last 4 mL of 5% (w/v) NaOH solution was added and the 
solution was mixed until all the potassium permanganate was dissolved. Staining and 
visualization were carried out as described above and yellow-brownish spots became 
visible on the pink background. 
Ninhydrin stain was used for staining amino alcohols. 1 g of ninhydrin were mixed in 100 
mL ethanol and 3 mL acetic acid were added at last. After heating the stained TLC plate 
purple spots became visible. 
NMR analysis 
NMR spectra were recorded either on a Bruker Avance II 300 MHz or on a Bruker Avance 
600 MHz spectrometers equipped with an inverse 1H/13C/15N/31P quadruple resonance 
cryoprobe head and z field gradients. The sample was dissolved in deuterated 
chloroform (CDCl3) and 1D proton, DEPT, COSY double quantum filter, and HSQC 
experiments were performed at 25°C. The regioisomers of chemically synthesised azido 
alcohols 31, 33 and 34 were identified by NMR spectroscopy employing COSY and 
HSQC techniques and further compared to the assignment of regioisomers by GC and 
GC-MS. 
Analytical data of the compounds 
trans-2,3-epoxyhexane (21): 
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1H NMR (300 MHz, CDCl3) δ = 2.74 (qd, J=5.2, 2.3, 1H), 2.63 (td, J=5.4, 2.3, 1H), 1.54 
– 1.40 (m, 1H), 1.29 (d, J=5.2, 1H), 0.95 (t, J=7.1, 1H). 
trans-2,3-epoxyheptane (22): 
1H NMR (300 MHz, CDCl3) δ = 2.74 (qd, J=5.2, 2.3, 1H), 2.62 (td, J=5.5, 2.3, 1H), 1.55 – 1.32 (m, 
2H), 1.29 (d, J=5.2, 1H), 0.91 (t, J=7.1, 1H). 
trans-4,5-epoxyhexanol (23): 
1H NMR (300 MHz, CDCl3) δ = 3.90 (ddd, J=12.5, 5.6, 2.5, 1H), 3.67 – 3.54 (m, 1H), 3.02 – 2.83 
(m, 2H), 1.98 (dd, J=6.9, 5.9, 1H), 1.62 – 1.35 (m, 4H), 0.95 (t, J=7.2, 3H). 
trans-3,4-epoxyheptane (24): 
1H NMR (300 MHz, CDCl3) δ = 2.72 – 2.61 (m, 2H), 1.61 – 1.40 (m, 6H), 0.99 (t, J=7.5, 3H), 0.96 
(t, J=7.2, 3H). 
trans-1-phenylpropylene oxide (25): 
1H NMR (300 MHz, CDCl3) δ = 7.40 – 7.20 (m, 5H), 3.57 (d, J=2.0, 1H), 3.04 (dq, J=5.1, 1H), 1.45 
(d, J=5.1, 3H). 
 
Diastereomeric mixture of 2-azido-3-hydroxyhexane (31a) and 3-azido-2-
hydroxyhexane (31b):  
1H NMR (600 MHz, CDCl3) δ = 3.90 – 3.81 (m, 1H, 31b), 3.65 – 3.58 (m, 1H, 31a), 3.52 
(dq, J=6.7, 3.9, 1H, 31a), 3.42 – 3.35 (m, 1H, 31b), 1.61 – 1.29 (m, 14H, 31a and 31b), 
1.25 (d, J=6.7, 3H, 31a), 1.19 (d, J=6.4, 3H, 31b), 0.96 (t, J=7.2, 3H, 31b), 0.94 (t, J=7.3, 
3H, 31a). 
13C NMR (151 MHz, CDCl3) δ 73.55 (31a), 69.99 (31b), 67.92 (31b), 61.77 (31a), 34.57 
(31a), 32.07 (31b), 19.65 (31b), 18.96 (31a), 18.13 (31b), 13.91 (31a), 13.80 (31b), 
13.11 (31a). 
ESI-HRMS: [M+Na+] = 166.09524 m/z (calculated [M+Na+] = 166.09508 m/z).  
2-azido-3-hydroxyheptane (32a) 
1H NMR (300 MHz, CDCl3) δ = 3.66 – 3.47 (m, 2H), 1.51 – 1.28 (m, 6H), 1.26 (d, J=6.6, 
3H), 0.92 (t, J=7.0, 3H). 
Diastereomeric mixture of 5-azidohexan-1,4-diol (33a) and 4-azidohexan-1,5-diol (33b):  
1H NMR (600 MHz, CDCl3) δ = 3.92 – 3.85 (m, 2H, 33b), 3.82 – 3.60 (m, 33a 3H, 33b 
1H), 3.50 – 3.44 (m, 1H, 33a), 3.42 – 3.40 (m, J=4.98, 1H, 33b), 2.86 (s, 1H, 33a), 2.63 
(s, 1H, 33b), 2.34 (s, 1H, 33a), 2.17 (s, 1H, 33b), 1.65 – 1.34 (m, 8H, 33a and 33b), 0.97 
(t, J=7.0, 3H, 33a), 0.96 (t, J=6.9, 3H, 33b). 
13C NMR (151 MHz, CDCl3) δ 73.80 (33a), 72.39 (33b), 67.04 (33b), 64.64 (33a), 63.33 
(33a), 62.60 (33b), 36.00 (33b), 32.83 (33a), 19.74 (33a), 19.01 (33b), 14.13 (33b), 
14.03 (33a).  
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ESI-HRMS: [M+Na+] = 182.09010 m/z (calculated [M+Na+] = 182.0905 m/z). 
Diastereomeric mixture of 3-azido-4-hydroxyheptane (34a) and 4-azido-3-
hydroxyheptane (34b): 
1H NMR (600 MHz, CDCl3) δ 3.72 – 3.64 (m, 1H, 34a), 3.62 – 3.55 (m, 1H, 34b), 3.42 – 
3.32 (m, 1H, 34b), 3.31 – 3.23 (m, 1H, 34a), 1.73 – 1.31 (m, 14H, 34a and 34b), 1.04 (t, 
J = 7.4 Hz, 3H, 34a), 1.00 (t, J = 7.4 Hz, 3H, 34b), 0.96 (t, J = 7.1 Hz, 3H, 34b), 0.95 (t, 
J = 7.2 Hz, 3H, 34a). 
13C NMR (151 MHz, CDCl3) δ = 75.64 (34b), 73.64 (34a), 69.46 (34a), 67.26 (34b), 34.70 
(34a), 31.74 (34b), 25.58 (34b), 22.90 (34a), 19.93 (34b), 19.20 (34a), 14.20 (34a), 
14.10 (34b), 11.24 (34a), 10.43 (34b).  
ESI-HRMS: [M+Na+] = 180.11081 m/z (calculated [M+Na+] = 180.1112 m/z). 
Obtained NMR data for 10[175,176] were consistent with literature data. 
2-amino-3-hydroxyhexane (41a): 
1H NMR (600 MHz, CDCl3) δ = 3.69 – 3.60 (m, 1H), 3.55 – 3.37 2.74 (m, 3H), 3,15 – 
3.06 (m, 1H), 1.60 – 1.27 (m, 4H), 1.10 (d, J=6.5, 3H), 0.94 (t, J=7.02, 3H). 
13C NMR (151 MHz, CDCl3) δ = 73.04, 50.85, 34.73, 19.31, 15.23, 14.11. 
2-amino-3-hydroxyheptane (42a): 
1H NMR (600 MHz, CDCl3) δ = 3.50 – 3.39 (m, 1H), 3.10 – 2.86 (m, 1H), 1.95 – 1.70 (m, 
3H), 1.55 – 1.18 (m, 6H), 1.01 (d, J=6.39, 3H), 0.91 (t, J=7.02, 3H). 
13C NMR (151 MHz, CDCl3) δ = 76.63, 50.34, 32.14, 28.38, 22.82, 16.77, 14.06. 
 
2.2.4 Biochemical and chemical reactions 
Enzymatic epoxidations 
Bioconversion using cytochrome P450 monooxygenases 
Purified CYP154C5 or CYP154H1 were dissolved in 50 mM potassium phosphate buffer 
pH 7.5 to a final concentration of 3 µM (protein concentration determined by CO-
difference spectroscopy[169]). PdR and Pdx concentrations were fixed to 3 and 16 µM 
respectively to ensure an electron transfer component activity of approximately 1 U/mL 
(determined by cytochrome c assay[170]). The substrate was added from a 500 mM stock 
solution in ethanol to a final concentration of 5 mM and the cofactor NADH (50 μM) was 
added. Formate dehydrogenase from Candida boidinii (0.5 U/mL) and sodium formate 
(150 mM) were applied for cofactor regeneration. The reaction was carried out in a final 
volume of 1.2 mL at 30 °C with magnetic stirring overnight. Finally, a 400 μL sample was 
prepared as described in section 2.2.3. 
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When whole cells were used cell pellets of E. coli C43 (DE3) overexpressing Pdx, PdR 
and CYP154C5 or CYP154H1 were resuspended in 50 mM potassium phosphate buffer 
pH 7.5. 20 mM glucose was added for cofactor regeneration and the reaction was carried 
out in final volume of 1.2 mL at 30 °C with magnetic stirring overnight. Control reactions 
were performed using the same biocatalyst with overexpressed Pdx and PdR only.  
Chemical epoxidation catalysed by MsAct 
The enzyme catalyses the perhydrolysis of a given ester to generate the relative peracid 
and alcohol. The peracid can then perform a spontaneous chemical epoxidation if a 
suitable substrate is present. For this 100 μg of purified MsAct were mixed in 200 mM 
potassium phosphate buffer pH 7.6 with different concentrations of ethyl acetate as ester 
(10, 20 and 30 % v/v) to a final volume of 1 mL. Cyclohexene from a 500 mM stock in 
ethanol was added to a final concentration of 10 mM and urea hydrogen peroxide (UHP) 
was supplemented in different proportions (1, 2, 3, 4, 10 and 2.5 x 4 equivalents) to 
slowly release hydrogen peroxide for the perhydrolysis. After 24 h incubation at 18 °C 
shaking at 900 rpm, 400 μL were taken and the sample was prepared for gas 
chromatography as described in the section 2.2.3. 
Epoxidation catalysed by the unspecific peroxygenase from Agrocybe 
aegerita  
The cell-free extract harbouring the unspecific peroxygenase from A. aegerita (42 μM) 
was kindly provided by Dr. Frank Hollman (TU Delft) and the standard protocol was 
adapted and applied to test trans-2-heptene (2) epoxidation.[63] The enzyme 
concentration was adjusted to 100 nM in 50 mM potassium phosphate buffer pH 7.5, 2 
was added from a 500 mM stock in ethanol to a final concentration of 20 mM. Finally, 
H2O2 was added dropwise over 8 h to a final concentration of 100 mM (5 eq.). After 24 h 
at 30 °C and at 900 rpm shaking, an aliquot was extracted according to the sample 
preparation protocol described previously. 
Styrene monooxygenase 
General whole cells epoxidation 
Small-scale biotransformations (1 mL) were performed in 50 mM potassium phosphate 
buffer at pH 7.5 containing 60 g/L (wet cell weight) of E.coli BL21 harbouring StyAB, 5 
mM substrate (1-2) and 40 mM glucose for cofactor regeneration at 30 °C. When no 
oxygen was used, the reactions were carried out in a 4 mL glass reaction tube with 
magnetic stirring to provide enough oxygen present in atmospheric air. Using an oxygen 
balloon, reactions were carried out in 1.5 mL tube in a thermomixer. The reaction was 
stopped after 1h by incubating a 400 µL sample on ice and by immediately adding 400 
50 
 
µL of TBME containing 0.1% (v/v) dodecane as an internal standard. The sample was 
prepared and analysed by GC as described above. 
Negative controls were carried out by using E.coli BL21 with an empty vector. 
The optimal cellular concentration was determined by adjusting the same cell pellet to 
different concentrations 7.5, 15, 30, 60 and 120 g/L and the activity was determined as 
described in section 2.2.2 (enzyme assays).  
General cell-free extract epoxidation 
The cell-free extract containing StyAB concentration was adjusted to 9.2 g/L (total protein 
content) in 50 mM potassium phosphate buffer at pH 7.5. 5 mM substrate (1 or 2) was 
added and the commercial FDH from C. boidinii (0.5 U/mL) was added with 150 mM 
NaCOOH for cofactor regeneration. The reactions with or without oxygen were 
performed as described in the previous section and the samples for GC analysis were 
prepared as described before. 
General cell-free extract epoxidation using BNAH for cofactor regeneration 
Cell-free extracts of E. coli BL21 harbouring recombinant StyA were dissolved in 50 mM 
potassium phosphate buffer at pH 7.5 to a final concentration of 9.2 g/L (total protein 
content), 5 or 10 mM of either substrate 1 or 2 were added and 2 or 4 equivalents of 
BNAH were added for cofactor regeneration. FADH2 was tested at different 
concentration (50 or 200 µM) to determine the optimal ratio. The reaction was 
magnetically stirred or shacked at 30°C for 1 h and samples taken for GC analysis were 
treated as described above. 
StyA stability was measured leaving concentrated cell-free extracts at 30 °C with 
magnetic stirring for as long as 24 h. At the desired time points the appropriate volume 
was taken and transferred to a new reaction tube containing 10 mM BNAH, 50 µM FADH2 
and 3.5 mM trans-2-heptene (2) (from a 50 mM stock). The reaction was carried out for 
5 min and the activity was measured according to the method described in section 2.2.2 
(enzyme assays). 
Design of Experiment (DOE) 
The experimental design simplifies the optimization of complex systems by creating a 
statistical model of a given reaction. The model needs some inputs (variables’ values) 
and outputs (responses). The aim is to determine which factors are significantly 
contributing to the response values. In this case, four different variables were considered 
(Table 16). The response factor considered was the concentration of epoxide 2 after 2 
h. The design was done using the software RStudio with the DOE plug-in installed. 
Screening was the chosen option in the experimental designs and 8 runs with 4 factors 
and 2 replicates were selected for the design. 
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The reactions were performed in 20 mL 50 mM potassium phosphate buffer at pH 7.5 
with 5 mM trans-2-heptene (2) with magnetic stirring. Glucose was used for cofactor 
regeneration at different concentrations, the rest of the settings used are shown in Table 
16. After 2 h of reaction time, a 400 µL sample was taken and prepared for the analysis 
on gas chromatography. 
Table 16 Factors and values used for low and high settings. *wcw = wet cell weight 
Factor Low setting High setting 
OD600 10 (15 g/L wcw) 40 (60 g/L wcw) 
Glucose 20 mM 100 mM 
Stirring speed 150 rpm 400 rpm 
Temperature 25 °C 30 °C 
 
General epoxidation on 40 mL scale in 50/100 mL round bottom flask 
To a solution of 50 mM potassium phosphate buffer at pH 7.5 and 5 mM substrate (2) 
(final concentration) 15 g/L (wcw) whole cells (E. coli BL21) harbouring StyAB were 
added. 2 or 4 equivalents of glucose were added and the reaction was magnetically 
stirred at 25 °C for 24 h. When applied, oxygen was provided through a double-necked 
round bottom flask where the O2 filled balloon was fitted via a syringe fitting the diameter 
of the flask neck and sealed with PTFE tape. Samples for GC analysis were prepared 
as described before. 
General epoxidation on 80 mL scale in 100 mL Schott bottle 
Epoxidations using CFE of E. coli BL21 harbouring StyAB and LsADH (9.2 g/L, total 
protein content) were carried out in 50 mM potassium phosphate buffer at pH 7.5, trans-
2-hexene (1) or trans-2-heptene (2) was added to a concentration of 50 mM from a 2 M 
stock in isopropanol (used as co-substrate for LsADH). CFE containing LkADH was 
added to a final concentration of 2.6 g/L (total protein content). Compressed air was 
provided through an HPLC frit with a 3 L/h flow. The reaction was mechanically stirred 
with overhead stirring for 24 h at 25 °C. Samples were periodically taken and analysed 
as described before. 
When substrate feed was used, the appropriate amount of the 2 M stock was 
supplemented 5 times every hour until the final 50 mM concentration was reached. 
When LkADH or LsADH were coexpressed only the cell-free extract harbouring StyAB 
and the ADH was used to a final concentration of 9.2 g/L (total protein content). 
When enzyme feed was used, the appropriate amount from the stock CFE solution (75 
g/L, total protein content) was supplement every hour for the first 5 hours until the final 
concentration of 9.2 g/L (total protein content) was reached. When a second organic 
phase was used (25% v/v) 400 µL samples were taken directly from the organic phase 
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containing 0.1% v/v dodecane. Afterwards, the samples were dried over anhydrous 
Na2SO4 and submitted to GC analysis. 
Figure 6 shows the setup where reactions were run. A three-port lid was used to ensure 
correct spacing between overhead stirring and compressed air input. The third port can 
be used for enzyme and substrate feed, for sampling and as exhaust. The 100 mL Schott 
flasks are inside a water bath to maintain the temperature and the air was finely 
dispersed in solution via a porous metal frit used as sparger. The mixer attached to the 
overhead stirrer is positioned slightly higher than the frit to maximize the resident time of 
oxygen in solution. 
 
Figure 6. The setup is composed of 100 mL Schott bottle with a three-port lid where overhead stirring and 
compressed air input can be inserted. The third port can be used for enzyme and substrate feed and for 
sampling. 
 
Oxygen measurements and kinetics 
The oxygen concentration was followed using an optic fibre oxygen sensor from Presens, 
connected to the respective meter (Microx 4, PreSens Precision Sensing GmbH). The 
meter shows the oxygen concentration in different units (µmol/L was chosen) and it was 
calibrated at 25 °C prior to each measurement to ensure accurate measurements. 
Enzyme kinetics towards O2 were determined according to a published protocol.[177] The 
enzyme rate derived from equation 1 (r0). While the oxygen volumetric mass transfer 
coefficient without aeration present (kLa’0) was estimated before starting the kinetics 
experiment using equation 2. 
𝑑𝐶𝑂2
𝑑𝑡
= 𝑘𝐿𝑎′0 ∙ (𝐶𝑂
∗
2
− 𝐶𝑂2) − 𝑟0                 (1) 
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The overall oxygen volumetric mass transfer coefficient was estimated using the same 
reaction set up (4 mL glass reaction tube). The air was removed from 1 mL of 50 mM 
potassium phosphate buffer pH 7.5 containing CFE (2.3 g/L total protein content) using 
an N2 flow until oxygen concentration dropped to 0. Afterwards, the nitrogen flow was 
stopped and the atmospheric oxygen was let flow back in the solution. The O2 
concentration curve over time was used to calculate the overall oxygen volumetric mass 
transfer coefficient (Eq. 2) using non-linear regression analysis. 
𝑑𝐶𝑂2
𝑑𝑡
= 𝑘𝐿𝑎
′ ∙ (𝐶𝑂
∗
2
− 𝐶𝑂2)                            (2) 
When the overall oxygen volumetric mass transfer coefficient is estimated, the 
dependence of StyAB on the oxygen concentration can be determined using equation 1. 
The desired oxygen concentration was adjusted by using nitrogen to remove the proper 
amount of air. When the predetermined O2 concentration was reached the enzyme 
solution was added and the rate at which the oxygen diffuses back in solution was 
measured. Since the oxygen is consumed by the enzyme activity as well it is possible to 
measure its initial rate but subtracting eq. 2 from eq.1. The first part of the curve (linear) 
was used to estimate the enzyme activity. It was appreciable that at lower oxygen 
concentrations the diffusion rate was faster than the enzyme rate. 
Epoxidation on 200 mL scale in 250 mL Schott bottle (100 mM substrate) 
The last scale up set up was similar to the previous protocol where the cell-free extract 
harbouring StyAB and LsADH was hourly fed to a final concentration of 9.2 g/L. 2 M 
stock in isopropanol of alkene 2 was fed hourly to a final concentration of 100 mM. 50 
mM potassium phosphate buffer pH 7.5 was used as buffer and heptane (25% v/v) was 
used as second phase. The reaction was mechanically stirred at 300 rpm in a water bath 
at 25 °C for 24 h. Samples were taken directly from the organic phase containing 0.1% 
v/v dodecane, dried over anhydrous Na2SO4 and submitted to GC analysis. 
Chemical epoxidations 
Jacobsen epoxidation 
The Jacobsen’s catalyst is generally designed for terminal alkenes but as it was readily 
available it was tested using the standard protocol.[40] To 10 mM of trans-2-heptene (2) 
in saturated NaHCO3 pH 8.0 at room temperature, 0.2 equivalents of either (R,R)- or 
(S,S)-Jacobsen’s catalyst were added. 2 equivalents of NaOCl were added in portions 
to support the epoxidation. After 24 h incubation at 900 rpm shaking, a sample of 400 μL 
was taken and prepared and analysed by GC as described before.  
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Shi epoxidation 
The typical Shi epoxidation was done in either 2 or 50 mL scale using different acetonitrile 
concentrations (5, 10 and 20% v/v). The test reaction was carried out in ddH2O to a final 
volume of 2 mL. 2 mM of the Shi epoxidation catalyst were used to convert 10 mM of 
alkene 2 using 2 equivalents of Oxone© added in portions over the first 2h to start the 
catalytic cycle at room temperature for 24 h at 900 rpm shaking, NaHCO3 was added to 
maintain the pH 8.0. The optimization was carried out in 50 mL scale using K2CO3 to 
maintain the pH at 11. Different concentrations of alkene 1 or 2 were used taking care of 
always using 0.2 equivalents of the Shi epoxidation diketal catalyst and 4 equivalents of 
Oxone© added in portions over the first 8 h together with K2CO3 to keep the pH constant. 
At fixed time points, a sample was taken and prepared as described in section sample 
preparation. 
Epoxide ring opening by HHDHs and rational design of HHDHs 
General biotransformation experiment 
Small-scale biotransformations (1 mL) were performed in 50 mM potassium phosphate 
buffer at pH 7.5 containing 150 µg/mL of purified HHDH, 5 mM substrate (21-25) and 20 
mM sodium azide (NaN3) at 25 °C. After 15 h (substrates 21-24) or 4 h (substrate 25) 
incubation samples were taken for GC analysis. Chemical background azidolysis was 
monitored in reactions using the same reaction conditions but omitting HHDH enzyme. 
Alternatively, whole cells (60 g/L wet cell weight) or cell-free extract (9.2 g/L total protein 
content) of E. coli BL21 harbouring the desired HHDH were used to convert 10 mM or 
higher concentrations (50-300 mM) with respectively 40 mM or 2 equivalents of NaN3 at 
25 °C. Generally, after 4h and 24 h, a sample was taken and extracted as described 
above. 
For conversions of cyclohexene oxide or 2-chlorocyclohexanol 20 mM of each substrate 
were used with 40 mM NaN3 or NaCN as nucleophile. The catalyst containing HheG and 
the different mutants was used as whole cells (60 g/L wet cell weight) in 50 mM Tris∙SO4 
pH 8 in a final volume of 2 mL. The reactions were incubated at 22 °C and mixed with 
magnetic stirring at 500 rpm. At different time points, 400 µL samples were taken and 
analysed by gas chromatography. 
Preparative scale biotransformation 
Preparative-scale conversions of 21 and 22 were performed in 40 mL of 50 mM 
potassium phosphate buffer at pH 7.5. Whole cells of E. coli BL21 harbouring either 
HheE or HheE5 (60 g/L wet cell weight) were used to convert 50 mM of either 21 or 22 
and 100 mM sodium azide (NaN3) were used as nucleophile. After 24 h at 25 °C the 
reaction mixture was extracted with 40 mL TBME and filtered through Celite®. The 
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extracted organic layer was washed with brine (1×) and MilliQ water (1×), dried over 
Na2SO4 and filtered before solvent evaporation. 142 mg (50% yield) of 31a and 151 mg 
(48% yield) of 32a were recovered after column chromatography using 
cyclohexane/diethyl ether, 90:10.  
Docking studies 
Molecular docking of MM2-force field energy minimized (S,S)-, (R,R)-21-25 into the 
active site of a monomeric representation of HheC (PDB-ID: 1ZMT) HheD2 
(unpublished) and HheG (PDB-ID: 5O30) was performed using the AutoDockVina 
algorithm present in YASARA Structure.[143,144] All ten substrates were docked into a 
simulation cell (X size = 25 Å, Y size = 25 Å, Z size = 25 Å; angles: α = 90°, β = 90°, γ 
=90°) around the following four residues: K91, L155, E197 and E216 for HheC the 
corresponding residues L96, Y160, K198 and E218 for HheD2 and the corresponding 
residues, D111, I175, E214 and E233 in HheG. For each substrate, 999 docking runs 
were performed while all atoms of the corresponding substrates were set as rigid with 
the only exception of substrate 3 and HheG where a flexible ligand was necessary to 
obtain one cluster with productive bind. The structure for each cluster was then energy 
minimized using YASARA2-force field after inserting the molecule of water as fixed 
element. This water molecule represents the nucleophile in its binding pocket and it is 
present in the respective crystal structures. 
In-silico mutagenesis 
The “coupled moves” protocol allows the user to improve the enzyme-ligand interaction 
of a given structure or to radically change the substrate specificity by manually docking 
a non-natural substrate into the enzyme active site.[149] As there is no available crystal 
structure of HheG with bound substrate or nucleophile in the active site, the cyclohexene 
oxide, and (1S,2R)-2-cyanocyclohexanol were manually docked using available HheC 
crystal structures with styrene oxide or (R)-4-cyano-3-hydroxybutyrate in the active site. 
In detail, the respective ligands were aligned taking care to overlap the important 
moieties (i.e. epoxide ring, OH- and CN- groups) to the known crystal after 
superimposition of HheG over HheC co-crystallised with the substrate (1ZMT for styrene 
oxide and 4IXT for (1S,2R)-2-cyanocyclohexanol). The ligand rotamer library was 
generated by the free online tool Frog2[178] with default options, as these are rigid ligands 
and only one rotamer was generated. The same published setting[149] (command line) to 
run the coupled moves were used and are reported below:  
~/Rosetta/main/source/bin/coupled_moves.linuxgccrelease  
–s pdb_file –resfile res_file –database ~/Rosetta/main/database –mute 
protocols.backrub.BackrubMover –extra_res_fa params_file –ex1 –ex2  
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–extrachi_cutoff 0 –nstruct 20 –coupled_moves::mc_kt 0.6 –coupled_moves::ntrials 
1000 –coupled_moves::initial_repack false –coupled_moves::ligand_mode true   
–coupled_moves::ligand_weight N 
The assisted mutagenesis produces typically 2000 unique sequences that were 
combined into a single FASTA file and submitted to the online tool WebLogo for 
visualization.[179] 
Hydrogenation 
Azides hydrogenation using heterogeneous palladium catalyst kit I 
2-azido-3-hydroxyhexane (31a) or 2-azido-3-hydroxyheptane (32a) was dissolved in 4 
mL of methanol containing 0.1% dodecane as internal standard to a final concentration 
of 5 mM, palladium on the different supports (1 mg/mL) was added and hydrogen was 
bubbled in the reaction mixture for 5 min prior to close the vial with the lid pierced by a 
needle with the H2 balloon attached. After 30 and 60 min, an aliquot of 400 µL was taken, 
dried over MgSO4 and directly submitted to GC analysis. 
Preparation of Pd@apoferritin nanoparticles 
Apoferritin from horse spleen (AFHS, Sigma Aldrich) was dissolved in EPPS buffer (100 
mM EPPS, 10 mM NaCl, pH 8) to a concentration of 5 mg/mL. K2PdCl4 stock solution 
(50 mM in EPPS buffer) was added dropwise until the ratio with the 24er (number of 
AFHS monomers required for the assembly of the cage to store iron) was 250. The 
mixture was stirred overnight at room temperature to allow the Pd to diffuse inside the 
apoferritin complex. Afterwards, the palladium in excess was removed using a PD-10 
column and the nanoparticles were formed by reducing Pd2+ using H2. At first, hydrogen 
was bubbled through the yellowish solution for 15 min to remove all the oxygen present 
and subsequently the reaction was stirred for additional 2 h with the hydrogen balloon 
still connected but with the lid screwed to avoid bubbling. The nanoparticle formation can 
be appreciated as the liquid gradually turn dark grey testifying palladium aggregation. 
The nanoparticles were stored at 4 °C in a sealed tube. 
The microscopic characterization was kindly carried out by Dr. Wuyuan Zhang (TU Delft) 
diluting the samples ten times with ddH2O and using uranyl acetate as stain to allow 
visualization with TEM. 
The hydrogenation was carried out by dissolving azide 32a in 50 mM potassium 
phosphate buffer pH 7.5 to a final concentration of 10 mM and the proper amount of 
nanoparticles to have 3.5 µM of Pd was added. Hydrogen was bubbled for the first 5 min 
to remove all the oxygen present and subsequently the reaction was stirred for additional 
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48 h with the hydrogen balloon still connected but with the lid screwed. Samples were 
taken after 4, 24 and 48 h and treated as described previously prior to GC analysis. 
Cascade reactions 
Peak assignment of the diastereoisomers of the azido alcohols (31, 32, 35) 
The assignment of the four peaks deriving from the unselective azidolysis of epoxides 
(21, 22 and 25) was achieved by conversion of enantiopure (S,S)-21, (S,S)-22, (S,S)-25 
and (R,R)-25 using each a regioselective and a non-regioselective HHDH. To do this, 
HheG and HheD5 were used as non-stereoselective HHDH while HheE and HheE5 were 
used as regioselective enzymes. (S,S)-21 and (S,S)-22 were selectively produced in 50 
mM potassium phosphate buffer at pH 7.5  by using CFE harbouring StyAB and FDH as 
cofactor regeneration  (as described previously). After 24 h reaction, 150 µg/mL HHDH 
and 20 mM sodium azide at 25 °C were added. After 15 h, 400 µL sample was taken 
and prepared for GC analysis. By using non-regioselective enzymes (HheG for 21 and 
HheD5 for 22), (2R,3S)-31a, (2S,3R)-31b, (2R,3S)-32a and (2S,3R)-32b were produced 
while only (2R,3S)-31a and (2R,3S)-32a were produced by using regioselective HHDH 
(HheE for 21 and HheE5 for 22). GC-MS analysis of the same material was performed 
to assign the different regioisomers of 31 and 32.  
A similar strategy was used to assign the peaks of azido alcohols 35a and 35b. This 
time, (S,S)-25 and (R,R)-25 were commercially available. The azidolysis of (S,S)-25  to 
an excess of (1R,2S)-1-azido-1-phenylpropan-2-ol (35b) next to a small amount of 
(1S,2R)-2-azido-1-phenylpropan-1-ol (35a) while ring-opening of the opposite 
enantiomer (R,R)-25 generated (1S,2R)-1-azido-1-phenylpropan-2-ol (35b) in excess 
and a small amount of (1R,2S)-2-azido-1-phenylpropan-1-ol (35a) due to the SN2-type 
mechanism and the observed regioselectivity of the chemical azidolysis. 
Catalysts cross-interactions  
Epoxide ring opening in presence of heptane  
The influence of heptane (25% v/v) on the halohydrin dehalogenase was tested in 50 
mM potassium phosphate buffer at pH 7.5. 10 mM substrate (21 or 22) and 50 mM 
sodium azide (NaN3) were added and the solution was magnetically stirred at 25 °C, 600 
rpm. After 4h and 15 h incubation, samples were taken for GC analysis. The biocatalyst 
was used as whole cells (60 g/L wet cell weight) harbouring HheE (substrate 21) or 
HheE5 (substrate 22). 
Epoxide ring opening in presence of acetonitrile and Oxone© 
The influence of acetonitrile (5%, 10% or 20 % v/v) and Oxone (50 mM or 10 mM) on the 
halohydrin dehalogenases was tested in 50 mM potassium phosphate buffer at pH 7.5. 
10 mM substrate (21 or 22 respectively for HheE and HheE5) and 40 mM sodium azide 
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(NaN3) were added and the solution was magnetically stirred at 25 °C, 600 rpm. After 4 
and 15 h incubation, samples were taken for GC analysis. The biocatalysts were used 
as whole cells (60 g/L wet cell weight) or cell-free extract (9.2 g/L total protein content) 
harbouring HheE (substrate 21) or HheE5 (substrate 22). 
Epoxidation and ring opening in presence of Pd/C 
The effects of Pd/C on the epoxidation carried out by the styrene monooxygenase was 
carried out by adding 1 mg/mL of heterogeneous catalyst to the epoxidation reactions 
carried out in 1 mL scale of either 50 mM potassium phosphate buffer pH 7.5. Whole 
cells (30 g/L wcw) or cell-free extract (4.6 g/L total protein content) harbouring 
respectively StyAB and StyA were used as catalyst to convert 5 mM of alkene 2 and 
respectively glucose and BNAH were use as cofactor regeneration. After 1 h, the reaction 
was sampled for GC analysis as described before. 
1 mg/mL of Pd/C was also added to a solution where whole cells harbouring HheE5 (60 
g/L wet cell weight) and 5 mM of epoxide 22 were present. 20 mM of NaN3 was 
supplemented as nucleophile and the reactions were carried out for 1h at 25 °C in a 
thermomixer at 800 rpm. After 1 h, the reactions were sampled for GC analysis as 
described before. 
Compatibility of the hydrogenation catalyst with the enzyme catalysts 
The effect of the presence of cell-free extract, whole cells, BNAH and FADH2 was studied 
as well. The hydrogenation was performed in 50 mM potassium phosphate buffer pH 7.5 
where Pd/C (1 mg/mL) with 5 mM of racemic 2-azido-3-hydroxyheptane (32a) as 
substrate. In separate experiments Cell-free extract (4.6 g/L total protein content), whole 
cells (60 g/L wcw) BNAH (10 mM) and FADH2 (200 µM) were added to assess to which 
extent the reaction is slowed down.  After 15, 30 and 60 min an aliquot of 400 µL was 
taken and 10 µL of a solution of 250 mM KOH were added. The sample was extracted 
with the same volume of tert-butylmethylether (TBME) containing 0.1 % v/v dodecane 
as internal standard. The resulting organic phase was dried over anhydrous MgSO4 prior 
to injection on GC. 
Cascade reaction using StyAB, HHDH and Pd/C 
The epoxidation of trans-2-heptene (2) (fed hourly to a final concentration of 20 mM) was 
carried out in 60 mL (+20 mL of heptane) of 50 mM potassium phosphate buffer pH 7.5. 
CFE harbouring StyAB and LsADH was added hourly to a final concentration of 9.2 g/L 
(total protein content). After 24 h, cell-free extract containing HheE5 and 50 mM of 
sodium azide was added in one portion to start the epoxide ring opening. After 48 h of 
total reaction time, Pd/C was added (2 mg/mL) and 3 equivalents of triethylsilane (TES) 
were supplemented in portions over 8 h to generate H2 in situ. After 72 h of reaction, the 
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mixture was basified to pH 14 using NaOH pads and saturated with NaCl, the reaction 
mixture was divided into four falcon tubes and extracted 4 times with TBME. The phases 
were separated by centrifuging 2 min at 6000 rpm. The organic layers were combined, 
dried over anhydrous Na2SO4 and the solvent was removed in vacuum. The enantiopure 
(2R,3S)-2-amino-3-hydroxyheptane (42a) was purified by column chromatography as 
described previously yielding 3.8 mg of pure product (2.4% isolated yield). 
Alternatively, giving the low yield of the full cascade the last step was separated. The 
first 48 h of the cascade were performed as described above using either HheE or HheE5 
if alkene 1 or 2, respectively were used as substrates in the first step. Afterwards, the 
reaction mixture was basified and saturated with NaCl. The mixture was divided into four 
falcon tubes and extracted 4 times with TBME. The phases were separated by 
centrifugation for 2 min at 6000 rpm. The organic layers were combined, dried over 
anhydrous Na2SO4 and the solvent was removed in vacuum. The crude extract was 
either submitted to column chromatography to purify enantiopure (2R,3S)-2-azido-3-
hydroxyhexane (41a) or (2R,3S)-2-azido-3-hydroxyheptane (42a) or dissolved in 20 mL 
methanol for further reduction. The reduction was performed at RT and magnetically 
stirred at 500 rpm, hydrazine (100 mM) was added dropwise to prevent the generation 
of heat. After approx. 4 h the reaction mixture was filtered through Celite® and the 
solvent was removed in vacuum. The pure amino alcohols were obtained by column 
chromatography using a mixture of chloroform:methanol:ammonia (90:9:1). 
Cascade reaction using Shi epoxidation diketal catalyst, HHDH and Pd/C 
The first step was carried out at -2 °C in 47.5 mL ddH2O with 2.5 mL of acetonitrile (5% 
v/v). 0.2 equivalents of Shi epoxidation were used to convert 50 mM of alkene 2. 4 
equivalents of Oxone© were added in portions over the first 8 h and solid K2CO3 was 
used to maintain the pH at 11 after addition of Oxone©. After incubation for 24 h at 300 
rpm, the temperature was adjusted to 25 °C before lowering the pH to 7.5 using 95 % 
H2SO4. After the reaction conditions were adjusted, whole cells (60 g/L wcw) harbouring 
HheE5 were added together with 50 mM of NaN3 and the reaction was continued for 
additional 24 h. After 48 h of total reaction time, Pd/C was added (2 mg/mL) and 3 
equivalents of triethylsilane (TES) were supplemented in portions over 8 h to generate 
H2 in situ. After 72 h of reaction, the mixture was basified to pH 14 using NaOH pads and 
saturated with NaCl, the reaction mixture was divided into four falcon tubes and extracted 
4 times with TBME. The phases were separated by centrifuging 2 min at 6000 rpm. The 
organic layers were combined, dried over anhydrous Na2SO4 and the solvent was 
removed in vacuum. The enantiopure (2S,3R)-2-amino-3-hydroxyheptane (42a) was 
purified by column chromatography as described previously yielding 10.9 mg of pure 
product (3% isolated yield). 
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As for the cascade where StyAB is used in the first step, it was necessary to separate 
the hydrogenation giving the low yield of the complete cascade. The first 48 h of the 
cascade were performed as described above taking care of using the correct HHDH 
depending on the substrate used in the epoxidation. Afterwards, the reaction mixture 
was basified saturated with NaCl. The mixture was divided into four falcon tubes and 
extracted 4 times with TBME. The phases were separated by centrifugation for 2 min at 
6000 rpm. The organic layers were combined, dried over anhydrous Na2SO4 and the 
solvent was removed in vacuum. The crude extract was either submitted to column 
chromatography to afford (2S,3R)-2-azido-3-hydroxyhexane (41a) or (2S,3R)-2-azido-3-
hydroxyheptane (42a) with a fairly good ee% or dissolved in 20 mL methanol for further 
reduction. The reduction was performed at RT and magnetically stirred at 500 rpm, 
hydrazine (100 mM) was added dropwise to prevent the generation of heat. After 
approx.4 h the reaction mixture was filtered through Celite® and the solvent was 
removed in vacuum. The pure amino alcohols were obtained by column chromatography 
using a mixture of chloroform:methanol:ammonia (90:9:1). 
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3. Results 
This chapter is divided into two main sections; the first section (section 3.1) presents the 
data concerning the setup and optimization of two cascades converting linear alkenes to 
the corresponding aminoalcohols. Section 3.2 deals with a third cascade starting from a 
cyclic alkene. All cascades are composed of three steps: epoxidation, epoxide ring 
opening using azide as nucleophile and hydrogenation of the azido group. All alkenes 
substrates and corresponding epoxides, azido alcohols and aminoalcohols used in this 
work are visible in Table 17. 
Table 17. List of compounds used in this work. 
 
Alkenes Epoxides Azido alcohols Amino alcohols 
 
(1) trans-2-
hexene 
 
(21) trans-
2,3-
epoxyhexan
e 
 
(31a) 2-azido-3-hydroxyhexane, (31b) 
3-azido-2-hydroxyhexane 
  
(41a) 2-amino-3-hydroxyhexane, 
(41b) 3-amino-2-hydroxyhexane 
 
(2) trans-2-heptene 
 
(22) trans-2,3-
epoxyheptane 
 
(32a) 2-azido-3-hydroxyheptane, (32b) 
3-azido-2-hydroxyheptane 
  
(42a) 2-amino-3-hydroxyheptane, 
(42b) 3-amino-2-hydroxyheptane 
 
(3) trans-4-hexen-1-
ol 
 
(23) trans-4,5-
epoxyhexanol 
 
(33a) 5-azidohexane-1,4-diol, (33b) 4-
azidohexane-1,5-diol 
  
(43a) 5-aminohexane-1,4-diol, 
(43b) 4-aminohexane-1,5-diol 
 
(4) trans-4-heptene 
 
(24) trans-3,4-
epoxyheptane 
 
(34a) 3-azido-4-hydroxyheptane, (34b) 
4-azido-3- hydroxyheptane 
  
(44a) 3-amino-4-hydroxyheptane, 
(44b) 4-amino-3-hydroxyheptane 
 
(5) trans-β-methyl 
styrene 
 
(25) trans-1-
phenylpropylene 
oxide 
 
(35a) 2-azido-1-phenylpropan-1-ol, 
(35b) 1-azido-1-phenylpropan-2-ol 
  
(45a) 2-amino-1-phenylpropan-1-ol     
(45b) 1-amino-1-phenylpropan-2-ol 
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3.1 Cascades starting from acyclic alkenes 
3.1.1 First step: Epoxidation of vicinally di-substituted alkenes 
3.1.1.1 Cloning of styrene monooxygenase from Rhodococcus sp. ST-10 
Previous characterization of the styrene monooxygenase from Rhodococcus sp. ST-10 
demonstrated significant activity of this enzyme on the chosen substrates (1 and 2).[68] 
Therefore, codon-optimized synthetic genes coding for the two subunits, StyA and StyB, 
have been ordered from the company GeneArt (Thermo Fisher Scientific division) for 
expression in Escherichia coli. The pETDuet vector was selected as expression vector 
as it harbours two multiple cloning sites (MSC). Both MSCs are controlled by the E. coli–
bacteriophage T7 RNA polymerase/promoter.[180] StyA and styB genes were ordered as 
a 5’-fusion construct (Figure 7) with a single NdeI restriction site in between. Moreover, 
the HindIII restriction site at the 3’ end of styA was present two times in the pETDuet 
vector. Hence, the best cloning strategy (Figure 7) was to modify the restriction sites at 
both styA ends by PCR. The styB gene was first cloned into the MSC-2 using NdeI and 
XhoI as restriction enzymes. After transformation of chemically competent E.coli DH5α, 
the successful insertion was verified by colony PCR (Figure 8, C) and sequencing. At 
the same time, styA was amplified via PCR to change the NdeI restriction site at the 5’ 
end to NcoI and the HindIII restriction site at the 3’ end to BamHI. The styA gene and 
pETDuet with styB present in MSC-2 were both double digested with the above-
mentioned restriction enzymes and ligated in two different cloning experiments. After 
transformation into chemically competent E.coli DH5α, successful insertion was verified 
by colony PCR (Figure 8, B) and sequencing. Additionally, digestion of the newly 
generated pETDuet-styAB using NdeI, XhoI, NcoI and BamHI as restriction enzymes 
was performed to ensure the presence of both genes (Figure 8, A). 
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Figure 7. Cloning of styA and styB in MSC-1 and MSC-2, respectively, of the pETDuet expression vector. 
Restriction sites of styA were modified by PCR using primers with a mismatch to fit the corresponding 
endonucleases. 
 
In Figure 8 (A), the result of the digestion using purified vectors from three different 
clones is presented. Digested vectors of clones 6 and 7 show visible bands at the 
expected sizes (1.2 kb for sytA and 0.5 kb for styB) and therefore, both were submitted 
to sequencing for validation. Additionally, styA was also sub-cloned into the pRSFDuet-
1 with styB already present in its MSC-2. This time, styA was cut from pETDuet-styAB 
using NcoI and BamHI as restriction enzymes and inserted in pRSFDuet-styB cut with 
the same set of enzymes. This additional vector was created to co-express StyAB with 
the alcohol dehydrogenase from Lactobacillus kefir (LkADH) encoded on a pET21(+) 
vector. Moreover, the alcohol dehydrogenase from Leifsonia sp. S749 (LsADH) was also 
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tested since it had been reported as a regeneration system for StyAB.[68,85] Hence, the 
LsADH-encoding gene was ordered cloned in the pCDF-Duet-1 vector as it would be 
compatible with both pETDuet and pRSFDuet-1 vectors both containing styA and styB. 
 
 
Figure 8. Gel A shows the digestion on three different colonies using NdeI, XhoI, NcoI and BamHI as 
restriction enzymes. Line “D” shows the digested samples and around 1.2 kb, styA is substantially more 
visible than the styB’s band (0.5 kb). Lines “P” and “-“ both represent the undigested plasmid although on 
the “-“ samples the digestion buffer was also added to control for possible DNase contaminations. The 
successful insertion of styA in pETDuet-styB verified by colony PCR is shown in gel B. Gel C shows the 
colony PCR to confirm the insertion of styB. A stronger band at 1 kb and a faint band at 750 kb due to the 
forward primer that binds in the T7 promoter area of both MSC verify successful insertion. 
 
3.1.1.2 Expression of styrene monooxygenase from Rhodococcus sp. ST-
10 
Different conditions for the heterologous expression of StyAB were tested to achieve 
best expression levels and simultaneously ensuring the highest activity. E.coli BL21 
(DE3) and E. coli C43 (DE3) were used as expression hosts. Expression using BL21 
(DE3) cells was carried out at 20 °C, whereas for C43 (DE3) 25 °C and 30 °C were 
tested. Additionally, both Luria-Bertani (LB) as well as Terrific Broth (TB) media were 
tested to analyse a possible influence on the expression. Lastly, the expression of StyAB 
in presence or absence of the chaperones was studied. To do this, the expression of 
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styrene monooxygenase was carried out with a second plasmid encoding the chaperone 
proteins (pG-KJE8).[74] 
Two exemplary SDS-PAGE gels of StyAB expression are shown in Figure 9 together 
with the corresponding StyAB activities (Table 18). The activity was determined by 
measuring the epoxide formation over 5 min as described by Panke et al.,[78] in this case 
trans-2-heptene was used as substrate instead of styrene. 
 
 
Figure 9. Exemplary gels showing the expression levels of StyAB in E.coli BL21 (DE3) (A) and E.coli C43 
(DE3) (B). The table shows the activity measured for the different combinations of strain, temperature and 
IPTG concentration. The activity was measured determining the trans-2,3-epoxyheptane formation over 5 
min.[78] All measurements were performed using whole cells with a concentration of 60 g/L (wet cell weight). 
 
Overall, higher StyAB activity was obtained for expression in E. coli BL21 (DE3). 
Furthermore, co-expression of chaperons from vector pG-KJE8 had a positive effect on 
enzyme activity, perhaps allowing more StyB to be correctly folded during expression. 
However, the difference in activity between the samples with and without chaperones is 
not as remarkable as for the influence of the chosen expression host. Here, 2-fold higher 
activity was obtained with BL21 (DE3) as host. In contrast, increasing the IPTG 
concentration from 0.2 mM to 0.5 mM gave no or only a very limited improvement in 
activity. The best expression was achieved with E. coli BL21 (DE3) as host at 20 °C 
using 0.2 mM IPTG for induction. Co-expression of the chaperones did not appear crucial 
for StyAB expression even though slightly higher activities could be obtained. 
 
 
 
 
 
 
Table 18. The best expression conditions of StyAB were determined using different expression host, 
temperature, IPTG concentration and presence of chaperon system 
Strain Catalyst T (°C) 
[IPTG] 
(mM) 
mU 
mU/mg (wet 
cell weight) 
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C43 StyAB, 25 0.5 59.7 0.995 
C43 StyAB + pG-KJE8 25 0.5 75.52 1.26 
C43 StyAB 30 0.5 79.18 1.32 
C43 StyAB + pG-KJE8 30 0.5 82.84 1.38 
BL21 StyAB 20 0.2 178.3 2.97 
BL21 StyAB + pG-KJE8 20 0.2 180.2 3.00 
BL21 StyAB 20 0.5 180.6 3.01 
BL21 StyAB + pG-KJE8 20 0.5 168.6 2.81 
 (1 U = 1 μmol/min) 
 
In addition, co-expression of StyAB with a cofactor regeneration system was tested to 
provide sufficient NADH for biocatalytic reactions. As mentioned previously, two different 
ADHs were ordered as synthetic genes to test the encoded proteins for cofactor 
regeneration. LkADH appears to have a higher overexpression compared to LsADH 
(Figure 10). On the other hand, more StyAB seems to be present when co-expressed 
together with LsADH from the pETDuet vector. Likely, the high overexpression of LkADH 
has a direct negative effect on the monooxygenase expression. In contrast, a more 
balanced expression was obtained for StyAB and LsADH co-expression, especially 
when the pETDuet vector was used to express the monooxygenase. With these data in 
hand, the co-expression of StyAB and LsADH from pETDuet and pCDFDuet-1, 
respectively, was tested in a 2 L bioreactor. 
 
Figure 10. Exemplary gels showing the expression levels of StyA (45kDa) and StyB (not visible) and relative 
ADH (LkADH 26 kDa, LsADH 26.5 kDa) in different expression vectors. LkADH expresses significantly better 
but at the same time, it suppresses StyA expression. 
The use of a bioreactor compared to a shake flask allows fine-tuning of several 
parameters. For example, it is possible to maintain a desired dissolved oxygen 
concentration (e.g. 30%) and setting the agitation speed and air input dependent on this 
value. This generally results in a gradual increase of the agitation speed directly 
dependent on the cellular concentration giving that biomass consumes more oxygen as 
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it grows. The gradual increase in agitation speed over time can be used as proof of the 
cells’ growth and; it is also possible to maintain the pH constant to the desired level by 
titrating either a base or acid solution when the pH is higher or lower than the set value 
respectively. StyAB and LsADH were coexpressed in E. coli BL21 (DE3) at 20 °C using 
0.2 mM of IPTG as determined in shake flask experiments (Table 18). In a typical 
experiment with E. coli BL21 (DE3), the dissolved oxygen is set constant to 30 %, 
agitation speed starts at 200 rpm and it can increase until 800 rpm to maintain the dO2 
level. 800 rpm is the maximum speed at which the bacteria can still withstand the 
mechanical stress. After this value is reached, the airflow volume, typically depending on 
the culture volume (e.g. 1.5 L/h for 1.8 L culture), starts to increase. Figure 11 shows the 
time course of two fermentations and in both cases, the agitation speed increased to 
maintain a dO2 level of 30%. The agitation speed first reached a plateau and then 
decreased in correspondence of the stationary phase due to a slower cellular metabolism 
caused by nutrients depletion. In both runs, the maximum obtained OD600 was around 
20. The activity was measured during the course of the fermentation to determine an 
optimal time to harvest the cells. The activity was measured by monitoring the product 
formation by GC after 5 min (as mentioned previously); in this case, cell-free extract was 
used instead of whole cells. Highest epoxidation activity was reached in early-stationary 
phase (Table 19, Fermentation A, t=12 h induction time). The activity appears to 
decrease as the bacteria enter the stationary phase and therefore the harvest should be 
planned accordingly to maximise cellular concentration and activity. 
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Figure 11. Fermentation graphs of the two expressions run. Important parameters are continuously recorded 
during the run. The green line (dissolved oxygen) stayed relatively stable around 30% while the stirring 
speed (black line) increased until the stationary phase (10-12h). Samples were taken at fixed times (Table 
19) to measure the activity in the epoxidation of trans-2-heptene. 
 
Table 19. Activity and final OD600 data corresponding the fermentation graphs shown in Figure 11. Samples 
were taken at different times after induction and the activity was measured by product formation over 5 min 
using CFE. 
 
 
A 
B 
Fermentation Induction time OD600 mU/mg (total protein content) 
A 12h 18.72 5.97 ± 0.012 
A 16h 22.8 4.83 ± 0.01 
A 21h 20.2 4.48 ± 0.009 
B 3h 4.5 4.29 ± 0.009 
B 18h 19.0 5.59 ± 0.011 
 = (1U= 1 μmol/min)  
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3.1.1.3 Expression and purification of the cytochrome P450 
monooxygenases CYP154H1 from Thermobifida fusca and CYP154C5 from 
Nocardia farcinica as well as respective electron transfer components 
The styrene monooxygenase from Rhodococcus sp. ST-10 was not the only 
monooxygenase tested in the conversion of the selected substrates. Two cytochrome 
P450s, CYP154H1 from Thermobifida fusca and CYP154C5 from Nocardia farcinica, 
were expressed and purified together with putidaredoxin (Pdx) and putidaredoxin 
reductase (PdR) from Pseudomonas putida as electron transfer components using an 
established protocol.[159,181] E. coli C43 (DE3) was used as expression host as 
demonstrated previously and additionally, each cytochrome P450 was coexpressed with 
PdR and Pdx to test in whole cell biocatalysis experiment. Both monooxygenases carried 
an N-terminal His-tag, hence the purification was carried out via immobilized metal 
affinity chromatography (IMAC) using a Ni-NTA column connected to an FPLC system 
(Äkta). The chromatogram and SDS-PAGE gel of the purification of CYP154C5 are 
shown in Figure 12 as an example purification. The green line shows the progress of the 
gradient used for the elution. For the gradient, a solution with a high imidazole 
concentration (500 mM) is mixed in increasing quantities with the equilibration buffer (30 
mM imidazole). Imidazole competes with the histidines in the his-tag of the target protein 
in binding the metal in the column causing the protein to elute. Non-target proteins elute 
directly after the column is loaded, as visible in the large peak at the beginning of the 
chromatogram in Figure 12 (blue line). The target protein started to elute from the column 
at approximatively 170 mM imidazole concentration (30% of the gradient). 
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Figure 12. Typical purification chromatogram of a His-tagged protein where almost the total content of non-
tagged protein in the cell-free extract elutes in the first fractions while the target protein starts eluting only 
after the imidazole concertation increases (UV signal, light blue line). The chromatogram shows the 
imidazole concentration in % (green line) of the highest concentrated buffer relative to the solution used to 
equilibrate the column. In the gel, only the fractions containing the target protein are shown. All fractions 
appear to be clean except a small band visible around 14.4 kDa. 
 
Only the fractions of the elution of the target protein (~45 kDa) are shown in the gel in 
Figure 12). All fractions appeared clean except for a small band visible around 14.4 kDa. 
It was possible to follow the progression of the purification of all cytochromes P450 due 
to the characteristic red-brown colour of the P450s caused by the heme prosthetic group. 
Final pure protein yields were for CYP154H1 and CYP154C5 52 and 43 mg/L (mg per 
litre of culture), respectively. The concentration of both cytochromes was determined by 
CO-difference spectroscopy measuring the absorbance maximum of CO-bound 
CYP154C5 or CYP154H1 at 450 nm (ε450= 91 mM-1 cm-1).[169] In contrast, the electron 
transfer components PdX and PdR were expressed without any affinity tag and they 
required a different purification strategy. PdR purification was carried out in two steps (I) 
anion exchange (AIXC) and (II) hydrophobic interaction (HIC) chromatography, while for 
Pdx purification, the strategy was to combine anion exchange chromatography with an 
ultrafiltration step using a 30 kDa cut-off membrane to remove larger proteins. Figure 13 
shows the chromatograms of PdR purification, in the first step a Q-Sepharose FF ion 
exchange column was used and the progression of the purification was followed by the 
characteristic yellow colour that indicates the presence of the FAD cofactor. A good 
[Imidazole] 
gradient 
start 
CYP154C5 
elution 
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amount of the E. coli proteins was eliminated in the first step as visible in the first 
chromatogram in Figure 13. In the second step, a Phenyl-Sepharose FF hydrophobic 
interaction matrix was used to complete the purification and obtain a clean single band 
in the SDS-PAGE gel (Figure 13). 
 
Figure 13. Two steps purification of PdR. The first chromatogram shows the anion exchange purification 
(AIXC, first step) where PdR started to elute at 350 mM KCl (70% of the gradient). The second chromatogram 
(HIC) shows the hydrophobic interaction purification (second step) where PdR started to elute at about 1.12 
M KCl (15% of the gradient). The gel picture shows that the second step is needed to afford the reductase 
in pure form. After the AIXC step, some impurities from the cellular proteome are still present as shown in 
the line “Q-seph”. 
 
The concentration of pure PdR was determined by measuring the absorbance at 454 nm 
(ε455=10.0 mM-1 cm-1).[170] After concentration by ultrafiltration with a 30 kDa cut-off 
membrane, the purification yielded 82 mg/L culture. As mentioned before, Pdx was 
purified in two steps whereas the first purification was the same as for PdR, anion 
exchange chromatography using Q-Sepharose FF as matrix. The second step was 
ultrafiltration using a 30 kDa cut-off membrane. This step was used to filter out the larger 
proteins, while Pdx having a molecular weight around 11 kDa could pass through. The 
flow-through can then be concentrated with a 10 kDa cut-off membrane. Figure 14 shows 
that many of the impurities were eliminated in the first purification step and several peaks 
PdR 
AIXC 
HIC 
PdR 
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preceding the target protein can be seen in the chromatogram. Additionally, the 
impurities in the latter appeared to be significantly less when comparing the bands “CFE” 
with the fractions containing Pdx in the gel. Nevertheless, it is only after the 
ultracentrifugation that it was possible to yield the redoxin in pure form yielding 7 mg/ L 
culture. As for the previous cases, the purification progress could be followed by the 
typical brown colour of proteins containing an iron-sulphur cluster. The concentration of 
pure Pdx was determined at 455 nm (ε455=10.4 mM-1 cm-1).[170] 
 
 
Figure 14. Two steps purification of Pdx. The chromatogram shows the first purification step using the anion 
exchange column (AIXC), Pdx started the elution around 300 mM KCl (60% of the gradient). The gel shows 
the fractions after the first step purification where several bands at higher kDa than Pdx can be seen. The 
last line “Pdx” shows the pure protein after filtration through a 30 kDa cut-off membrane and after 
concentration using a 10 kDa cut-off membrane. 
  
Pdx 
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3.1.1.4 Screening of enzymatic and chemical epoxidation catalysts 
All acyclic alkenes used in this work are prochiral molecules that, upon epoxidation, 
result in two different enantiomers of the corresponding epoxides. Hence, our strategy 
for the production of enantiopure amino alcohols from these acyclic alkenes was to 
control the stereocenters already in the first step (epoxidation) by synthesizing 
enantiopure epoxides. For this, a set of different enzymatic and chemical catalysts were 
tested for their ability to yield enantiopure epoxides using trans-2-heptene as a model 
substrate. The results of all active catalysts are shown in Figure 15. Unfortunately, none 
of the cytochromes P450 described in the previous section displayed activity towards the 
selected substrates. Hence, no further tests were done using these enzymes. Notably, 
only the styrene monooxygenase and the Shi epoxidation catalyst displayed significant 
activity. Conveniently, the styrene monooxygenase synthesized the (S,S)-epoxide 
almost exclusively with an enantiomeric excess higher than 95%, whereas the Shi diketal 
epoxidation catalyst produced the (R,R)-enantiomer with an enantiomeric excess around 
90%. Hence, two catalysts could be identified yielding opposite epoxide enantiomers in 
the first step. Ultimately, this will also enable the synthesis of opposite enantiomers of 
the final aminoalcohol products. 
 
 
Figure 15. First screening for the epoxidation of trans-2-heptene catalysed by different enzymatic or chemical 
catalysts. First two entries are enzymatic catalysis and last three entries are chemical catalysts.  
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3.1.1.5 Optimization of styrene monooxygenase-catalysed epoxidations on 
small scale 
The styrene monooxygenase is a two-component system that requires NADH and 
FADH2  to provide the electrons necessary to activate molecular oxygen (Scheme 9). 
Hence, a cofactor regeneration system is desirable to avoid the addition of cofactors in 
stoichiometric amounts. For the experiments in Figure 16, two possible strategies for 
cofactor regeneration were used. If whole cells (WC) are used, glucose can be added to 
fuel cellular metabolism that can regenerate NADH. However, when cell-free extract 
(CFE) is used the cellular metabolism is not working anymore. Thus, an enzyme 
oxidizing a co-substrate is used to reduce NAD+ to NADH. For these reactions, the 
formate dehydrogenase from Candida boidinii was used to oxidise formate for cofactor 
regeneration. 
The setup of an efficient epoxidation using a monooxygenase is a complex task requiring 
the analysis of many variables. At first, the use of whole cells or cell-free extract in 
combination with a balloon of pure oxygen or just leaving sufficient air in the headspace 
was investigated (No O2 entries, Figure 16). Both model substrates trans-2-hexene and 
trans-2-heptene (1 and 2) were analysed using similar conditions and in both cases, the 
highest conversion in reactions using 5 mM substrate was obtained when the styrene 
monooxygenase was used as cell-free extract coupled with the formate dehydrogenase 
from Candida boidinii added as cofactor regeneration system (Figure 16). Furthermore, 
the use of pure oxygen showed an additional beneficial effect and almost 100% 
conversion of trans-2-heptene could be achieved within 1 h.  
 
Figure 16. Comparison of the performance of StyAB when used as whole-cell biocatalyst (WC, 60 g/L wet 
cell weight) or as cell-free extract (CFE, 9.6 g/L total protein content). FDH (0.5 U/mL) was used as cofactor 
regenerating enzyme coupled with CFE, while glucose was added for cofactor regeneration in the WC 
system. Oxygen was either supplied via the air in the headspace (“No O2”) or using pure oxygen (“O2”) 
provided in a balloon. 
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Another recently developed strategy is to simplify the reaction system by removing StyB 
and cofactor regeneration using a molecule that can transfer electrons directly to the 
FAD thanks to its specific redox potential (as mentioned in section 1.4, Scheme 10). One 
of these molecules, 1-benzyl-1,4-dihydronicotinamide (BNAH), was proven to be a good 
non-enzymatic regeneration system for the styrene monooxygenase from Rhodococcus 
opacus 1CP.[91] Hence, different concentrations of BNAH and FAD were tested to 
investigate the feasibility of this system for the epoxidation of trans-2-heptane as model 
substrate. In Figure 17, it is shown that the use of 2 equivalents of BNAH (with respect 
to the substrate concentration) efficiently provided electrons for StyA in order to perform 
the epoxidation of 5 mM substrate. In contrast, varying the FAD concentration had no 
significant effect. In both cases, it was possible to reach over 90% conversion in 1h. 
However, when the BNAH concentration was doubled while keeping the same substrate 
concentration, the conversion dropped to 13% indicating a negative influence on the 
epoxidation by BNAH. A similar effect is obtained when the substrate concentration is 
increased to 10 mM, restoring the 1:2 ratio of substrate:BNAH, as the conversion 
reached only 21%. This made BNAH not an ideal candidate for a possible scale-up, as 
significantly higher substrate loadings are required. 
 
 
Figure 17. Conversions obtained after 1h in reactions using different substrate, BNAH and FAD 
concentrations and cell-free extract harbouring StyA (9.5 g/L, total protein concentration). Trans-2-heptene 
was first used to find optimal conditions (5 mM substrate, 10 mM BNAH, 50 µM FAD) and then they were 
used in the conversion of trans-2-hexene where similar conversions could be achieved. 
 
The availability of O2 is a critical factor that needs to be optimised when working with 
monooxygenases. If glucose is used for the cofactor regeneration, the cellular 
metabolism consumes additional oxygen lowering its overall availability for enzyme 
activity. Therefore, a good compromise must be found to maximize the availability of O2 
and reduced cofactor for the enzyme. Figure 18 shows the activity values measured with 
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different concentrations of whole cells harbouring StyAB using 2.5 mM. All activities were 
determined by measuring the product formation over 5 min.[78] It is visible that the highest 
activity was reached when only 15 g/L (wet cells weight) of biomass was present. 
Doubling the concentration of biocatalyst caused a 10% decrease in the activity and 
further increased cellular concentration did not show a significant effect. It appears that 
there is an optimal cellular concentration to ensure the best use of O2 between cellular 
metabolism and enzyme activity. In fact, when the biomass concentration is too high it 
consumes most of the available oxygen in solution leading to lower activity. 
 
 
Figure 18. Activity measured for StyAB used as whole cell biocatalyst using glucose for cofactor 
regeneration. The highest activity in the conversion of 2.5 mM trans-2-heptene is reached with 15 g/L wet 
cell weight. 
 
After the optimization of cellular concentration, the stability of StyA was tested over time. 
BNAH was used to reduce FAD to be able to exclude a possible deactivation of StyB. 
The assay was carried out with CFE containing StyA at 30 °C with magnetic stirring in 
potassium phosphate buffer. At different time points, samples were taken and the activity 
was measured and compared with the fresh sample’s activity. As can be seen in Figure 
19, almost complete loss of activity was observed after 6 h. This might indicate low 
stability of StyA; however, it could be also due to mechanical stress caused by the 
magnetic stirrer. 
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Figure 19. Residual activity of StyA after incubation at 30 °C for different time points. After 6h most of the 
activity is lost. 
 
3.1.2 Ring-opening of di-substituted epoxides 
After successful synthesis of di-substituted epoxides, a set of 22 HHDHs was tested for 
their activity in the ring opening of these epoxides using azide as nucleophile. Until 
recently, only terminal epoxides had been reported to be accepted as substrates by 
HHDHs.[111] Only in one paper by Hasnaoui-Dijoux et al., it is briefly noted that HheC was 
observed to catalyse the ring-opening of 2,3-epoxyheptane with nitrite as nucleophile but 
without experimental detail.[182] 
Within our study, several di-substituted epoxides were chosen to further explore the 
substrate scope of our newly identified HHDHs. Scheme 17 shows that two different 
regioisomers can be formed in the azidolysis of a di-substituted epoxide depending on 
the site of nucleophilic attack. 
 
 
Scheme 17. General scheme for the HHDH-catalysed azidolysis of di-substituted epoxides resulting in the 
formation of two possible regioisomeric azidoalcohols. 
 
As described in the aim of the project (section 1.8), a regioselective epoxide ring opening 
was required as the second step in order to set up a viable cascade for the production 
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of enantiopure amino alcohols from alkenes. Therefore, the major goal was to identify 
regioselective HHDHs with high activity towards the target substrates. 
3.1.2.1 Expression and purification of halohydrin dehalogenases in shake 
flasks 
Expression and purification of all HHDHs were performed according to optimized 
protocols previously reported by Koopmeiners et al.[167] All HHDHs were produced in E. 
coli BL21 (DE3) or C43 (DE3) transformed with pET28a(+) vector containing the 
respective hhdh gene. All purifications were performed via immobilized metal affinity 
chromatography (IMAC) using a Ni-NTA column connected to an FPLC system (Äkta) 
making use of the enzyme´s N-terminal hexa-histidine tag. An example of a typical 
chromatogram and SDS-PAGE gel of the purification of HheE2 is shown in Figure 20. 
Elution fractions containing the target protein are shown in the gel (Figure 20). All 
fractions appeared to be clean except for a small band visible around 14.4 kDa. Purified 
HHDHs were usually obtained in yields of 2-26 mg/L culture.[105,167] 
 
 
Figure 20. Classic purification chromatogram of His-tagged HHDH, HheE2 in this case. All HHDHs started 
to elute around 300 mM of imidazole concentration. The gel only shows the fractions containing the target 
protein. All fractions appear to be fairly pure. 
HheE2 
elution 
[Imidazole] 
gradient start 
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Expression of HheE and HheE5 was also tested in a 2L bioreactor. Both enzymes were 
produced in E. coli BL21 (DE3) at 20 °C using 0.1 mM of IPTG as inducer, and using the 
same protocol adopted for the styrene monooxygenase (Section 3.1.1.2). As seen in 
Figure 11, the HHDHs’ fermentations showed a similar graph (data not shown), after 
overnight expression samples were taken to compare the activity with shake flasks 
fermentations (Table 20). 
 
Table 20. Specific activities of HheE and HheE5 after expression in the 2 L bioreactor. Samples were taken 
after overnight expression and the activity of the CFE was measured by using the spectrophotometric pH 
assay (Methods, Enzyme assays). Specific activity values are based on total protein content. 
Enzyme Cultivation 
Final 
OD600 
Specific activity 
(mU/mg) 
HheE Fermentation 1 10.3 3.98 
HheE Fermentation 2 13.4 6.6 
HheE Shake flask 6.1 7 
HheE5 Fermentation 1 9.74 26.2 
HheE5 Fermentation 2 15 11 
HheE5 Shake flask 9 44.5 
= (1U= 1 μmol/min) 
 
The values in Table 20 show that HHDHs produced in the bioreactor have lower specific 
activity than HHDHs produced in shake flasks. HheE5, especially, reached up to 4 fold 
less activity compared to shake flasks experiments. Possibly, HheE5 requires shorter 
expression times as the main difference between the samples is the significantly higher 
final OD600. This is compatible with Koopmeiners et al., as HheE5 was typically harvested 
after 7 h from induction at 30 °C.[167] In a bioreactor, longer times are needed to reach 
sufficient OD600 to start induction and production would end a later time than the one 
allowed by the safety measures. HheE’s activity, in contrast, does not seem to be 
dependent on the induction time.  
 
3.1.2.2 Selective ring opening of di-substituted epoxides 
A subset of 22 HHDHs from our panel, containing enzymes from all six phylogenetic 
HHDH subtypes, was tested in bioconversions of different di-substituted epoxides (21-
25) using azide as exemplary nucleophile (Scheme 17). The majority of the tested 
HHDHs (17 out of 22) displayed activity in the conversion of the two aliphatic substrates 
trans-2,3-epoxyhexane (21) and trans-2,3-epoxyheptane (22), affording the 
corresponding azidoalcohols in varying yields. In contrast, significantly fewer HHDHs 
converted the sterically more demanding epoxides trans-4,5-epoxyhexan-1-ol (23), 
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trans-3,4-epoxyheptane (24) and trans--methylstyrene oxide (25). HheG from 
Ilumatobacter coccineus was active on all five epoxide substrates yielding highest 
conversion for substrates 21, 23, 24 and 25 among all tested HHDHs. Significant 
conversion of 25 by HheG was unexpected as the enzyme was previously shown to 
exhibit only very little activity on styrene oxide, a structurally very similar but terminal 
epoxide.[167] HheA2 and HheB2 hardly showed any product formation with any of the 
substrates, which is in agreement with previous findings.[111,182] Interestingly, the addition 
of a terminal hydroxyl group on the opposite end of the substrate compared to the 
epoxide ring completely suppressed activity of all tested HHDHs that displayed activity 
on the corresponding non-hydroxylated epoxide 21. As shown in Figure 21 (gold-yellow 
bar), HheG was the only exception still able to convert trans-4,5-epoxyhexan-1-ol (23) 
with a significant yield, notably HheG2 showed no conversion at all, albeit both enzymes 
share 74% sequence identity at the protein level.[105] Comparing substrates 22 and 24, 
which differ in the position of their epoxide ring, only a reduced number of HHDHs was 
still active on trans-3,4-epoxyheptane (24). Enzymes HheA3, HheD, HheD2, HheD3 and 
HheD5, as well as HheG2 gave low to moderate conversions, whereas HheG converted 
24 completely within 15 h reaction time (Figure 21, Green). 
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Figure 21. Conversions and ratios of regioisomeric products a and b obtained in biocatalytic reactions of 
substrates 21-25 with HHDHs using azide as the nucleophile. The ratios of regioisomeric products a and b 
are represented in different colours within the bar representing the conversion. 
 
The vicinally di-substituted epoxide substrates 21-25 each contain two stereocenters. 
Depending on the site of the nucleophilic attack and the stereoconfiguration of the 
substrate during HHDH-catalysed epoxide ring-opening, two regioisomers and their 
respective pairs of enantiomers can be attained (Scheme 18). In agreement with our 
cascade strategy for selective synthesis of enantiopure aminoalcohols from non-terminal 
alkenes, the regioselectivity of the catalyst in the second step is of paramount 
importance. Thus, the regioselectivity of active HHDHs in the conversion of substrates 
21-25 was studied. Most enzymes formed both regioisomeric products a and b in varying 
ratios (Figure 21). HheA3, HheC and all tested enzymes from the E subfamily exhibited 
high regioselectivity for substrates 21 and 22, giving 2-azido-3-hydroxyhexane (31a) and 
2-azido-3-hydroxyheptane (32a) almost exclusively. In contrast, enzymes from HHDH 
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subfamily D as well as HheG and HheG2 formed both regioisomers (31a and 31b, as 
well as 32a and 32b) in roughly equal amounts. The same was observed for chemical 
background azidolysis of 21 and 22 (“Control” in Figure 21). Compared to the conversion 
of 21, the terminal hydroxyl group present in 23 had a positive effect on HheG’s 
regioselectivity. The enzyme produced 5-azidohexane-1,4-diol (33a) with high 
preference (Figure 21). 
 
 
Scheme 18. Possible regio- and stereoisomers in the azidolysis of vicinally di-substituted trans-epoxides 
21–25. The site of attack (α: less sterically hindered, shown in blue; β: sterically more hindered, shown in 
plum) defines the regioisomers obtained, while the enantioselectivity of the enzyme and the SN2-type 
mechanism define the absolute configuration found in each set of regioisomers. Hence, a total of two 
regioisomers a and b, each with their respective (R,S)- and (S,R)-enantiomers, can be obtained. Adapted 
from Calderini et al.[183] 
 
None of the active enzymes seemed to display high regioselectivity in the conversion of 
24 as in all cases both azido alcohol regioisomers 34a and 34b were formed. This might 
not be surprising since the substituents of the epoxide ring are more similar in size, 
compared to (22). In accordance with literature,[184,185] none of the tested enzymes 
exhibited preference towards a nucleophilic attack on the sterically more hindered carbon 
atom, except for substrate 25. In this specific case, the nucleophilic attack on the benzylic 
carbon is favoured due to the electronic resonance effect of the aromatic substituent. 
Here, HheG and HheG2 gave azido alcohol 35b almost exclusively, whereas HheD3 and 
HheF formed also small amounts of regioisomer 35a. Chemical azidolysis of epoxide 25 
afforded 35b almost exclusively as well. In this specific case, nucleophilic attack on the 
benzylic carbon is favoured due to the electronic resonance effect of the aromatic 
substituent.  
Furthermore, the enantioselectivity of all active enzymes in the ring-opening of racemic 
epoxides 21 and 22 was analysed. For this, product enantiomeric excesses (eeP) and 
corresponding apparent E-values for each of the two possible product regioisomers were 
determined. As a result, most azidoalcohols were formed with low to moderate 
enantioselectivity (Table 21). Several HHDHs, however, displayed good 
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enantioselectivity (E> 15) in the formation of azido alcohol regioisomers 21b and 22b. 
Hence, nucleophilic attack on the unfavoured carbon atom occurred with higher 
enantioselectivity. Interestingly, most azido alcohol products in the conversion of 21 and 
22 were preferentially formed in 2S,3R-configuration. This indicates that epoxides 21 
and 22 with R,R-configuration were preferentially attacked at the sterically less hindered 
carbon atom (C2), whereas regioisomers 21b and 22b were preferentially formed by 
nucleophilic attack of (S,S)-21 and (S,S)-22 at the sterically more hindered carbon atom 
(C3). In contrast, nucleophilic attack of azide at C2 in (S,S)-21 and (S,S)-22 yields 
azidoalcohols 21a and 22a in 2R,3S-configuration, as found for HheA3, HheE2, HheF 
and HheG2 with epoxide 21 and HheE4 and HheF with epoxide 22 (Table 21). A detailed 
analysis of the enzymes’ regiopreferences in the azidolysis of R,R- and S,S-enantiomers 
of epoxides 21 and 22 is given in Supporting table 1 the appendix. Interestingly, D-type 
HHDHs displayed a slightly higher preference for nucleophilic attack of (S,S)-21 and 
(S,S)-22 at the sterically more hindered carbon atom, whereas most other HHDHs 
exhibited a clear preference for nucleophilic attack of the sterically less hindered carbon 
atom independent of the substrate’s stereoconfiguration. Additionally, the 
enantioselectivity of active HHDHs in the ring-opening of rac-25 was determined and 
results are given in Supporting table 2 in the appendix. No enantioselectivity was 
observed in the chemical epoxide ring opening of 21, 22 and 25 on preparative scale 
with azide as nucleophile (data not shown). 
Table 21. Conversions (C), enantiomeric excesses (eeP) and calculated apparent enantiomeric ratios (Eapp) 
of regioisomeric azidoalcohols 21a, b and 22a, b formed in the HHDH-catalysed azidolysis of epoxides 21 
and 22. The absolute configuration of the preferentially formed enantiomer of each regioisomer is given in 
parentheses. Table taken from Calderini et al.[183] 
 6a 6b 7a 7b 
HHDH C 
[%] 
eeP 
[%] 
Eapp 
C 
[%] 
eeP 
[%] 
Eapp 
C 
[%] 
eeP 
[%] 
Eapp 
C 
[%] 
eeP 
[%] 
Eapp 
HheA3 48 47 
4.2 
(R,S) 
4.1 46 
2.8 
(S,R) 
93 0.7 
1.0 
(S,R) 
3.4 25.5 
1.7 
(S,R) 
HheB3 9.7 35 
2.2 
(S,R) 
3.6 66 
5.0 
(S,R) 
8.7 30 
1.9 
(S,R) 
4.3 77 
7.7 
(S,R) 
HheB5 52 25 
2.1 
(S,R) 
7.1 86 
14 
(S,R) 
85 24 
1.6 
(S,R) 
13 95 
39 
(S,R) 
HheB6 69 24 
2.6 
(S,R) 
7.6 89 
18 
(S,R) 
88 16 
1.4 
(S,R) 
11 93 
28 
(S,R) 
HheB7 73 24 
2.9 
(S,R) 
8.1 93 
30 
(S,R) 
89 17 
1.4 
(S,R) 
11 94 
32 
(S,R) 
HheC 43 34 
2.6 
(S,R) 
1.3 n.d.[b] n.d.[b] 97 4.6 
1.1 
(S,R) 
2.3 90 
19 
(S,R) 
HheD 22 28 
1.9 
(S,R) 
22 86 
17 
(S,R) 
51 60 
4.0 
(S,R) 
43 87 
14 
(S,R) 
HheD2 32 22 
1.7 
(S,R) 
32 84 
17 
(S,R) 
45 57 
3.7 
(S,R) 
45 78 
8.1 
(S,R) 
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HheD3 44 65 
7.7 
(S,R) 
44 43 
3.4 
(S,R) 
56 76 
7.4 
(S,R) 
43 80 
9.0 
(S,R) 
HheD5 64 46 
6.5 
(S,R) 
36 44 
3.2 
(S,R) 
50 13 
1.3 
(S,R) 
50 11 
1.2 
(S,R) 
HheE 98 4.9 
1.1 
(S,R) 
1.7 n.d.[b] n.d.[b] 99 3.5 
1.1 
(S,R) 
0.8 n.d.[b] n.d.[b] 
HheE2 10 71 
6.4 
(R,S) 
1.1 n.d.[b] n.d.[b] 83 11 
1.2 
(S,R) 
1.5 n.d.[b] n.d.[b] 
HheE3 14 4.5 
1.1 
(R,S) 
1.8 n.d.[b] n.d.[b] 90 2.3 
1.0 
(S,R) 
1.4 n.d.[b] n.d.[b] 
HheE4 <0.1 n.d.[b] n.d.[b] n.d.[b] n.d.[b] n.d.[b] 14 33 
2.0 
(R,S) 
0.5 n.d.[b] n.d.[b] 
HheE5 84 13 
2.2 
(S,R) 
1.8 n.d.[b] n.d.[b] 99 3.5 
1.1 
(S,R) 
0.6 n.d.[b] n.d.[b] 
HheF 48 54 
5.4 
(R,S) 
8.0 32 
2.0 
(S,R) 
58 32 
1.9 
(R,S) 
12 19 
1.5 
(S,R) 
HheG 50 16 
1.6 
(S,R) 
50 15 
1.5 
(S,R) 
60 63 
4.4 
(S,R) 
40 89 
17 
(S,R) 
HheG2 13 54 
3.6 
(R,S) 
13 67 
5.6 
(S,R) 
48 7.4 
1.2 
(S,R) 
48 10 
1.2 
(S,R) 
[b] not determined 
 
To gain first structural insights into the observed regioselectivities, a docking study on 
selected halohydrin dehalogenases with solved crystal structure was performed. The 
following crystal structures were chosen as a starting point: i) the (R)-para-nitro styrene 
oxide-bound structure of HheC (PDB: 1ZMT)[185] representing a regioselective enzyme, 
ii) the substrate-free structure of HheG (PDB: 5O30)[105], as this enzyme was able to 
convert all five epoxides, and iii) a yet unpublished substrate-free structure of HheD2 
representing a non-regioselective enzyme.  
De Jong et al.[185] could show for HheC that a very specific geometry between the 
nucleophilic the epoxide ring, the catalytic triad (S132, Y145, and R149) and the 
nucleophile is required for the nucleophilic attack to occur. This specific orientation 
determines which of the two carbons of the epoxide ring will react with the nucleophile 
present in the binding pocket. For HheC, the dockings were in agreement with the 
experimental data, both substrate enantiomers of 21 and 22 bind in similar productive 
orientations with the methyl-substituted carbon atom in closer proximity to the 
nucleophile binding pocket (Figure 22, A and B). HheC, in fact, converted both substrates 
21 and 22 with high regioselectivity but poor enantioselectivity and no productive binding 
was found for substrates 23, 24 and 25. In particular, substrates 24 and 25 appear 
correctly orientated but having the epoxide ring too far away from the catalytic triad. This 
is again in agreement with the experimental data obtained for HheC, which did not 
convert epoxides 24 and 25. Epoxide 23 revealed a more interesting binding mode, in 
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fact, the terminal hydroxyl group of both substrate enantiomers is pointing towards the 
catalytic amino acid residues (Figure 22, C). This flipped binding mode of 23 found for 
HheC might also occur in other HHDHs and could thus explain the lack of activity of most 
HHDHs toward this epoxide.  
 
 
Figure 22. Docking results for HheC (PDB: 1ZMT) with substrates 21 (A), 22 (B), 23 (C), 24 (D) and 25 (E). 
Substrates with R,R-configuration are shown in light blue, whereas substrates with S,S-configuration are 
shown in orange. Hydrogen bonds between epoxide oxygen and catalytic residues S132 and Y145 are 
represented as green dotted lines. The water molecule present in the nucleophile binding pocket is shown 
as a green sphere to indicate the position of the nucleophile. Taken from Calderini et al.[183] 
 
The same dockings of epoxides 21-25 were also performed with HheD2. Docking of 
substrate 21 resulted in productive binding modes for both enantiomers (Figure 23, A), 
which is in agreement with experimental data. The binding geometry of (S,S)-21 would 
favour a nucleophilic attack on the sterically more hindered carbon resulting in the 
production of (2S,3R)-31b, while the opposite binding pose was not found in the docking 
study, again in agreement with the experimental data (Figure 23). Epoxide 22 gave 
productive bindings only for the (R,R) enantiomer and interestingly, this-enantiomer 
showed two possible binding modes with either the longer or shorter substituent entering 
the active site first. The docking of trans-4,5-epoxyhexan-1-ol (23) revealed one 
productive binding mode which is not in agreement with experimental data. Additionally, 
a flipped binding mode, similar to the one found for HheC (Figure 23, C), was obtained 
in the docking of (S,S)-23. This may actually represent the favoured binding mode given 
that HheD2 displayed no activity in the conversion of this epoxide. Docking of substrate 
24 resulted in productive binding modes as opposed to HheC, although both enzymes 
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showed no or little conversion with this substrate. Once again, different enantiomers 
have opposite orientations; these poses may occur in other HHDHs from the D 
phylogenetic subtype and might explain the observed regioselectivity. Finally, both 
enantiomers of trans-1-phenylpropylene oxide (25) yielded binding poses that are too far 
away from the catalytic triad for conversion, which is again in agreement with 
experimental data. 
 
 
Figure 23. Docking results for HheD2 (unpublished PDB) with substrates 21 (A), 22 (B), 23 (C), 24 (D) and 
25 (E). Substrates with R,R-configuration are shown in light blue, whereas substrates with S,S-configuration 
are shown in orange. Hydrogen bonds between epoxide oxygen and catalytic residues S117 and Y130 are 
represented as green dotted lines. The water molecule present in the nucleophile binding pocket is shown 
as a green sphere to indicate the position of the nucleophile. 
 
The docking results for HheG are overall in agreement with experimental data (Figure 
24). However, for epoxides 23-25 the docking results look less accurate as not all 
substrate enantiomers yielded correct geometries. It is important to note that substrates 
21-24 yielded two possible binding modes, where the longer substituent points in 
opposite directions. Flipped orientations would favour the nucleophilic attack on opposite 
carbons of the epoxide ring. This is confirmed by our experimental data as no or only low 
regioselectivity was observed with these substrates. Dockings of trans-1-
phenylpropylene oxide (Figure 24, E) resulted in only a productive binding mode for 
(S,S)-25. Interestingly, the orientation of both epoxides would favour the nucleophilic 
attack on the carbon closer to the aromatic ring, in agreement with experimental data. 
This is also the favoured site of attack in the chemical azidolysis as the intermediate 
 3. Results 
 
87 
 
carbocation is stabilized by electronic resonance with the aromatic ring. Indirectly this 
may give hints on the regioselectivity observed for HheF. This HHDH may favour the 
opposite binding mode resulting in a higher ratio of 35a compared to the other active 
HHDHs. Although, the overall yield is very low and no crystal structure is available yet to 
confirm this hypothesis.  
 
 
Figure 24. Docking results for HheG (PDB: 5O30) with substrates 21 (A), 22 (B), 23 (C), 24 (D) and 25 (E). 
Substrates with R,R-configuration are shown in light blue, whereas substrates with S,S-configuration are 
shown in orange. Hydrogen bonds between epoxide oxygen and catalytic residues S152 and Y165 are 
represented as green dotted lines. The water molecule present in the nucleophile binding pocket is shown 
as a green sphere to indicate the position of the nucleophile. Adapted from Calderini et al.[183]  
 
3.1.2.3 Characterization of regioselective halohydrin dehalogenases 
After identification of a few regioselective HHDHs in the ring opening of epoxides 21 and 
22, enzymes of subtype E were studied in more detail to determine the most suitable 
ones for combination with the styrene monooxygenase and/or with the Shi epoxidation 
diketal catalyst in cascade reactions. For this, the enzymes were applied in the form of 
whole cells (60 g/L, wet cell weight). Overall, HheE (light blue) and HheE5 (blue) 
performed evidently better in the conversion of the two substrates. HheE appears to be 
the most active enzyme in the epoxide ring opening of 21 (Figure 25, A) showing a higher 
slope in conversion within the first 4 h compared to HheE5. In contrast, HheE5 is slightly 
faster in the conversion of 22 (Figure 25, B) compared to HheE. Both enzymes are 
significantly faster in the synthesis of 2-azido-3-hydroxyhexane (31a) and 2-azido-3-
hydroxyheptane (32a) compared to other members of the E-type. 
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Figure 25. Conversion of epoxide 21 (graph A) and epoxide 22 (graph B) using the regioselective HHDHs 
from the E-type as whole cells catalysts (60 g/L, wet cell weight). Each reaction was carried out in duplicate 
using 10 mM of each substrate, 50 mM of NaN3. 
 
Their kinetic parameters of these two enzymes were determined to further characterise 
their catalytic properties using epoxides 21 and 22 as well as the nucleophile NaN3. The 
reactions were analysed using GC as no reliable colourimetric assay was available. 
Table 22 shows a summary of the kinetic data obtained using the Hill or Michaelis-
Menten equations to fit the experimental data (Appendix, Enzyme kinetics). Both 
enzymes displayed relatively high K50\KM values between 18 to 27 mM demonstrating 
that they possess a rather low affinity for the given substrates. HheE5 exhibited the 
highest overall maximal reaction velocity as expected from whole cell biotransformations 
(Figure 25). Both enzymes displayed a higher reaction velocity in the azidolysis of 22 
and it is likely that the maximal reaction velocity of HheE5 with epoxide 21 would be 
lower than the one of HheE giving its lower activity in whole cells reactions. Furthermore, 
the maximal reaction velocity of HheE in the epoxide ring opening reactions might be 
influenced by the fixed nucleophile concentration (50 mM) which is ~4-fold higher than 
its KM for the nucleophile. In contrast, HheE5’s K50 for azide is ~8-fold lower than the 
nucleophile concentration (50 mM) having a better affinity for azide. This may have 
contributed to the higher Vmax of HheE5 compared to HheE in the conversion of 22. The 
kinetic data of HheE with trans-2,3-epoxyhexane (21) are lower compared to the ones 
obtained for 22; in agreement with whole cells biotransformations as both enzymes 
converted this substrate less efficiently. Surprisingly no product formation was observed 
in the first hour and; initial reaction rates were calculated starting from 1h for the following 
15 minutes. The Hill coefficient suggests cooperative binding for both substrates (except 
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for HheE with 21) which may have been the cause of the observed delay. However, no 
further analysis was done to elucidate the reasons for this delayed reaction start. 
Table 22. Kinetic parameters of HheE and HheE5 for epoxides 21 and 22 using NaN3 as the nucleophile. 
Enzyme Substrate KM /K50 (mM) 
Vmax 
(µmol min-1) 
kcat 
(s-1) 
kcat/ KM 
or 
kcat/K50 
n[a] 
HheE 21 27 55.2 0.75 2.76∙10
-3 -[b] 
HheE 22 18 114.9 0.155 8.62∙10
-3 2.3 
HheE NaN3 (21) 12 - - - -[b] 
HheE5 22 20 152.4 0.206 10.29∙10
-3 3.4 
HheE5 NaN3 (22) 6 - - - 2.6 
[a]Hill coefficient ([b] Michaelis-Menten equation was used for the fitting) 
 
3.1.3 Hydrogenation of azidoalcohols 
Chemical reduction of an azido group to an amino group is an established reaction that 
can be performed by a number of metal catalysts.[32,119] Hence, a first selection based on 
price and reaction conditions was carried out to exclude some of the metals. Several 
catalysts required extreme conditions, for example the hydrogenation using ruthenium 
requires 70-80 °C and a pressure of 60-70 atmospheres. These metals were directly 
excluded as milder conditions were more desirable. In the end, a screening kit containing 
palladium on different supports was ordered and tested in the conversion of azido-
hydroxyheptane (32) to amino-hydroxyheptane (42). Palladium is a cheap alternative to 
platinum and it can perform hydrogenations at atmospheric pressure and room 
temperature, and therefore, it is an ideal catalyst to combine with the previously selected 
catalysts. In the kit, six different heterogeneous catalysts are provided, which differ in the 
amount of palladium present and in the material used as support. It is well known that 
the matrix on which palladium is immobilized can have a great effect on the kind of 
reaction that is catalysed. A common example is shown in Figure 26, second entry; here 
the palladium is immobilized on calcium carbonate and it is poisoned with Pb to reduce 
its activity. This poisoning is typical for catalysts designed to perform hydrogenations on 
alkynes in order to produce the corresponding alkenes. Therefore, it is not surprising that 
the lowest conversion was observed using this catalyst. Overall, the fastest 
heterogeneous catalyst to synthesize amino-hydroxyheptane (42) was palladium on 
carbon (entry 1 and 5 Figure 26). Palladium hydroxide on carbon (Figure 26, entry 3) 
appeared to have a good reaction rate too. However, it contained twice as much 
palladium (20 wt. %) compared to the catalyst in entry 1 or 5. Finally, Palladium (10 wt. 
%, entry 1 in Figure 26) on activated carbon was chosen as the catalyst for combination 
with steps one and two of the cascade. 
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Figure 26. Conversions of the racemic azido hydroxyheptane (32) by Pd on different supports. 1 Palladium 
on carbon, 10 wt. % loading, matrix activated carbon support. 2 Palladium on calcium carbonate, 5 wt. % 
loading, poisoned with lead. 3 Palladium hydroxide on carbon, 20 wt. % loading (dry basis), matrix carbon, 
wet support. 4 Palladium on barium sulphate, reduced, 5 wt. % loading. 5 Palladium on carbon, 10 wt. % 
loading (dry basis), matrix activated carbon, wet support, Degussa type E101 NE/W. 6 Palladium on alumina, 
10 wt. % loading, powder, reduced, dry. 
 
An interesting alternative option for the hydrogenation step is to immobilize palladium 
nanoparticles inside apoferritin. Ferritin is a protein known to store iron in several 
bacteria. Hence, it is possible to exploit this function to encapsulate different metals 
including palladium inside the ferritin cage. This would maximize the compatibility of the 
metal catalyst with the enzyme catalysts of the cascade as the enzymes would be 
separated from the metal and vice versa. The synthesis of this catalyst requires several 
steps (section 2.2.4, Hydrogenation): at first the apoferritin is incubated with palladium 
salt to promote the encapsulation. Afterwards, the excess of palladium is washed using 
a PD10 column, and lastly the mixture is incubated under an H2 atmosphere for a few 
hours. The picture in Figure 28, shows the last step of the synthesis. In particular, 
hydrogen is bubbled through the solution of palladium entrapped into the apoferritin 
cage. This step is crucial as the reduction of the metal leads to aggregation and formation 
of the nanoparticles. The aggregation is reflected in the change of colour from pale yellow 
to dark grey. To further confirm the successful palladium encapsulation, a microscopic 
characterization was kindly carried out by Dr. Wuyuan Zhang (TU Delft). Figure 27 shows 
a TEM picture of the nanoparticles. Particularly on the left picture, it is possible to see 
the homogeneous size distribution of the particles calculated to be 5 ± 1 nm in size. 
Additionally, the higher magnification picture on the right allows to see apoferritin from 
horse spleen (AFHS) in white and the palladium nanoparticles as dark spots in inside 
the AFHS. 
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Figure 27. TEM images of Pd@AFHS nanoparticles stained with uranyl acetate at different scale (100 nm 
and 50 nm). The nanoparticles show a very narrow size distribution of 5 ± 1 nm. The picture on the right 
clearly shows the nanoparticles with a white coating that represents the apoferritin from horse spleen (AFHS) 
and a black core composed of Pd. 
 
The graph in Figure 28 shows the conversion of 5 mM racemic 2-azido-3-
hydroxyheptane (32) to 2-amino-3-hydroxyheptane (42) over time. After 4 h, the reaction 
was almost complete using an amount of Pd@AFHS corresponding to 3.5 µM of Pd. 
Despite this successful conversion, Pd@AFHS nanoparticles were not considered for 
further application as the synthesis of this catalyst is quite time consuming. Additionally, 
apoferritin from horse spleen is an expensive component. Therefore, palladium on 
carbon was chosen for further experiments having in mind a possible commercial 
exploitation of the cascade in the future. 
 
 
Figure 28. Conversion of 5 mM racemic azido-hydroxyheptane (32) to amino-hydroxyheptane (42) using Pd 
nanoparticles entrapped in apoferritin from horse spleen (AFHS). On the right, the photo shows the solution 
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of Pd and AFHS before and after the reduction of Pd using H2 that causes the aggregation of Pd in 
nanoparticles that causes the solution to turn dark grey. 
 
3.1.4 Catalyst selectivity and assignment of azido alcohol 
stereoisomers 
 
Scheme 19. The epoxidation of a non-terminal trans-alkene generates two new stereocenters. 
Consequently, in the epoxide ring opening, following the typical SN2 mechanism, four possible azido alcohols 
are obtained. Lastly, hydrogenation of the azido alcohols does not affect the stereocenters, hence, yielding 
the four corresponding amino alcohols. 
 
Scheme 19 illustrates the formation of all possible product isomers of a fully unselective 
cascade for amino alcohol synthesis starting from non-terminal alkenes. Epoxidation of 
a non-terminal trans-alkene will yield the corresponding epoxide in (S,S)- and (R,R)-
configuration. Subsequently, unselective epoxide ring opening following an SN2 
mechanism will result in the formation of four different azido alcohol stereoisomers: 
(2R,3S)- and (2S,3R)-2-azido-3-alcohol as well as (2S,3R)- and (2R,3S)-3-azido-2-
alcohol. Finally, hydrogenation of the azido groups will not affect the stereochemistry of 
the compounds. According to our strategy, having a stereoselective epoxidation would 
reduce the possible azido- and aminoalcohols isomers from four to two. Consequently, 
a regioselective epoxide-ring opening would further reduce the possibilities from two to 
one, thus, leading to an enantiopure product. 
To confirm this, a first cascade was set up involving the enantioselective styrene 
monooxygenase and a non-regioselective HHDH. In particular, for trans-2-hexene (1) as 
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substrate StyAB was coupled with HheG and for trans-2-heptene (2) StyAB was coupled 
with HheD5. As shown in section 3.1.1.4, StyAB only produces (S,S)-trans-2,3-
epoxyhexane (21) or (S,S)-trans-2,3-epoxyheptane (22). Thus, coupling it with an 
unselective HHDH should result in the production of similar quantities of (2R,3S)-2-azido-
3-hydroxyhexane (31a) and (2S,3R)-3-azido-2-hydroxyhexane (31b) or (2R,3S)-2-
azido-3-hydroxyheptane (32a) and (2S,3R)-3-azido-2-hydroxyheptane (32b). This is 
explained by the catalytic mechanism of HHDHs, which leads to the inversion of the 
stereocenters due to nucleophilic attack following an SN2 reaction. Hence, epoxide ring 
opening of the (S,S)-enantiomer produced by the styrene monooxygenase leads to an 
inversion of the attacked stereocenter yielding the corresponding azido alcohol in 
(2R,3S)- or (2S,3R)-configuration for regioisomer a and b, respectively. Comparison of 
the chiral GC data from these cascade reactions with the regioselectivity data obtained 
from GC-MS in the ring-opening experiments (section 3.1.2.2) would allow the 
assignment of the corresponding stereoconfiguration of the four peaks.  
The respective chiral GC chromatograms for the two cascade reactions combining StyAB 
with HheG (A) or HheD5 (B) are shown in Figure 29. These reactions were run in a 
sequential mode, the epoxidation for the first 8 h, and afterwards the respective HHDHs 
and sodium azide were added and the epoxide-ring opening was run for further 16 h. 
Interestingly, both enzymes displayed some regioselectivity in this cascade reaction. 
Originally, the two HHDHs were selected as they formed both product regioisomers in 
similar amounts (regioisomeric ratio of 50:50) in the conversion of racemic epoxides 21 
and 22, respectively (Appendix, Supporting table 1). However, when starting from the 
corresponding (S,S)-epoxides, the determined regioisomeric ratio was 40:60 (31a:31b) 
and 22:78 (32a:32b) for HheG and HheD5, respectively. This means that both enzymes 
preferentially catalysed the nucleophilic attack on the sterically more hindered carbon 
atom leading to higher quantities of the (2S,3R)-enantiomer.  
 
 
Figure 29. Comparison of chiral chromatograms of the azidoalcohols chemically produced starting from 
racemic epoxides (blue) or synthesised in starting from (S,S)-21 (A) or (S,S)-22 (B) synthesised by StyAB 
(orange). The epoxide-ring opening was catalysed by HheG for the production of (2R,3S)-2-azido-3-
hydroxyhexane (31a) and of (2S,3R)-3-azido-2-hydroxyhexane (31b) (orange line in A) and by HheD5 for 
A  B 
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the production of (2R,3S)-2-azido-3-hydroxyheptane (32a) and of (2S,3R)-3-azido-2-hydroxyheptane (32b) 
(orange line in B ). 
 
To validate the peak assignment, cascades reactions coupling enantioselective 
epoxidation with regioselective epoxide-ring opening were carried out. This way, the 
reactions would afford a single diastereoisomer with the azido group in the sterically less 
hindered carbon (e.g. 31a and 32a). In particular, coupling the Shi diketal epoxidation 
with either HheE or HheE5 (Figure 30, orange line) resulted in higher amounts of 
(2S,3R)-2-azido-3-hydroxyhexane (31a), (2S,3R)-2-azido-3-hydroxyheptane (32a) 
respectively. In this case, both enantiomers are visible as the enantiomeric excess 
values obtained were 60% and 48%, respectively. In contrast, coupling the styrene 
monooxygenase with the same HHDHs (Figure 30, grey line) resulted in the production 
of the opposite enantiomers, (2R,3S)-2-azido-3-hydroxyhexane (31a), (2R,3S)-2-azido-
3-hydroxyheptane (32a), respectively. The styrene monooxygenase showed significantly 
higher enantioselectivity, hence only one peak is visible. Furthermore, the peak order is 
reversed compared to Figure 29, this is due to the different columns used for the chiral 
separation. The chromatograms in Figure 29 have been generated at TU Braunschweig 
using a Lipodex E chiral column while the chromatograms in Figure 30 have been 
generated at Enzymicals, Greifswald using a Lipodex G column. The inversion is very 
likely due to the different matrix compositions. 
 
Figure 30. Chiral chromatograms of 2-azido-3-hydroxyhexane (A) and 2-azido-3-hydroxyheptane (B). The 
grey line represents 31a (A) and 32a (B) produced in cascades composed by the styrene monooxygenase 
and HheE (A) or HheE5 (B). These reactions preferentially produce (2R,3S)-31a (A) or (2R,3S)-32a (B). The 
orange line represents 31a (A) and 32a (B) produced in cascades composed by the Shi epoxidation diketal 
catalyst and HheE (A) or HheE5 (B). These reactions preferentially produce (2S,3R)-31a (A) or (2S,3R)-32a 
(B). The blue line represents racemic azidoalcohols 31a (A) and 32a (B) for reference. 
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3.1.5 StyAB – HHDH – Pd/C cascade 
According to our strategy, coupling a stereoselective epoxidation step with a 
regioselective epoxide ring opening step will yield an enantiopure azido alcohol. Lastly, 
reduction of the azido group produces the corresponding amino alcohol. In the first 
cascade, the styrene monooxygenase, synthesising epoxides (S,S)-21 and (S,S)-22, is 
combined with regioselective HHDHs HheE (for 21) or HheE5 (for 22) and Pd/C as 
hydrogenation catalyst. This catalyst combination allows the selective synthesis of 
respective azido- and aminoalcohols in (2R,3S)-configuration (Scheme 20).  
Each reaction, composing the cascade, was first optimized separately and cross-
interactions were studied before setting up the cascade. Cross-interaction studies are 
important to determine components that could have a negative effect on other catalysts 
of the cascade. This allows finding an effective compromise to maintain reasonable 
working conditions for all catalysts. 
 
Scheme 20. General scheme of the cascade composed of the styrene monooxygenase in the first step, a 
halohydrin dehalogenase in the second step and palladium on carbon in the last step. Enantioselective 
epoxidation of the trans-alkene combined with regioselective epoxide ring-opening leads to the formation of 
only one out of four possible stereoisomers enabling the synthesis of an enantiopure amino alcohol. 
 
 3.1.5.1 Optimization and scale-up of the StyAB-catalysed epoxidation  
At first, a design of experiment (DOE) optimization was performed in order to identify 
critical variables of this reaction step. Design of experiment enables the identification of 
important variables as well as determining optimal combinations by statistical analysis 
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(DOE plugin in the software for statistical analysis R). Four variables were selected for 
the epoxidation using whole cells and glucose as co-substrate for cofactor regeneration: 
cellular concentration, glucose concentration, stirring speed and temperature. For each 
of the variables two values were examined and the product concentration after two hours 
was used as response value. The main effects plot is given in Figure 31 showing that for 
two variables (OD600 and rpm) significantly steeper slopes are obtained compared to the 
rest. Of these, the cellular concentration had the strongest negative effect on the product 
concentration in agreement with previous results (Figure 18). In contrast, higher stirring 
speed showed a positive effect on the product concentration with a 9% improvement. 
The glucose concentration exhibited a negative slope as seen for the cellular 
concentration indicating that adding more glucose for cofactor regeneration probably 
boosts the cellular metabolism and as a result, the oxygen availability for the enzyme is 
reduced. Overall, most of these effects can be explained with oxygen limitation. A higher 
concentration of biomass consumes more oxygen, which is also required by the 
monooxygenase (see below). A faster stirring speed can improve the oxygen resident 
time in solution and at the same time, it can reduce mass transfer limitations. Hence, 
substrate and oxygen are better distributed in the reaction mix and higher conversions 
were reached. Finally, the temperature had only a minor effect, but slightly less epoxide 
product was formed at 30 °C. This could point once more at an insufficient oxygen 
availability as gasses are normally more soluble in aqueous systems at lower 
temperatures. The obtained conversions, however, are very low compared to the 
analytical scale reactions where almost full conversion was achieved already after 1 h. 
Here, as visible in Figure 31, a maximum product concentration of 0.185 mM was 
reached after 2 h, which corresponds to a conversion of 3.7%. Very likely, mass transfer 
limitation together with oxygen availability appeared are the important parameters to 
optimize order to improve epoxide production in the StyAB-catalysed step.  
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Figure 31. Main effects plot for the DOE for optimization of the StyAB-catalysed epoxidation of trans-2-
heptene (5 mM). Two values for each of the four variables were taken into account. The concentration of the 
epoxide after 2 h was selected as response factor. All reactions were performed in duplicate. 
 
No further progress in the epoxide production could be made by only relying on cofactor 
regeneration by cellular metabolism. Hence, an enzymatic cofactor regeneration 
catalysed by ADH was tested in combination with SyAB. As mentioned in section 3.1.1.2, 
the alcohol dehydrogenases from Lactobacillus kefir (LkADH) and Leifsonia sp. S749 
(LsADH) were selected as cofactor regeneration enzymes. At first, StyAB and LkADH 
were produced separately and mixed together for the reaction. Using cell-free extract 
and cofactor regeneration could already improve the epoxide production in comparison 
with whole cells reactions where cellular metabolism was used for cofactor regeneration 
(Figure 32, WC - 40mL and first entry for CFE - 80 mL). Additional improvements were 
achieved by using substrate feed (Figure 32, Orange No S feed vs S feed) confirming 
that StyAB suffers from substrate inhibition. Unfortunately, LkADH, when coexpressed, 
almost completely dominated enzyme production resulting in very low StyAB levels 
(Section 3.1.1.2) and no product formation (data not shown). In contrast, LsADH, 
showing a more balanced expression, could reach a product formation comparable with 
experiments where LkADH was added separately (Figure 32, LkADH / S feed vs LsADH 
coexpressed / S feed). In these experiments, a lower overall conversion was reached 
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compared to LkADH added separately, but this way the total protein content could be 
reduced as two different cell-free extracts are not mixed.  
In small scale experiments, it appeared that StyAB’s activity drops to almost zero in 6 h 
(Figure 19, Section 3.1.1.5), hence enzyme feed was tested. Feeding cell-free extract as 
well as substrate could further improve epoxide production (Figure 32, Red S feed vs 
Enzyme + S). At last as done previously,[68,84] an organic phase acting as substrate and 
product sink was tested to see if it would improve the final epoxide concentration. The 
presence of a second organic phase resulted in a 4-fold improvement compared to the 
second highest product concentration reached (Figure 32, LsADH coexpressed / 
Enzyme + S/ 25% organic phase vs LkADH / S feed). In conclusion, using cell-free 
extract and enzymatic cofactor regeneration could improve the epoxide production 
compared to whole cells experiments with metabolism as cofactor regeneration. Enzyme 
and substrates feed further improved production, however the presence of an organic 
phase showed the highest positive effect among all variables tested (Figure 32, blue). 
 
Figure 32. Different experimental conditions used for the epoxidation of trans-2-heptene (2) catalysed by 
StyAB. Reactions using StyAB as CFE and LkADH for cofactor regeneration added as CFE separately with 
or without substrate feed are given in (Orange). Reactions using StyAB coexpressed with LsADH as CFE 
with substrate feed and with or without enzyme feed are given in red. The same reaction (with enzyme feed) 
using 25% heptane as organic phase is shown in blue.  
The best conditions among the tested setup were achieved by using enzymatic cofactor 
regeneration, enzyme and substrate feed, an organic phase and compressed air input. 
The beneficial effect of compressed air could not be quantified with these experiments, 
however the presence of oxygen appeared to be an extremely important variable to 
control during the reaction. Thus, an oxygen sensor was used to measure O2 
consumption in reactions with cell-free extract and enzymatic cofactor regeneration or 
whole cells and cellular metabolism as cofactor regeneration to further investigate the 
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oxygen limitation. Figure 33 A shows that the O2 concentration dropped to 0 µmol/L in 
about 7 minutes when whole cells (OD600=10, corresponding to 15 g/L wet cell weight) 
were used as biocatalyst. In contrast, in reactions containing cell-free extract (from 
OD600=10, corresponding to 2.3 g/L total protein) the oxygen concentration dropped to 
around 80 µmol/L without compressed air input. This could explain the extremely low 
epoxide formation reached in whole cells reactions, as cellular metabolism would 
consume all the oxygen. Adding compressed air (3 L/h) maintained the oxygen saturated 
in cell-free extract reactions for the entire tested time, whereas whole cells consumed 
oxygen at a faster rate (than 3 L/h) keeping the oxygen concentration below 100 µmol/L 
for the first seven hours (Figure 33, B). However, the difference in oxygen consumption 
between the two reactions does not correlate with the final product concentrations, as 
only 0.9 mM epoxide were formed in the reaction containing whole cells and 1.4 mM in 
the CFE reaction. In this case, a second organic phase could not be used as the oxygen 
sensor would be damaged by organic solvents. 
 
Figure 33. Oxygen consumption in styrene monooxygenase-catalysed reactions using whole cells and 
cofactor regeneration by cell metabolism (orange) or cell-free extract harbouring StyAB and coexpressed 
LsADH for cofactor regeneration (blue). The curves show the oxygen concentration in solution after addition 
of the respective co-substrates for cofactor regeneration (glucose and isopropanol, respectively). In A no 
compressed air was added, whereas in B compressed air was constantly introduced at a flow of 3 L/h and 
the oxygen concentration was measured for longer times.  
 
The final epoxide concentration does not reflect the final epoxide concentration reached 
by the two reactions system, hence apparent kinetic data using different O2 
concentrations were measured for StyAB co-expressed with LsADH applied as cell-free 
extract.  
The O2 concentration was adjusted by removing excess O2 by bubbling nitrogen in the 
solution until a user-defined O2 concentration (7,10, 20, 30, 40, 100, 150 µmol/L). 
Afterwards, the time needed for the oxygen to diffuse back into the solution is measured 
after addition of the substrate. This time is then compared with the diffusion rate of 
oxygen when no substrate is added. The differential rate between these two 
A B 
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measurements is the enzymatic reaction; as the monooxygenase reaction would 
consume some of the oxygen diffusing in solution, hence O2 would saturate the solution 
faster when no substrate is present.[186] StyAB displayed a good affinity for O2 with a 
rather low KM of 14.6 µmol/L. As a rule of thumb oxygen concentration should be kept 
above ten times the KM (approx. 146 µmol/L) to work at velocities close to Vmax. This 
could explain the lower productivity of StyAB when whole cells are used as the 
biocatalyst. 
 
 
Figure 34. Apparent KM and Vmax measured for StyAB coexpressed with LsADH applied as cell-free extract 
using different O2 concentrations. Kinetic data were collected in duplicate. 
 
Figure 32 (blue) demonstrated that the use of a second organic phase (25% v/v) could 
improve trans-2,3-epoxyheptane (22) production 4-fold compared to the second highest 
product concentration reached (Figure 32, LsADH coexpressed / Enzyme + S/ 25% 
organic phase vs LkADH / S feed). Therefore, different organic solvents were tested in 
order to find the best for the epoxidation of trans-2-heptene (2) as a model substrate. 
Several organic solvents ranging from hydrophobic (isooctane) to polar (ethyl acetate) 
were tested using the optimal setup found (StyAB coexpressed with LsADH, enzyme 
and substrate feed and compressed air input and 25% organic phase). Overall the 
epoxidation of 2 seems to be improved by a hydrophobic second phase (Figure 35), 
while the polar solvents tested did not yield any significant amount of epoxide product 
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(data not shown). Among them, pentyl acetate and hexyl acetate are worth mentioning 
as StyAB was reported to reach high product concentrations on small scale in presence 
of these solvents.[68] On big scale, however, all polar solvents caused considerable 
protein denaturation in short time leading to extremely low product concentrations (data 
not shown). Adding 100 µmol NADH and 50 µmol FAD did not seem to affect the final 
product concentration. In conclusion, heptane appeared to be the best compromise as it 
would allow better downstream processing having a lower boiling point compared to 
isooctane and would be easier to remove in vacuum. Finally, addition of expensive 
cofactors can be omitted since they did not show any positive effect on the final product 
concentration. 
 
Figure 35. Comparison of different organic solvents used as second phase for the production of trans-2,3-
epoxyheptane (22). All reactions were performed using the best setup found (StyAB coexpressed with 
LsADH, enzyme and substrate feed and compressed air input and 25% organic phase).  
 
Heptane could successfully act as a substrate and product reservoir for the styrene 
monooxygenase as it would be necessary to reach a total epoxide concentration of 100 
mM to reach 20 mM in the aqueous phase (Figure 36). On the other hand, heptane might 
be a problem for the halohydrin dehalogenase as a low epoxide concentration would be 
present in the aqueous phase (under 10 mM) giving that the styrene monooxygenase on 
average could reach a product concentration of 28 mM. Interestingly, it appeared that 
epoxide 22 concentration in the aqueous phase is higher than 21, although epoxide 22 
as a longer chain that should make it more hydrophobic, whereas trans-2-hexene (1) is 
the least soluble in water compared to the epoxides. The partition of trans-2-heptene (2) 
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could not be determined due to analytics limitation, as heptane has a similar retention 
time, in GC, hence it covers trans-2-heptene (2) peak completely. 
 
Figure 36. The graph shows the concentrations of the different compounds found in the aqueous phase 
when 50% (v/v) heptane was used. When the compounds were present at a concentration of 5, 50 or 100 
mM in aqueous phase before extraction.   
 
After optimising the reaction system for epoxidation of trans-2-heptene, the optimised 
setup (Figure 32, blue) was also tested for the synthesis of trans-2,3-epoxyhexane (21) 
in 80 mL scale and in larger-scale reactions (250 ml) for the conversion of trans-2-
heptene (2). The reactions were carried out at 25 °C and 300 rpm, with heptane as 
second phase (25% v/v). Substrate and enzyme were fed hourly until a final 
concentration of 100 mM and 9.2 g/L (total protein concentration), respectively. In Figure 
37, the orange curve shows the epoxide formation in a reaction using trans-2-hexene (1) 
as substrate, where only a low epoxide concentration (6 mM) could be achieved 
compared to the epoxidation of trans-2-heptene under similar conditions (Figure 35). 
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Figure 37. StyAB coexpressed with LsADH, enzyme and substrate feed and compressed air input and 25% 
organic phase were used for the production of trans-2,3-epoxyhexane (21) (Orange). The blue line shows 
the same reaction setup for the epoxidation of trans-2-heptene (2) on 200 mL scale (blue line).  
On the other hand, the blue curve (Figure 37) shows the result of trans-2-heptene (2) 
epoxidation on 200 mL scale, for which surprisingly a final epoxide concentration of 69 
mM (69% conversion) could be achieved. This represents the highest product 
concentration reached in this work, which, however, could not be reproduced in further 
tests. This might be due to varying expression levels of StyAB in the CFE used as 
catalyst. All in all, the relatively low StyAB productivity would very likely limit the overall 
final product concentration when used in cascade reactions. Nonetheless, the reaction 
conditions could be significantly improved to reach acceptable epoxide concentrations 
for a proof of concept of the whole cascade for enantiopure amino alcohol synthesis. 
3.1.5.2 Scale-up of the epoxide-ring opening step 
All HHDH experiments were performed using 5 mM substrate concentration, however 
higher substrate concentrations are desirable during scale up. Whole cells (60 g/L wet 
cell weight) harbouring either HheE or Hhe5 were used to convert racemic epoxides 21 
and 22, respectively, ranging from 50 to 300 mM. In all cases, two equivalents of the 
nucleophile (NaN3) were added (Figure 38). HheE showed reasonable conversions 
compared to the chemical background (dashed lines) only using 50 mM substrate (21) 
concentration (Figure 38, A). Using 200 and 300 mM of epoxide 21 resulted in almost 
complete suppression of the enzymatic reaction. Although, this is very likely due to the 
high azide concentration used, as it would be sufficient to use 1.1 equivalents to still have 
a concentration significantly higher than KM. Chemical background observed in the 
epoxidation of 22 is generally lower compared to 21, however 200 and 300 mM 
concentration also showed considerable background reaction lowering the 
regioselectivity of HheE5 to 70% (Figure 38, B). In all cases, the high azide concentration 
may have contributed to the overall decrease in regioselectivity and low conversion at 
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high substrate concentrations. On the other hand, the styrene monooxygenase showed 
a rather low productivity, hence no further experiments with HHDHs were done to 
improve regioselectivity at higher than 50 mM epoxide concentration.  
Finally, preparative scale reactions using 50 mM (approx. 200 mg) of 21 or 22 coupled 
with HheE and HheE5 respectively were set up. The catalysts were applied as whole 
cells and the reactions were carried out in 50 mL reaction volume. HheE could produce 
142 mg of 31a (50% isolated yield) and using HheE5 151 mg of pure 32a (48 % isolated 
yield) could be isolated. 
 
 
Figure 38. Whole-cell bioconversions of epoxide 21 (graph A) and epoxide 22 (graph B) at different substrate 
concentrations using HheE and HheE5 (60 g/L, wet cell weight), respectively. Each reaction was carried out 
in duplicate using the stated substrate concentrations and 2 eq. of NaN3. Dashed lines represent negative 
control reactions using E. coli cells carrying an empty vector. 
 
3.1.5.3 Compatibility tests 
One of the main challenges in setting up cascade reactions is the compatibility of the 
different reactions. Specific reagents used in a given step can influence the performance 
of the other catalysts and vice versa. Thus, it is important to determine if reactions can 
proceed in one pot, either at the same time or one after the other, by testing if single 
compounds from different steps negatively influence another reaction step.  
In small scale, no compatibility issues were found for both enzymatic steps as sodium 
azide present during the epoxidation did not alter StyAB epoxidation (data not shown) 
hence, epoxidation and epoxide ring opening can run simultaneously or sequentially. 
Halohydrin dehalogenases could achieve full conversion when added after the 
A B 
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epoxidation step (section 3.1.4) to further validate this conclusion. However, scale-up of 
the StyAB catalysed epoxidation reaction highlighted the need for a second organic 
phase to reach reasonably high epoxide concentrations (section 3.1.5.1). Hence, 
epoxide ring opening catalysed by the HHDHs was tested in the presence of heptane as 
second phase (25% v/v). Corresponding conversions of racemic trans-2,3-epoxyhexane 
(21) and trans-2,3-epoxyheptane (22) carried out by HheE and HheE5, respectively, are 
shown in Figure 39. For both enzymes, the presence of the organic solvent had a 
considerably negative effect on enzyme activity. Especially for HheE, only 33% 
conversion could be achieved within 24 h (Figure 39, A), whereas HheE5 still reached 
87% conversion, however, after significantly longer reaction time compared to the 
reaction without second organic phase (Figure 39, B). This important negative effect 
would very likely be one of the challenges to overcome in the setup of this cascade 
reaction. 
 
Figure 39. HheE (A) and HheE5 (B) conversion of 10 mM of their respective substrates (12 for HheE and 22 
for HheE5). The blue dashed lines represent control epoxide ring opening reactions without a second organic 
phase. The orange lines represent conversions in presence of 25% (v/v) heptane. All experiments were 
done in duplicate. 
 
Similarly, the influence of Pd/C on the epoxidation and epoxide ring opening steps was 
analysed. In this case, only trans-2-heptene (2) for the epoxidation reaction and trans-
2,3-epoxyheptane (22) for the epoxide ring opening were used as model substrates. The 
presence of palladium on carbon caused a decrease in the conversion values for all 
reactions within 1 h (Figure 40). The biggest effect was observed for the epoxidation 
reaction when StyAB was employed as whole-cell catalyst (30 g/L wet cell weight) with 
cellular metabolism for cofactor regeneration. Possible the nanoparticles are toxic to the 
cells and hence, cofactor regeneration did not work properly. This effect was reduced 
when BNAH was used for cofactor regeneration and StyA was applied as cell-free extract 
(4.6 g/L total protein content), confirming again that higher conversions can be achieved 
in this step when using cell-free extract instead of whole cells. Activity of HheE5, when 
A B 
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employed as whole cell catalyst, was less affected by Pd/C addition, but still a decrease 
in conversion was evident within 1 h of reaction. 
 
Figure 40. Influence of Pd/C (1 mg/mL) on the different catalysts for step 1 and step 2. All reactions were 
carried out for 1h using the model substrate were trans-2-heptene (2) for StyA/StyAB and trans-2,3-
epoxyheptane (22) for HheE5. StyA was used as cell-free extract (4.6 g/L total protein content), with BNAH 
for cofactor regeneration. StyAB was used as whole cells (30 g/L wet cell weight), with glucose as cofactor 
regeneration system. HheE5 was used as whole cells (60 g/L wet cell weight). 
 
Finally, the influence of different components from steps 1 and 2 on the azido alcohol 
hydrogenation was tested. In an optimal cascade setup, Pd/C would be added directly 
after the epoxide ring opening without workup in between, as the cascade is intended to 
work in one pot. Hence, a hydrogenation reaction of 5 mM racemic 2-azido-3-
hydroxyheptane (32a) using 1 mg/mL Pd/C and a hydrogen-containing balloon was 
performed in aqueous buffer in the presence of single components from step 1 and step 
2.  Interestingly, all tested components exerted a negative effect on the reaction rate 
although conversions >90% could still be reached in almost all cases after prolonged 
reaction time (Figure 41). The most pronounced effect was observed for the cofactors 
BNAH (10 mM, yellow line) and FAD (200 µM, dark blue line) used by the styrene 
monooxygenase. Whole cells (60 g/L wet cell weight, green line) had a similar negative 
effect as the cofactors, whereas the influence of free protein (4.6 g/L, orange line) from 
the CFE was less and 90% conversion was achieved already after 30 min reaction. The 
negative influence of by whole cells, BNAH and FAD on Pd/C leaves the option of using 
both catalysts in step 1 and step 2 as cell-free extract (CFE). In conclusion, ideally the 
cascade reaction could be run having the first two steps running simultaneously or 
consequently and adding the hydrogenation catalyst separately after the first two steps 
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are done. This would avoid having O2 and H2 input at the same time and prevent contact 
between Pd/C and cell-free extract before any azido alcohol product is present. 
 
Figure 41. Hydrogenation of 5 mM racemic 2-azido-3-hydroxyheptane (32a) using 1 mg/mL Pd/C in aqueous 
buffer. H2 was supplied via a balloon connected with a needle. The hydrogenation reaction performed only 
with Pd/C and H2 is given as dashed line (control). Components from other cascade steps were added 
individually: CFE (Cell-free extract 4.6 g/L total protein content, orange line). WC (whole cells 60 g/L wet cell 
weight, green line). BNAH (10 mM, yellow line) and FAD (200 µM, dark blue line) All reactions were 
performed in duplicate. 
 
3.1.5.4 Combination of the three reaction steps 
After optimization of individual step and cross-interaction studies, the catalysts were 
combined to perform the cascade reaction for the conversion of 20 mM trans-2-heptene 
(2) to (2R,3S)-2-amino-3-hydroxyheptane (42a) as the final product. In detail, the styrene 
monooxygenase and coexpressed LsADH were applied as cell-free extract using a 
second organic solvent (heptane 25% v/v) to maximise epoxide production. Giving that 
the epoxidation reaction is much slower compared to the epoxide ring opening, the first 
step was run separately for the first 24 h. This delay would allow the production of a 
critical amount of epoxide and prevent long incubation of the HHDHs with heptane, 
proven to be toxic for the HHDH. From 24 h to 48 h reaction time, epoxidation and 
epoxide ring opening occurred in parallel. Using hydrogen for the last step was not 
possible as the available equipment did not allow a safe and efficient hydrogen handling. 
For this, alternatives for in situ hydrogen generation were explored. Among these, the 
generation of molecular hydrogen by dropping hydrochloric acid on zinc dust showed an 
insufficient generation rate under safe conditions. Hydrazine was used for in situ H2 
generation in the preparation of authentic compounds (Methods, Section 2.1.1)[158] but 
did not show any conversion in aqueous solutions and was abandoned. Finally, 
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triethylsilane (TES) was the only in situ hydrogen generation system that gave a 
reasonable conversion in aqueous buffer. Hence, the final step was performed by adding 
after the first two steps Pd/C (2 mg/mL) and 3 equivalents of triethylsilane (TES) 
dropwise for the first 8 h.  
Figure 42 presents the progression of the cascade reaction steps over time for the 
conversion of trans-2-heptene (2) as model substrate. The hydrogenation reaction was 
monitored by following the consumption of the corresponding azido alcohol (32a), as it 
was not possible to detect 42a in GC. According to Figure 42, running the three-step 
cascade in one pot is feasible although the amino alcohol isolated yield (2.4%) was very 
low, however compatible with the low azido alcohol produced in the first two steps.  
All catalysts reached rather low productivity which added up to the final low yield. In this 
case, the last two steps appear to be the limiting factors as HheE5 did not fully convert 
the epoxide produce as well as the hydrogenation catalyst. The epoxide ring opening is 
negatively influenced by the presence of heptane which cannot be removed as it would 
significantly decrease the epoxide production.     
The hydrogenation could be improved by using an autoclave reactor to provide H2 
overpressure to increase the efficiency of the hydrogenation reaction and fully convert 
the azido alcohol at least. 
 
 
Figure 42. Concentrations (mM) of 22 and 32 produced during the cascade composed of StyAB, HheE5 and 
Pd/C in 80 mL scale (60 mL + 20 mL heptane as second phase) in the conversion of 20 mM of trans-2-
heptene. Each catalyst was added sequentially; grey bars show for how long each reaction was performed.   
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Alternatively, the hydrogenation could be separated by an intermediate work up and run 
in methanol where full conversion could be reached. Hence, exemplary preparative scale 
reactions were performed with an intermediate workup before the last (hydrogenation) 
step. The crude extract was directly dissolved in methanol where hydrazine can be used 
for an efficient hydrogen generation as used for the synthesis of reference compounds 
(Methods, Section 2.1.1). Isolated yields for cascade with only the first two steps were 
determined for comparison. Overall, the reactions where no hydrogenation was 
performed afforded similar product concentration, however slightly lower isolated yields 
were obtained. Running the hydrogenation in methanol separately significantly improve 
the isolated yield compared to the cascade mentioned previously (Figure 42) where only 
2.4% isolated yield was reached. Very likely removing free protein significantly improved 
Pd/C conversion Moreover, extraction of a polar compound from the aqueous buffer is a 
challenging process and a rather significant amount of product could not be isolated. 
Very likely the epoxide ring opening step has a strong negative effect as only a maximum 
of 6.47 mM of 42a were produced. In all cascade reactions, similar azido alcohol 
concentrations were reached, although HheE showed a significantly higher sensibility to 
heptane compared to HheE5 (Figure 39). In all reactions, the corresponding azido 
alcohols were produced with exquisite enantiomeric excess (> 99%). However, HheE 
regioselectivity decreased resulting in a regioisomeric ratio of 92:8 (31a:31b) (entries 1 
and 2, a:b, Table 23) probably due to a higher chemical background reaction. Whereas 
HheE5 displayed a regioselectivity comparable with previous experiments. The high 
product enantiomeric excess (azido alcohol products) confirmed the validity of this 
synthetic strategy, yet further optimization is needed to improve the moderate isolated. 
 
Table 23. Summary of the cascade runs combining StyAB, HHDH-catalysed epoxide ring opening and 
hydrogenation using Pd/C. Entries 1 and 3 summarise the results of the cascades producing (2R,3S)-2-
amino-3-hydroxyhexane (41a) and (2R,3S)-2-amino-3-hydroxyheptane (42a) respectively. Entries 2 
(production of 31a) and 4 (production of 32a) summarise the results of the cascades without hydrogenation 
step. In all cascades, 50 mM of the respective alkenes 1 (entries 1 and 2) an 2 (entries 3 and 4) were used 
as substrate.   
# Cascade 
2-azido- 3-
alcohol (mM) 
Theoretical 
yield (mg) 
Isolated 
Yield (mg) 
Isolated 
Yield [%] 
ee 
(epoxid
e) 
ee | a:b 
(azide) 
1 
StyAB, HheE 
and Pd/C 
5.67 39.89 29.8 8.5 95% 
>99% | 
92:8 
2 StyAB, HheE 6.14 52.76 31.7 7.0 95% 
>99% | 
92:8 
3 
StyAB, HheE5 
and Pd/C 
6.16 48.52 40.9 10.5 98% 
>99% | 
99:1 
4 StyAB, HheE5 6.47 61.08 42.9 9.1 98% 
>99% | 
99:1 
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3.1.6 Shi epoxidation diketal catalyst – HHDH – Pd/C cascade 
Scheme 20 illustrated that regioselective epoxide ring opening of epoxides 21 and 22 in 
S,S-configuration results in the production of the corresponding enantiopure azido- and 
amino alcohol 31a and 32a in (2R,3S)-configuration. Replacing the StyAB of the first step 
with a catalyst producing the (R,R)-epoxide enantiomers but keeping the same HHDH 
for the second step would result in a complementary cascade for the synthesis of 
enantiocomplementary azido- and aminoalcohols (Scheme 21). Thus, combining the Shi 
epoxidation catalyst with HheE or HheE5 and Pd/C would result in the production of 
(2S,3R)-2-azido-3-hydroxyhexane (31a) and (2S,3R)-2-azido-3-hydroxyheptane (32a) 
respectively. As for the cascade described in 3.1.5, single steps were optimized 
separately and compatibility tests were run to determine the best way to combine the 
catalysts.  
 
 
Scheme 21. Example of the cascade composed of the (R)-selective Shi epoxidation diketal catalyst in the 
first step, a regioselective halohydrin dehalogenase in the second step and palladium on carbon in the last 
step. As seen for cascade 1 in Scheme 20, the combination of enantioselectivity and regioselectivity leads 
to the formation of only one of the four possible product stereoisomers. 
 
3.1.6.1 Optimization of Shi epoxidation 
The Shi epoxidation diketal catalyst is an organocatalyst and in particular, it is a chiral 
ketone. According to the reaction mechanism, the keto group reacts with Oxone© to form 
a dioxirane moiety, necessary to perform the epoxidation. The surrounding of the keto 
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group must be chiral to carry out an asymmetric epoxidation.[187] In the first small scale 
reaction, 10 mM trans-2-heptene (2) concentration was used and the epoxidation 
reaction was run for 24 h keeping the pH at 8 by adding NaHCO3. In this case, the product 
enantiomeric excess obtained was only 60% (data not shown). Shi et al. determined that 
in some cases performing the reactions at low temperature (-2 °C) and at pH>10 could 
help to prevent the catalyst decomposition.[187] With these reaction conditions it was 
possible to yield (R,R)-trans-2,3-epoxyheptane (22) in 94% product enantiomeric excess 
(Figure 15, Section 3.1.1.4). In all small scale reactions, the acetonitrile concentration 
used was 20% (v/v), however the amount needed may vary depending on the substrate 
reactivity, hence different concentrations were tested. Additionally, both HHDHs showed 
sensibility to the presence of a second organic phase (section 3.1.5.3), hence lower 
acetonitrile concentrations were tested (5 and 10% v/v). The reaction was first optimized 
in 50 mL scale as Oxone© should be added portion wise. Giving that Oxone© is a powder, 
a larger scale reaction allows the experimenter to use a spatula to add it in a reproducible 
way. 50 mM substrate concentration and 0.2 equivalents of the catalyst were used. Up 
to four equivalents of Oxone© were added to the reaction in portions. For both substrates 
1 and 2 a 20% (v/v) concentration of acetonitrile resulted in the best conversion values. 
The product enantiomeric excess decreased to 80-85% compared to the high eeP 
obtained in small scale reactions. Overall, better conversions were obtained in the 
epoxidation of trans-2-hexene (1) compared to when trans-2-heptene (2) was used as 
substrate (Figure 43). Decreasing the amount of acetonitrile resulted in significantly lower 
conversions using both substrates. Lowering acetonitrile concentration to 10% (v/v) 
caused a decrease in conversion below 50% for both substrates, however the product 
enantiomeric excess remained around to 80-85% (Figure 43). Interestingly a further 
decrease of acetonitrile to 5% (v/v) did not cause any decrease in conversion, although 
the eeP decreased to approx. 50%. Very likely, Oxone© could better dissolve in solution 
at lower acetonitrile concentrations causing auto-oxidation of the Shi diketal epoxidation 
catalyst leading to the formation of acetone. Acetone can perform the same epoxidation 
cycle, however, displaying no enantioselectivity. As mentioned previously, acetonitrile is 
proposed to participate in the reaction mechanism, hence lowering its concentration 
resulted in lower yields in agreement with this hypothesis.   
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Figure 43. Conversion and product enantiomeric excess (eeP) obtained at different acetonitrile (ACN) 
concentrations. The epoxidations were carried out using 0.2 equivalents of the Shi epoxidation catalyst and 
four equivalents of Oxone in the conversion of 50 mM of either 1 or 2.  
 
A higher substrate concentration (250 mM) was tested to investigate if the reaction could 
be upscaled without additional challenges. Furthermore, this way the ratio 
Oxone©:acetonitrile would increase similarly to reactions with only 5% acetonitrile 
concentration. Hence, a decrease of eeP would reveal if an excess of Oxone© compared 
to acetonitrile is causing the lower eeP or acetonitrile alone. Figure 44 shows that 
although it was possible to produce 6 g/L (59 mM) of trans-2,3-epoxyhexane and 8 g/L 
(69 mM) of trans-2,3-epoxyheptane the overall conversion was below 50%. The product 
enantiomeric excess did not decrease as observed for lower acetonitrile concentrations 
(Figure 43). Thus, Oxone© seems to have only a minor effect on the enantioselectivity of 
the reaction. Overall, the product concentrations reached in the Shi epoxidation are 
higher compared to reactions with StyAB, although the products are formed with a lower 
product enantiomeric excess. 
 
Figure 44. Conversion (light blue), product enantiomeric excess (eeP, dark blue) and final epoxide 
concentration (grey) obtained for the epoxidation of 250 mM of alkene substrates (1) and (2). In all cases, 
0.2 eq. of Shi diketal catalyst, acetonitrile to a concentration of 20 % (v/v) and 4 eq. of Oxone added portion 
wise were used. Both reactions were carried out at -2 °C.    
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3.1.6.2 Compatibility tests 
As described in section 2.2.4, the Shi epoxidation diketal catalyst requires extreme 
reaction conditions; in fact, a temperature below zero is required together with a pH of 
11 to ensure catalyst stability. Hence, this cascade must be run in sequential mode, as 
the high pH and low temperature are not compatible with the optimal reaction conditions 
required by halohydrin dehalogenases. Furthermore, the epoxidation reaction requires a 
significant amount of acetonitrile (Figure 43) to reach good conversions and to preserve 
the enantioselectivity of the catalyst. Considering that HheE and HheE5 activity was 
significantly affected by the solvent heptane, the effect of acetonitrile on both enzymes 
was studied as well. Similarly, the influence of other components present in the Shi 
epoxidation was investigated on the epoxide ring opening of 12 or 22 using HheE and 
HheE5, respectively (Figure 45). Again, both HHDHs exhibited a sensibility to acetonitrile 
as the activity was already reduced substantially at 10% acetonitrile concentration within 
the first 4 h. 5% acetonitrile had a significantly lower effect on HheE and no differences 
with the control reaction were observed for HheE5. In the presence of 20% acetonitrile, 
however, HheE5 activity was almost abolished. These reactions were carried out using 
whole-cell biocatalysts (60 g/L wet cell weight), but additionally, a reaction using HheE5-
containing cell-free extract was performed in the presence of 5% acetonitrile. Whole cells 
yielded a slightly better conversion indicating that the cellular envelope probably protects 
the enzyme against the organic solvent improving the conversion.  
Additionally, two different concentrations of Oxone© (50 mM and 10 mM) were tested in 
combination with HheE5 to check if any unreacted compound from step 1 (epoxidation) 
could be an issue for the HHDHs. The respective graphs in Figure 45 indicate that higher 
concentrations of Oxone© significantly affected HheE5 activity and only 27% conversion 
could be achieved after 24 h in the presence of 50 mM Oxone©. However, significant 
foaming was observed after NaN3 addition, Oxone© can oxidise the azide to form N2 and 
N2O in ratio 2:1,[188] resulting in a lower concentration of the nucleophile for epoxide ring 
opening. When only 10 mM Oxone© was added, substrate conversion was reduced less. 
In this case, if all Oxone© would have reacted with azide in a 1:1 ratio, a theoretical 
amount of 30 mM azide (3 eq.) would still have been available. Moreover, it appeared 
that Oxone© had a greater effect on HheE5 than on HheE, for which the presence of 
Oxone© even seems to be beneficial as a slightly higher conversion was reached after 4 
h compared to the positive control reaction without Oxone© addition.  
In summary, the presence of acetonitrile will be the limiting factor for cascade setup as 
seen for cascade 1 (section 3.1.5.3), especially in the case of HheE. Moreover, the effect 
of Oxone© on HheE5 at high concentration would be less critical if step 2 (epoxide ring 
opening) would be started after completion of the first step (epoxidation), once all added 
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Oxone© has either reacted with the Shi epoxidation diketal catalyst or spontaneously 
decomposed.[189] 
 
 
Figure 45. Epoxide ring opening catalysed by HheE (A, 10 mM of 12 as substrate) and HheE5 (B, 10 mM of 
22 as substrate) using whole cells (60 g/L wet cell weight) or cell-free extract (purple line in graph B, 9.2 g/L 
total protein content) and NaN3 (40 mM) in presence of different components of the Shi epoxidation reaction. 
All reactions were performed in duplicate. Control reactions without acetonitrile or Oxone© are given as 
dashed lines. 
 
As mentioned previously, cascade reactions often require a compromise between 
optimal conditions of the separate reaction steps. According to Figure 43, the best 
acetonitrile concentration for the Shi epoxidation is 20%. In contrast, due to the sensibility 
of the selected HHDHs to organic solvents, maximum 5% acetonitrile should be used.  
All in all, this cascade should be run as a 1-pot-3 steps cascade reaction giving the 
extremely different reaction conditions of the first two steps. Moreover, as shown in 
Figure 41, the hydrogenation catalyst is negatively affected by the presence of whole 
cells. Hence, an intermediate workup to remove whole cells from the reaction mix before 
the hydrogenation may be necessary resulting in a 2-pot reaction. 
3.1.6.3 Combination of the three reaction steps 
Finally, as for cascade 1, a preparative cascade run on 50 mL scale using an acetonitrile 
concentration of 5% was performed for the conversion of 50 mM trans-2-heptene (2) to 
(2S,3R)-2-amino-3-hydroxyheptane (42a) (Figure 46). The epoxidation step was run first 
for 24 h, as the required low temperature (-2 °C) and the high pH (11) did not allow a 
direct combination with HheE5. Hence, after heating the reaction mix to 25 °C and 
adjusting the pH to 7.5, HheE5 (60 g/L, wet cell weight) and sodium azide (50 mM) were 
added and the epoxide ring opening was carried out for additional 24 h. At last, Pd/C (2 
mg/mL) and 3 equivalents of TES were added stepwise for 8 h, as mentioned previously. 
The progress of the three reaction steps is displayed in Figure 46. The reaction was 
A B 
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followed by formation of epoxide 22 and azido alcohol 32, whereas the hydrogenation 
step was followed by consumption of 32. In general, this 1-pot-3-step cascade appeared 
feasible, however, the first step seemed to be the bottleneck yielding only a conversion 
of 33% and a low eeP of 34% in accordance with previous experiments (Figure 43). 
HheE5 performed better in this cascade with only 5% acetonitrile concentration, whereas 
in other cascade runs using 10% or 20% acetonitrile concentration no further conversion 
could be observed in the epoxide ring-opening step (data not shown). Compared to 
cascade 1, a higher conversion was achieved in the hydrogenation step reaching 64% 
after 24h and the final isolated yield (3%) was slightly better than cascade 1 (2.4%). In 
conclusion, despite the rather low eeP obtained, this process with further process 
engineering to overcome the acetonitrile limitation could result in the production of 
enantiopure molecules. 
 
 
Figure 46. Conversion values of the sequential cascade composed of Shi epoxidation, HheE5-catalysed 
epoxide ring opening and hydrogenation using Pd/C in 50 mL scale (5% acetonitrile concentration) starting 
from 50 mM trans-2-heptene. The epoxidation and epoxide ring opening reactions were monitored via GC, 
the hydrogenation was monitored via 32 consumption.   
 
Similarly to cascade 1, preparative scale reactions were set up separating the 
hydrogenation reaction from the first two steps (2-pot-3-step cascade). This generally 
improved the efficiency of reaction work up as amino alcohols are polar compounds and 
are typically difficult to extract from the aqueous phase. Hence, performing the 
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hydrogenation step in methanol could improve the overall yield as no amino alcohol 
extraction from the aqueous phase was needed. Entries 1 and 3 in Table 24 display the 
isolated yields of the cascade for the production of (2S,3R)-2-amino-3-hydroxyhexane 
(41a) and (2S,3R)-2-amino-3-hydroxyheptane (42a), respectively, whereas entries 2 and 
4 summarise the data corresponding to the 2-step cascades including only epoxidation 
and epoxide ring opening. Despite the lower kinetics, the cascades involving HheE 
achieved similar azide concentrations. For all cases, the products were obtained with 
rather low eeP as a direct result of the poor enantioselectivity achieved in the epoxidation 
step. Enantiomeric excesses were further improved in the HHDH-catalysed step as both 
enzymes preferentially converted the epoxide in (R,R)-configuration. Moreover, lower 
regioselectivity is observed for entry 1, which might be caused by a higher chemical 
background reaction. However, as discussed before, the two regioisomers can be 
separated by silica column chromatography (Appendix, Supporting figure 25). Compared 
to cascade 1 higher isolated yields were achieved, however with significantly lower eeP. 
Increasing the acetonitrile concentration in the first step would further increase 
conversion and highly increase the eeP of the overall cascade. However, further process 
engineering would be required to efficiently remove or decrease the presence of 
acetonitrile before starting the epoxide ring opening reaction. 
Table 24. Summary of the cascade runs combining Shi epoxidation, HHDH-catalysed epoxide ring opening 
and hydrogenation using Pd/C. Entries 1 and 3 summarise the results of the cascades producing (2S,3R)-
2-amino-3-hydroxyhexane (41a) and (2S,3R)-2-amino-3-hydroxyheptane (42a), respectively. Entries 2 
(production of 31a) and 4 (production of 32a) summarise the results of the cascades without hydrogenation 
step. In all cascades, 50 mM of the respective alkenes 1 (entries 1 and 2) and 2 (entries 3 and 4) were used 
as substrate.   
# Cascade 
2-azido- 3-
alcohol (mM) 
Theoretica
l (mg) 
Isolated 
Yield (mg) 
Isolated 
Yield 
ee% 
(epoxide) 
ee% | a:b 
(azide) 
1 
Shi, HheE and 
Pd/C 
24 157.5 86.1 26% 42% 
60% | 
88:12 
2 Shi, HheE 19.8 158.77 60.5 15% 45% 61% | 97:3 
3 
Shi, HheE5 
and Pd/C 
15.45 113.53 67.5 18% 53% 58% | 98:2 
4 Shi, HheE5 12.35 108.73 83.9 19% 47% 56% | 99:1 
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3.2 Cascade starting from cyclic alkenes 
The main difference of this cascade compared to the cascades described in section 3.1 
is the use of a cyclic alkene, cyclohexane, as starting substrate. Epoxidation of this 
compound leads to a prochiral epoxide, hence, the strategy in this cascade was slightly 
different. Enantioselectivity is not required in the first step but in the subsequent epoxide 
ring opening. Thus, MsAct was selected for its high perhydrolysis/hydrolysis ratio in water 
to induce the chemical epoxidation (step 1), whereas HheG was selected as the catalyst 
to perform the stereoselective epoxide ring opening (step 2), as this HHDH was the only 
known enzyme with significant activity towards this substrate.[105] Finally, palladium on 
carbon was used for the last step to reduce the azido group and to produce the final 
enantiopure amino alcohol (Scheme 22). 
 
Scheme 22. Reaction scheme for cascade 3 starting from cyclohexene combining epoxidation in the first 
step, azidolysis of the corresponding epoxide in the second step and chemical hydrogenation of the azido 
group in the last step to form an amino alcohol. Stereoselectivity is required in the second step to generate 
an enantiopure product. 
 
3.2.1 Epoxidation 
3.2.1.1 Expression and purification of the acyl transferase from 
Mycobacterium smegmatis (MsAct) 
The heterologous expression of the acyl transferase was established previously.[161] 
pET28a(+) was used as expression vector and E. coli BL21 (DE3) was chosen as the 
host organism for heterologous production of the N-terminally His-tagged protein. MsAct 
was purified using the IMAC purification protocol. However, the standard imidazole 
gradient resulted in a slow elution of the target protein as shown by the broad MsAct 
peak in the chromatogram in Figure 47. To limit the further dilution of the sample, 
imidazole concentration was set to 500 mM around fraction 47 (Figure 47). This 
concentration increase resulted in a prompt elution of MsAct, which is reflected by a 
sudden increase in the absorbance at 280 nm as well as a stronger protein band in the 
corresponding SDS-PAGE gel starting from fraction 48. After concentration of the 
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combined elution fractions by ultrafiltration using a 30 kDa cut-off membrane, a yield of 
160 mg/L of pure MsAct was obtained. 
 
 
Figure 47. The upper picture shows the purification chromatogram of the His-tagged MsAct. UV signal 
representing the protein elution is given in blue, whereas the gradient progression is represented by the 
green line. In the SDS-PAGE gels, only the fractions containing the target protein are shown.  
 
3.2.1.2 MsAct-catalysed perhydrolysis and subsequent chemical 
epoxidation 
 
Scheme 23. General reaction scheme of the epoxidation of cyclohexene catalysed by MsAct. The enzyme 
catalyses the perhydrolysis of ethyl acetate using hydrogen peroxide. The resulting peracid spontaneously 
reacts with cyclohexene producing cyclohexene oxide.  
 
MsAct 
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As shown in Scheme 23, the actual role of the acyl transferase from Mycobacterium 
smegmatis in the first reaction step of this cascade is the generation of a peracid 
(peracetic acid in this specific case). The peracid promotes chemical epoxidation of 
cyclohexene resulting in the formation of cyclohexene oxide, an achiral epoxide. Hence, 
stereoselectivity is not required in this step. Several lipases have also been shown to 
catalyse the perhydrolysis of esters, however, usually their hydrolysis activity is 
significantly higher in the presence of water. Hence, perhydrolysis using lipases is often 
performed in an organic solvent such as ethyl acetate to reduce hydrolysis.[190] In 
contrast, MsAct has an extremely hydrophobic cavity resulting in a preference of the 
enzyme for perhydrolysis over hydrolysis. This way, the reaction using MsAct can be run 
in aqueous buffer in the presence of ethyl acetate as substrate. This characteristic made 
MsAct a promising candidate for the combination of this epoxidation reaction with an 
epoxide ring opening catalysed by HheG. Next to the ester, the epoxidation reaction 
requires also the presence of hydrogen peroxide for the enzyme to produce the peracid. 
Three different concentrations of ethyl acetate (10, 20 and 30% v/v) and different 
amounts of H2O2 (1, 2, 3, 4, 10, 4x2.5 equivalents) were tested for the efficient 
epoxidation of 10 mM cyclohexene. As a result, 10% ethyl acetate resulted in significantly 
better conversions regardless of the amount of hydrogen peroxide used (Figure 48). 20% 
and 30% ethyl acetate showed very low conversion hinting at a possible enzyme 
inactivation caused by the solvent or the acid produced. Using a larger excess of 
hydrogen peroxide yielded higher product concentration. Furthermore, it appeared that 
adding hydrogen peroxide in portions was a better strategy (Figure 48). Possibly, 
hydrogen peroxide degrades over time and MsAct cannot effectively use all the 
supplemented H2O2 from the beginning, hence adding H2O2 in portions increased the 
total amount of peroxide that can be used by the enzyme.   
Additionally, acetic acid is produced during the reaction as by-product of the chemical 
epoxidation (Scheme 23) and by hydrolysis of ethyl acetate, although the latter is less 
probable giving the enzyme’s preference to catalyse perhydrolysis.  
Changing the buffer to saturated NaHCO3 solution to keep the pH at 8 resulted in high 
substrate and product evaporation due to the formation of CO2 and no product could be 
detected in GC-FID (data not shown). Very likely, a tight pH control could improve the 
overall reaction by balancing the excess of acetic acid formed during the chemical 
epoxidation and by the enzyme. Additionally, an optimal feed of hydrogen peroxide could 
further improve the obtained yields. This, however, was not further explored, as no HheG 
variant with sufficient enantioselectivity in the ring opening of cyclohexene oxide could 
be obtained during HheG engineering. Hence, also the combination of the two reaction 
steps was not tested. 
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Figure 48. Epoxidation of cyclohexene (5 mM) promoted by MsAct in the presence of ethyl acetate at 
different concentrations (% v/v) and using different amounts of H2O2 (1, 2, 3, 4, 10, 4x2.5 equivalents).  
 
3.2.2 Epoxide ring opening 
3.2.2.1 In silico mutagenesis of HheG using the Rosetta software suite 
HheG was previously found to be the only HHDH with significant activity towards 
cyclohexene oxide.[105] However, it formed the corresponding azido-cyclohexanol with 
only 40% enantiomeric excess. Hence, an in silico design was attempted to improve 
HheG´s enantioselectivity using the “coupled moves” application in the Rosetta 
framework.[149] This application efficiently introduces backbone as well as ligand 
movements in the design resulting in a significantly higher accuracy compared to the 
previous “fixed backbone” method. The coupled moves application requires a substrate 
bound PDB file and a list with the residues to be included in the in silico mutagenesis. 
Since no substrate-bound structure of HheG was available, cyclohexene oxide or 
(1R,2S)-2-cyanocyclohexanol were manually docked in HheG’s crystal structure (PDB-
ID: 5O30) after aligning it with the corresponding substrate-bound structures of HheC 
(PDB-ID: 1ZMT and 4IXT). For the design, all HheG residues within 5 Å from the ligand 
excluding the catalytic triad were included in the virtual mutagenesis (14 positions). The 
typical output of the application is a set of 20 FASTA files (one for each of the 20 runs 
performed) including all sequences that carry one or more mutations improving the 
protein-ligand interaction. The sequences were pooled and filtered for redundancy 
ending with approximatively 2000 unique amino acid sequences. The variability of the 
resulting sequences can then be visualized using sequence logos. 
 3. Results 
 
121 
 
 
Figure 49. Visualization using sequence logos of the two in silico mutagenesis with either cyclohexene oxide 
(A) or (1R, 2S)-2 cyanocyclohexanol (B) in the active site of HheG crystal structure (5O30).  
 
In Figure 49, sequence logos of two distinct runs are shown starting from HheG 
structures with cyclohexene oxide (A) and 2-cyanocyclohexanol (B) docked as ligands. 
The corresponding 2-azidocyclohexanol could not be used as ligand due to a software 
limitation as the azido group is not yet parametrised. Excluding the catalytic triad, 14 
residues within 5 Å distance from the ligand were randomized in HheG during the 
Rosetta run. Among these, six positions showed high variability in the resulting sequence 
set, as visible for positions M2, M8 to M11 and M14 in Figure 50. This indicates that the 
wild type amino acids in these positions were not the best option for optimal ligand 
binding. Of these, positions M2, M8, M9 and M14 were selected for mutagenesis 
including only the top three highest scoring amino acids in each position. All the desired 
mutations were introduced alone or in combination using site-directed mutagenesis. 
Resulting mutants were tested for their activity and enantioselectivity in epoxide ring 
opening reactions of cyclohexene oxide using azide as nucleophile. Most of the 
mutations resulted in slower epoxide ring opening and only a few mutants could reach 
100% conversion in the first hour of reaction as found for the wild type (Figure 49, A). 
A 
B 
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The latter mutants (MUT2, 6, 12, 14 and 22), however, displayed similar or worse 
enantioselectivity compared to the wild type (Figure 49, B). MUT23 on the other hand, 
formed the azido alcohol with a significantly enhanced enantiomeric excess (from 45% 
ee for the wild type to 71% for the mutant), however, with lower conversion rate. 
Surprisingly, five of the 24 generated mutants displayed a reversed selectivity (MUT8, 9, 
15, 16, 17, 18). In particular, MUT18 yielded 2-azidocyclohexanol with 66%ee after one 
hour but for the opposite enantiomer compared to the wild type (data not shown). This 
enantiomeric excess decreased to 37% after 22 h reaction time due to the high chemical 
background reaction and the low enzymatic activity. 
 
 
Figure 50. (A) Conversions of cyclohexene oxide with NaN3 as nucleophile catalysed by the different HheG 
mutants and (B) ratio of the different enantiomers produced. The reactions were carried out using whole 
cells, 20 mM cyclohexene oxide and 40 mM NaN3. EV = negative control using E. coli BL21 (DE3) cells 
containing empty vector. Enantiomer ratios are shown for the 22h reaction sample. 
 
Unexpectedly, using NaCN as nucleophile in the screening of the HheG variants 
produced quite different results. First of all, some of the mutants displayed such a low 
activity that it hardly exceeded the chemical background reaction. Hence, in such cases 
it was necessary to generate cyclohexene oxide in situ starting from 2-
chlorocyclohexanol as this resulted in lower chemical background in the cyanolysis of 
cyclohexene oxide. Moreover, most of the mutants were less active than the wild type 
A 
B 
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(Figure 51), which is not in agreement with the results obtained for the azidolysis reaction 
(Figure 50). Only variant MUT22 displayed higher conversion than wild-type HheG. 
Additionally, no improvement in the enantioselectivity was observed for any of the 
mutants (Figure 51, B), which contradicts the results obtained for the same mutants in 
the azidolysis of cyclohexene oxide. This seems to indicate that the enantioselectivity of 
HheG in the ring opening of cyclohexene oxide is dependent on the type of nucleophile 
used. As an example, MUT15 displayed inverted enantioselectivity in the azidolysis of 
cyclohexene oxide and a conversion similar to wild type, whereas no activity could be 
observed when cyanide was used as nucleophile. 
 
 
Figure 51. (A) Conversions of cyclohexene oxide with NaCN as nucleophile catalysed by the different HheG 
mutants and (B) ratio of the different enantiomers produced. The reactions were carried out using whole 
cells, either 20 mM 2-chlorocyclohexanol (cascade) or 20 mM cyclohexene oxide (epoxide ring opening) and 
40 mM NaN3. EV = negative control using E. coli BL21 (DE3) cells containing empty vector. Enantiomer 
ratios are shown for the 46 h reaction sample. 
 
In conclusion, the in silico mutagenesis of HheG could correctly predict positions with a 
significant effect on enantioselectivity, however, activity of the mutants was lower than 
for wild type in most cases. Interestingly, a few mutants displayed even inverted 
A 
B 
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enantioselectivity compared to wild type in the azidolysis of cyclohexene oxide. 
Unfortunately, no HheG variant producing 2-azidocyclohexanol with >90%ee could be 
identified. Hence, the combination of MsAct, HheG and Pd/C in one cascade was not 
tested.  
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4. Discussion 
In this work, a novel chemo-enzymatic cascade for the production of enantiopure vicinal 
amino alcohols from non-terminal alkenes was established. The synthetic route 
comprised three steps: 1) epoxidation of the alkene, 2) epoxide ring opening with azide 
as nucleophiles and 3) hydrogenation of the azido group. Stereoselectivity in the first 
step and regioselectivity in the second step enabled control of the stereoconfiguration of 
the two chiral centres in the final amino alcohol. The styrene monooxygenase from 
Rhodococcus sp. ST-10 and the Shi epoxidation diketal catalyst were selected to 
perform the epoxidation as they selectively synthesise opposite epoxide enantiomers. 
HheE and HheE5 were selected for the regioselective azidolysis of epoxides 21 and 22, 
respectively. Lastly, Pd/C was used to catalyse the reduction of the azido alcohols to the 
corresponding amino alcohols.    
The three cascade reactions were first optimized separately and possible cross-
interactions were determined. Afterwards, the catalytic steps were combined in either a 
1-pot-2-steps, 1-pot-3-steps or 2-pot-3-steps cascade to synthesise the desired amino 
alcohol products on preparative scale.  
4.1 Heterologous expression of the enzyme catalysts 
The styrene monooxygenase from Rhodococcus sp. ST-10 is the first example of a 
styrene monooxygenase able to perform the epoxidation of aliphatic alkenes, and it has 
been previously successfully expressed in E. coli BL21 (DE3).[74] However, Toda et al. 
reported that co-expression of a chaperon system further improved protein solubility, 
especially for StyB.[74] Within this work, however, expression in E. coli C43 (DE3) has 
been performed for comparison. E. coli C43 (DE3) is a strain optimized for the soluble 
production of membrane proteins as well as toxic and/or insoluble proteins and could, 
thus, improve StyAB production without the use of a chaperone system. Using E. coli 
C43 (DE3) already allowed soluble production of the two cytochrome P450s and the 
respective ferredoxin reductase and ferredoxin[159,181] with moderate to high yields per 
litre culture (see section 3.1.1.3). However, the expression of StyAB in E. coli C43 (DE3) 
resulted in a twofold lower epoxidation activity compared to the activities obtained for the 
production of StyAB in E. coli BL21 (DE3) (Table 18). In agreement with previous 
findings,[74] the addition of a chaperone system resulted in a slight improvement in activity 
compared to the chaperone-free system. The benefits, however, were too minor to justify 
co-expression of the chaperone system. Moreover, even a low soluble StyB expression 
should provide enough reduced FAD cofactor to maintain StyA activity at its maximum 
reaction velocity, as the specific activity of StyB was shown to be several thousand times 
higher than the specific activity of StyA.[74] 
126 
 
E. coli BL21 (DE3) was also the preferred expression host used for most of the halohydrin 
dehalogenases with purified protein yields (2-26 mg/L culture) comparable to the ones 
obtained for the cytochromes P450 enzymes produced in E. coli C43 (DE3) (see section 
3.1.2.1).[167] With 160 mg/L culture, MsAct gave the highest yield of purified protein 
compared to other enzymes produced in E. coli BL21 (DE3) in this work. Comparing 
StyAB production in co-expression experiments with alcohol dehydrogenases required 
for cofactor regeneration, StyAB production was significantly reduced by LkADH co-
expression compared to LsADH co-expression. LkADH appears to have a 5-10 fold 
higher overproduction compared to LsADH, In contrast, co-expression of styab with 
Lsadh resulted in a balanced production of both enzymes, in agreement with previous 
findings (Figure 10).[74] Protein production in E. coli depends on the higher demand for 
transcription or translation caused by the heterologous protein inserted as well as 
external conditions.[191] Thus, Lkadh overexpression may have suppressed StyAB 
production by occupying cellular machineries such as ribosomes, polymerases, or 
chaperones, whose abundance may be limiting.[191]    
Compared to shake flask experiments, cultivations in a bioreactor generally resulted in 
a 20% higher final optical density. This is likely due to better aeration during cultivation 
preventing oxygen limitations compared to shake flask expression. A lack of oxygen 
triggers the expression of over 200 genes utilized to adapt the cellular metabolism to 
lower O2 concentration, hence, resulting in slower cellular growth.[192] Interestingly, in 
bioreactor cultivations for the production of the HHDHs the final OD600 reached was 
significantly lower compared to StyAB cultivations, although only one antibiotic was 
supplied. In contrast, cultivation of cells co-expressing StyAB and LsADH required two 
antibiotics due to the presence of two plasmids. However, both plasmids (pETDuet-styab 
and pCDFDuet-1-Lsadh) carry resistance proteins that inactivate the respective 
antibiotic’s molecules by degradation or chemical modification[193,194] In contrast, 
kanamycin is not degraded by the resistance protein present in pET28 carrying the 
HHDHs[195], hence more cells harbouring StyAB and LsADH could grow towards the end 
of cultivation as the actual antibiotic concentration is lower, whereas the antibiotic 
concentration in HHDHs fermentations is constant throughout the fermentation.  
HheE and HheE5, however, generally reached higher expression levels and this might 
have limited the growth[191] compared to StyAB cultivations. Despite the better growth in 
the bioreactor compared to shake flasks, the resulting specific activity (U/mg of total 
protein content) of HheE5 was significantly lower than for shake flask expression. For 
HheE, this difference was less pronounced. In previous findings, optimal conditions for 
HheE5 production in E. coli BL21 (DE3) were found to be 7 h expression after induction 
at 30 °C.[167] Possibly, HheE5 folds at a slower rate and during the translation, its 
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hydrophobic stretches could interact causing the accumulation of inactive enzyme.[192] 
Better growth in the bioreactor could have led to faster transcription and translation and 
perhaps more inactive enzyme in agreement with SDS-PAGE gels where HheE5’s band 
is markedly thicker in the insoluble fraction (Appendix, Supporting figure 1).  
Similarly, StyAB’s specific activity decreased with longer expression times in the 
bioreactor. In this case, antibiotic degradation may have resulted in an enrichment of 
cells not carrying the plasmids and lower specific activity. Hence in StyAB production, 
cells should be harvested roughly 12 hours after induction to maximise optical density 
and enzyme activity. 
4.2 Epoxidation of linear alkenes  
Comparing the performance of all eight catalysts screened for epoxidation of substrate 
2, only StyAB and the Shi diketal epoxidation catalyst were able to reach >50% 
conversion. The remaining catalysts showed less than 5% conversion and poor product 
enantiomeric excesses (Figure 15), whereas both cytochromes P450 did not show any 
product formation.  
The Jacobsen catalyst, for instance, is designed to perform epoxidation of terminal 
alkenes and thus, its low activity in the epoxidation of non-terminal alkene 2 is not 
surprising. However, it is interesting that the catalyst in S,S-configuration produced more 
of the (R,R)-epoxide and vice versa. The unspecific peroxygenase from Agrocybe 
aegerita resulted only in very low conversion which may be, in part, due to non-optimal 
hydrogen peroxide supplementation. H2O2 is needed for catalytic activity and at the same 
time, it is extremely toxic for the heme prosthetic group present in the enzyme.[63,196] 
Moreover, the product enantiomeric excess was only close to 50% and hence, not 
sufficient for implementation in the cascade. Luckily, StyAB and the Shi epoxidation 
diketal catalyst produced opposite epoxide enantiomers, enabling two different pathways 
for the synthesis of opposite amino alcohol enantiomers.   
4.2.1 Styrene monooxygenase-catalysed epoxidations  
The styrene monooxygenase is a two-component system that requires NADH and 
FADH2 necessary to catalyse the epoxidation; it also requires molecular oxygen for its 
activity. The catalyst can be applied as whole cells or cell-free extract using cellular 
metabolism or a cofactor regeneration enzyme to recycle the needed cofactors. 
Overall, supplying StyAB as cell-free extract with a cofactor regeneration enzyme always 
resulted in higher conversion compared to whole-cell reactions. Three factors might be 
responsible for this: i) oxygen availability, ii) cofactor regeneration strategy and iii) 
substrate/product inhibition. When using a balloon of pure oxygen instead of O2 from the 
air, the conversions in both whole-cell and cell-free extract reactions improved 
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significantly. The performance of whole cells, however, still remained lower compared to 
reactions with cell-free extract. In whole-cell reactions, oxygen is being consumed by the 
cellular metabolism as well (resulting in growth), thus, its availability for the enzyme is 
lower. The optimal catalyst concentration ensuring sufficient oxygen, with no active input, 
for StyAB activity despite consumption via cell metabolism appeared to be 15 g/L (wet 
cell weight) and; adding more whole-cell catalyst decreased StyAB’s activity further 
(Figure 18). Subsequently, the different oxygen consumption between whole cells or cell-
free extract was quantified using an oxygen sensor. The dissolved oxygen concentration 
quickly dropped to zero when whole cells were present in solution, whereas in the 
presence of cell-free extract an equilibrium between O2 consumed by the epoxidation 
reaction and O2 diffusing in the solution was reached (Figure 33, A). The active input of 
compressed air (3 L/h) resulted in only low improvements in oxygen availability for whole-
cell reactions; in contrast, it maintained oxygen saturation in the presence of cell-free 
proteins (Figure 33, B).   
The efficient provision of NADH cofactor by the cellular metabolism strongly depends on 
the metabolic activity of the cells and the used co-substrate. The alkene substrate used 
in this work for StyAB may be toxic for the cells resulting in a slower cellular metabolism 
and hence, slow NADH regeneration in whole-cell reactions. In contrast, a cofactor 
regeneration enzyme does not require an intact cell and StyAB (as well as the 
regeneration enzyme) can be supplied as CFE. A cell-free system is independent of 
substrate toxicity for the metabolism and it also removes mass transfer through the 
cellular membrane which is normally one of the limiting steps. 
Toda et al. previously demonstrated that StyAB suffers from both substrate and product 
inhibition[74] and one strategy to overcome substrate inhibition is by supplementing lower 
amounts multiple times so that the substrate concentration is kept relatively low but 
reaching the total amount to be added over time. This strategy allowed to double the 
achieved epoxide concentration in reactions where LkADH (as separate CFE) was 
added as cofactor regeneration system (Orange in Figure 32); however, product 
inhibition was still present. A second organic phase is often used to prevent substrate 
and product inhibition, as it acts as a reservoir for hydrophobic compounds, such as the 
ones used in this work, while keeping substrate and product concentrations in the 
aqueous phase low. The use of hydrophobic solvents (logP>4) in StyAB reactions could 
improve the overall epoxide concentration. Particularly heptane and octane resulted in 
relatively high epoxide production, whereas the presence of cyclohexane yielded only 
moderate improvements. Using more polar organic solvents, such as ethyl acetate, 
pentyl acetate or hexyl acetate,[68] resulted in no product formation and significant protein 
degradation after just 2 hours. Toda et al. used whole cells that may have protected the 
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enzyme from the contact with the polar solvents used,[68] although using the same 
reaction conditions with whole cells but on larger scale did not show any product 
formation (data not shown). Organic solvents can disrupt the cellular membrane resulting 
in metabolism damage and cell death,[197] whereas in contact with enzymes they can 
disturb the network of non-covalent interactions necessary to keep intact the enzyme’s 
secondary and tertiary structures.[198] Interestingly, cyclohexane, pentyl- and hexyl 
acetate have more similar logP values (3.2, 2.30 and 2.87, respectively), however 
product formation was observed only when cyclohexane was used as second phase. 
Very likely, the two acetate esters can disrupt more easily the enzyme’s secondary and 
tertiary structures, whereas cyclohexane with no polar groups has a less dramatic effect. 
Generally, using organic solvents with a high logP (>4), such as heptane, can limit the 
interaction between enzymes and organic solvent only at the interface between the two 
phases. In contrast, using a more polar organic solvent (logP<3), hence more soluble in 
water, can result in more severe enzyme inactivation compared to less soluble organic 
solvents. Using heptane or octane as second phase resulted in similar product yields, 
however heptane has a lower boiling point and would simplify solvent removal during 
reaction workup. In short, StyAB-catalysed epoxide production could be significantly 
improved by active air input to remove oxygen limitations. Furthermore, using a cofactor 
regeneration enzyme and a second organic phase to limit substrate and product 
inhibition resulted in 100-fold improvement overall.  
Additionally, enzyme inactivation appeared to be another factor that seemed to limit the 
final epoxide concentration reached. On small scale, StyA lost almost all of its activity 
within the first 6 hours. This may have been caused by mechanical stress due to 
magnetic stirring as Toda et al. performed the epoxidations for 48 hours using horizontal 
shacking.[68] The set up used in this work for large scale reactions required overhead 
mechanical stirring that may also cause protein damage due to mechanical stress. 
Furthermore, the used organic solvent can cause enzyme inactivation as mention above. 
Hence, a substrate plus enzyme feed was used to further improve epoxide production 
compared to only substrate feed (Red in Figure 32).  
Using optimal conditions for the StyAB-catalysed epoxidation of 50 mM trans-2-heptene 
(2), a maximum conversion of 70% (35 mM epoxide) in 80 mL scale could be reached. 
A further increase in the reaction volume to 250 mL and 100 mM substrate concentration 
led to a final epoxide concentration of 69 mM (69% conversion). Reaction engineering 
could increase product formation almost 100 times and the use of a bioreactor, enabling 
even better control over several variables (e.g. dissolved oxygen and substrate feed), 
may further increase the overall reaction performance. Using a 30 L fed-batch reactor, 
Panke et al. could produce 388 g of styrene oxide in a using growing cells harbouring 
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the styrene monooxygenase from Pseudomonas sp. strain VLB120 and using its cellular 
metabolism for cofactor regeneration.[76] On the other hand, using a solvent tolerant 
microorganism as heterologous host could be used to prevent enzyme inactivation 
caused by the organic solvent as the cell membrane would not be disrupted as easily as 
the cell membrane of non-tolerant microorganisms. For example, Kocuria rhizophila 
DC2201 has been successfully applied for the production of industrially relevant epoxide 
concentrations.[199] Another example of a solvent tolerant organism used as heterologous 
host is Pseudomonas taiwanensis VLB120ΔC that was successfully applied in a 3.1 L 
reactor for the production of styrene oxide.[200]  
If reaction engineering is not sufficient, protein engineering is often used to improve the 
enzymes’ activity, stability or selectivity. Recently, the styrene monooxygenase from 
Pseudomonas sp. was engineered by fusing its two subunits resulting in a more active 
catalyst.[201] This styrene monooxygenase fusion results in a 1:1 ratio of the two subunits; 
thus FADH2 can easily diffuse from StyB to StyA and can be readily used in the 
epoxidation by StyA minimizing uncoupling.[201] Moreover, StyB solubility was indirectly 
improved by the production of a single protein containing both subunits. This approach 
could possibly also improve the catalytic efficiency of the styrene monooxygenase used 
in this work.  
Furthermore, different cofactor regeneration systems might influence the epoxidation 
reaction differently. For example, cofactor regeneration efficiency using alcohol 
dehydrogenases is driven by the thermodynamic equilibrium of the regeneration 
reaction, usually oxidation of an alcohol. As the alcohol is oxidised, the corresponding 
ketone/aldehyde builds up until the reverse reaction becomes more favourable.[202] This 
could be a limitation if there is not enough alcohol present to keep up the NADH 
regeneration for the reaction. At the same time, high alcohol concentrations can 
negatively affect the enzymes’ stability. Alternatively, formate dehydrogenases, for 
example, oxidise formate to reduce NAD+. The by-product, CO2, can freely diffuse out of 
the reaction mix shifting the reaction equilibrium towards NADH reduction. Moreover, the 
co-substrate formate has usually no negative or inhibitory effect on enzymes. Testing 
other cofactor regeneration system could result in further improvements in epoxide 
production. 
4.2.2 Epoxidations performed with the Shi epoxidation diketal 
catalyst 
In contrast to the styrene monooxygenase, the Shi epoxidation diketal catalyst was 
selected as it produces the (R,R)-enantiomers of 21 and 22 selectively, however, with a 
slightly lower enantiomeric excess (>90%, Figure 15). The eeP in this reaction strongly 
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depends on the catalyst’s stability throughout the reaction. Moreover, the reaction is run 
in presence of 20-30% acetonitrile at low temperatures and pH > 8, however optimal 
reaction conditions varied with the type of substrate used.[203] Acetonitrile (logP -0.334) 
is a water-miscible solvent and could negatively affect the HHDH in the second step of 
the cascade. Hence, different acetonitrile concentrations were tested in the Shi 
epoxidation to determine the minimum required amount that would still grant good 
conversion and high eeP. Generally, decreasing acetonitrile concentration strongly 
reduced both conversion and eeP to around 50% (Figure 43). Likely, the lower acetonitrile 
concentration might have had a positive effect on the amount of Oxone© dissolved in the 
aqueous phase. This would result in a higher excess of Oxone© compared to the Shi 
epoxidation diketal catalyst leading to a faster catalyst degradation via Baeyer-Villiger 
reaction pathway leading to acetone formation (Scheme 6). This way, acetone could 
build up faster, and catalysing an unselective epoxidation resulted in a lower final eeP. 
Whereas, at higher acetonitrile concentrations the Oxone© solubility is lower causing a 
slower reaction rate and longer Shi epoxidation diketal catalyst half-life. Furthermore, Shi 
et al. postulated that acetonitrile may participate in the reaction mechanism by mediating 
the dioxirane formation reacting with the oxidant, H2O2 in their case, forming peroxyimidic 
acid (Scheme 24).[203] Perhaps, this may also be the case and might explain why lowering 
acetonitrile concentration resulted in lower product yield and eeP. 
 
 
Scheme 24. The dioxirane necessary for the Shi epoxidation diketal catalyst may be generated via 
peroxyimidic acid produced by hydrogen peroxide reacting with acetonitrile (adapted from Shi et al.[203]) 
 
Another factor to consider here is substrate and catalyst solubility. The Shi epoxidation 
diketal catalyst, as well as substrates 1 and 2, are hydrophobic compounds with only low 
solubility in aqueous buffers. Epoxidation reactions run at 25 °C resulted in low eeP in 
the conversion of alkene 2 (data not shown) and only with a temperature of -2 °C an 
eeP>90% was reached. In the other hand, a temperature of -2 °C would further decrease 
substrate and Shi epoxidation diketal catalyst solubility. Notably, at low acetonitrile 
concentrations (5% or 10%) only around 30% conversion was reached, meaning that 
theoretically, each molecule of catalyst reacted only 1.5 times. It is very likely that only a 
small fraction of the catalyst was actually dissolved in solution and could react. This small 
amount of dissolved catalyst can then easily decompose via the Baeyer-Villiger pathway 
due to the high excess of Oxone© in solution. At this point, acetone, being more soluble 
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in water than the enantioselective catalyst, can catalyse unselective substrate 
epoxidation resulting in the poor eeP measured (Figure 43). In conclusion, acetonitrile 
concentration has a profound influence on the reaction performance and preferably the 
used acetonitrile concentration should be above 20% (v/v). 
4.3 Epoxide ring opening using HHDHs 
Regioselective epoxide ring opening in the 2nd step of the cascade from non-terminal 
alkenes to amino alcohol products was essential for the successful synthesis of 
enantiopure amino alcohols. As described previously, HHDHs are typically applied in the 
ring opening of terminal epoxides displaying high regioselectivity for nucleophilic attack 
of the terminal carbon. In the azidolysis of non-terminal epoxides, however, the observed 
regioselectivity was enzyme- and substrate-dependent.  
Of the five different tested epoxides, most HHDHs could convert trans-2,3-epoxyhexane 
(21) and trans-2,3-epoxyheptane (22) and fortuitously, seven enzymes displayed 
extremely high selectivity in the production of azido alcohols 31a and 32a with the best 
being HheA3, HheC and all E-type enzymes. 
In contrast, a significantly lower number of HHDHs could convert also more complex 
epoxides. For example, trans-4,5-hexan-1-ol (23) carries an additional hydroxyl group at 
the opposite end of the molecule with respect to the epoxide ring. This additional hydroxyl 
group suppressed the activity of all HHDHs except HheG. Docking experiments with 
HheC and HheD2 highlighted that this hydroxyl group may interact preferentially with the 
catalytic residues resulting in a reversed binding mode (Figure 22 and Figure 23, 
respectively). This opposite binding mode was not observed for HheG in agreement with 
experimental data. Co-crystallization of the epoxide in one of the HHDH’s active site 
could further confirm these data. Additionally, kinetic studies of epoxide ring opening in 
the presence of a terminal alcohol (e.g. 1-hexanol) could determine if a compound with 
a terminal alcohol can act as a competitive inhibitor by interacting with the catalytic triad.  
In trans-3,4-epoxyheptane (24) the epoxide ring is positioned more internally in the 
molecule compared to epoxide 22. This reduced the number of HHDHs able to convert 
24 compared to epoxide 22. Furthermore, all enzymes able to convert epoxide 24 
showed no regioselectivity in the azidolysis of 21 and 22 (Figure 21). Non-regioselective 
HHDHs may have a broader active site where epoxides with larger substituents can still 
adopt the correct geometry needed for catalysis. Epoxide 25 present a benzylic ring 
substituent instead of an aliphatic chain as for other epoxides tested in this work. Only 
HheG and HheG2 displayed significant activity towards this epoxide, whereas 
conversions using HheD3 and HheF were only slightly above the chemical background. 
Interestingly, HheC showed activity on the styrene oxide but no conversion with 25. In 
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this case, the resonance with the benzylic group favours the nucleophilic attack at the 
more sterically-hindered carbon, however HheC favoured the nucleophilic attack at the 
less sterically-hindered carbon. In contrast, HheG catalysed the azidolysis of styrene 
oxide with α-position regioselectivity,[204] as seen for epoxide 25. In contrast, HheD3 and 
HheF displayed preference for the formation of regioisomer 35a even though with very 
low conversions compared to HheG. For these enzymes, the epoxide ring seems to have 
adopted the correct geometry with serine and tyrosine to promote nucleophilic attack at 
the chemically un-favoured -carbon.     
The active site’s shape may influence the substrate scope and regioselectivity of the 
different HHDHs. Comparing the active sites of HHDHs with available crystal structure, 
it is noticeable that compared to HheD2 and HheG (PDB-ID: 5O30[105]), HheA2 (PDB-ID: 
1ZMO[205]), HheB2 (PDB-ID: 4ZD6[206]) and HheC (PDB-ID: 1PWZ[184]) possess a narrow 
tunnel leading to the active site with the nucleophile binding pocket (Figure 52). Hence, 
in these cases the converted substrates (21 and 22 for HheC) could only bind 
productively with the smaller substituent at the epoxide ring entering first (Figure 22, A 
and B). In contrast, HheD2’s active site appears to extend in both sides of the nucleophile 
binding pocket (unpublished data), and HheG active site cavity is broader and open 
compared to all other HHDHs enabling also the conversion of more bulky substrates.[105] 
This extra space may have allowed the di-substituted epoxides to adopt productive 
binding having the bulkier substituent on either side of the epoxide ring. This way, in non-
regioselective HHDHs, the nucleophilic attack is performed on either carbon of the 
epoxide ring depending on the geometry with the catalytic triad (Scheme 25). 
 
HheA2 HheB2 HheC 
HheD2 HheG 
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Figure 52. Active sites highlighted in deep teal for HHDHs with available crystal structure [HheA2 (PDB-ID: 
1ZMO[205]), HheB2 (PDB-ID: 4ZD6[206]), HheC (PDB-ID: 1PWZ[184]), HheG (PDB-ID: 5O30[105]) and HheD2 
(unpublished data)]. The water molecule present in the nucleophile binding pocket is shown as a green 
sphere to indicate the position of the nucleophile.  
Determination of product enantiomeric excesses (eeP) in the ring opening of racemic 
epoxides 21 and 22 evidenced that most of HHDH form the corresponding azido alcohols 
with low to moderate enantioselectivity (Table 21). Interestingly, azido alcohols 31 and 
32 were formed mostly in 2S,3R-configuration (Table 21). Meaning that regioisomers 
31a and 32a were preferentially formed by nucleophilic attack of the epoxides in (R,R)-
configuration at the sterically less hindered carbon, whereas regioisomers 31b and 32b 
were preferentially formed by nucleophilic attack of the epoxides in (S,S)-configuration 
at the sterically more hindered carbon. Generally, product enantiomeric excesses (eeP) 
for regioisomers 21a and 31a were rather low, in contrast formation of regioisomers 31b 
and 32b occurred with higher enantioselectivity in non-regioselective HHDHs. One 
explanation could be that, in non-regioselective HHDHs, the (R,R)-epoxide preferentially 
enters the catalytic site with the shorter chain first, whereas the (S,S)-epoxide 
preferentially adopts enters with the longer chain first. This way, the geometry between 
the epoxide ring and catalytic triad favours nucleophilic attack at opposite carbons of the 
epoxide ring (Scheme 25). Interestingly, HheG and HheD5 produced regioisomers a and 
b in equal amounts when racemic epoxides were used as substrates (Table 21). 
However, they preferentially synthesised regioisomers 31b (78% for HheG) and 32b 
(60% for HheD5) starting from the (S,S)-epoxide synthesised in cascade reactions by 
StyAB (Results, section 3.1.4). The change of regioselectivity in these two enzymes may 
validate the hypothesis that opposite enantiomers preferentially adopt different 
productive bindings (Scheme 25). Opposite binding modes for different enantiomers 
were found in docking studies for the non-regioselective HheG and HheD2, whereas for 
the regioselective HheC only one binding mode was found for both epoxide enantiomers.  
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Scheme 25. Possible epoxide ring opening scheme for non-regioselective HHDHs. Opposite epoxide 
enantiomers have reverse binding. The R,R-epoxide may preferentially adopt the canonical binding (A), 
whereas the S,S-epoxide may adopt a flipped binding mode (B) resulting in nucleophilic attack at opposite 
carbons of the epoxide ring. Trans-2,3-epoxyhexane (1) is used as model substrate and the enantiomer in 
R,R-configuration is shown in green, whereas the enantiomer in S,S-configuration is shown in orange. 
 
4.3.1 Regioselective HHDHs for application in cascades  
Among the regioselective HHDHs, HheA3 and HheC are well characterised enzymes 
already, a deeper investigation was performed on enzymes of the E-type, which are less 
studied. From the initial screening, HheE and HheE5 appeared to be the best candidates 
for the conversion of 21 and 22. A more detailed study of all E-type HHDHs confirmed 
HheE and HheE5 to be the best enzymes for epoxide ring opening of 21 and 22, as both 
displayed significantly better performance than HheE2, HheE3 and HheE4. In general, 
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HheE showed the best conversion in the azidolysis of 21, whereas HheE5 was faster in 
the conversion of 22. Analysis of the kinetic data confirmed that HheE5 is a significantly 
better catalyst than HheE in the epoxide ring opening of 22 with a maximal velocity 1.3-
fold higher. HheE showed significantly less affinity for epoxide 21 (1.5 timed higher KM) 
and lower maximal reaction velocity. However, in whole cell experiments HheE appeared 
to be much faster than all other enzymes of the E-type and it was selected for cascade 
reactions starting from substrate 1. Whereas, HheE5 was selected for cascade reactions 
starting from substrate 2 having better performance in the conversion of epoxide 22. 
The difference in maximal reaction velocity of HheE might have been influenced by the 
fixed nucleophile concentration (50 mM). This value is only ~4-fold higher than HheE’s 
KM for azide whereas it is ~8-fold higher than the K50 of HheE5 for azide. As a rule of 
thumb, a 10-fold higher concentration than the enzyme’s KM/K50 should be used to 
ensure maximal reaction velocity, hence HheE maximal reaction velocity might be less 
accurate than HheE5.  
At higher substrate loadings (50-300 mM), using two equivalents of sodium azide, the 
spontaneous azidolysis of epoxide 21 was considerably higher than that of epoxide 22 
in reactions with HHDH-containing whole cells. This may be related to the higher 
hydrophobicity of 22 carrying an additional CH2 group. Thus, epoxide 22 may diffuse 
more easily through the cellular membrane, where the azide concentration would be 
lower compared to the rest of the reaction solution. In contrast, a higher fraction of 
epoxide 21 may be left out of the cellular membrane where chemical azidolysis 
happened with higher probability due to the high concentration of azide added in the 
reaction solution. This could be proven by testing if the background reaction is the same 
for both epoxides in the absence of whole cells. On the other hand, epoxide 21 might be 
more reactive than 22 resulting in higher chemical background.  
The high chemical background reaction could be avoided by decreasing the nucleophile 
concentration as it is only important to maintain azide concentrations above the enzymes’ 
KM/K50 values to ensure an optimal reaction rate. For substrate concentrations below 10-
20 mM, it might be required to add a larger excess of sodium azide, however, at high 
substrate loadings a ratio of 1:1.1 (substrate:NaN3) should be sufficient to provide 
enough nucleophile to reach full conversion. 
Preparative scale using only 50 mM substrate were in agreement with small scale 
reaction and the same high regioselectivity was observed for both enzymes. However, 
rather low isolated yields were obtained (50% for 31a synthesised by HheE and 48% of 
32a synthesised by HheE5), this most likely can be improved by better downstream 
processing as some product loss occurred during product purification. 
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4.4 Chemical hydrogenation of azido alcohols 
The reduction of azido groups to their respective amino groups is a well-known reaction. 
As mentioned in section 3.1.3, several metals can split H2 on their surface and this 
property can be exploited to catalyse the addition of hydrogen to molecules that can 
accept it. The last step of the synthetic strategy adopted in this work involves 
hydrogenation of the azido alcohol produced in the first two steps to the corresponding 
amino alcohol. Using palladium as metal seemed to offer the best compromise between 
mild reaction conditions and catalyst costs.  
Generally, palladium is quite reactive and it essentially reacts with most reducible 
functionalities. Chemoselectivity can be changed using heterogeneous palladium on 
different supports or with adequate catalyst poisoning.[120] For instance, entry 2 in Figure 
26 (Section 3.1.3) is palladium on CaCO3 with Pb poisoning and it was designed primarily 
to catalyse the hydrogenation of alkynes to alkenes without further reduction of the 
resulting alkenes. Therefore, different supports were tested in the hydrogenation of azido 
alcohol 32 to determine which the best support for hydrogenation of azides. 
Using carbon as support resulted in higher activity compared to other matrices. The two 
slightly different carbon supports with 10 wt.% palladium yielded higher conversion 
compared to palladium hydroxide on carbon, although it contained a palladium content 
of 20 wt.%. Here, it seems that palladium in the form of palladium hydroxide has lower 
activity in the hydrogenation of 32 despite having twice as much of catalyst loading on 
the carbon support (entry 3, Figure 26). Overall, the palladium (as metal ions) on carbon 
catalysts (entries 1 and 5, Figure 26) performed equally well. Hence, the selection of the 
best catalyst for the final cascade was based on catalyst price. The Degussa type E101 
carbon support (entry 5, Figure 26) appeared to be 1.5 times more expensive (Sigma-
Aldrich quotation) than the regular activated carbon (entry 1, Figure 26). Therefore, the 
latter was used for hydrogenation of azido alcohols 31 and 32 in the final cascades. 
Heterogeneous palladium and nanoparticles in general are known to interact with 
proteins and living cells causing mutual inactivation as the latter can adsorb on Pd/C 
surface.[122] Ferritin from Pyrococcus furiosus or the commercially available ferritin from 
horse spleen were tested as a compartmentalization strategy to encapsulate the 
nanoparticles and overcome the mutual inactivation. This way substrate and hydrogen 
can freely diffuse through the protein wall isolating the nanoparticles from harmful 
compounds that reduce the activity of the metal, such as free enzymes or whole cells 
(Scheme 14). Ferritin’s quaternary structure is a 24mer suitable to encapsulate different 
metal ions. Unfortunately, using the self-produced thermostable ferritin from P. furiosus 
did not show any nanoparticle formation probably due to an incomplete iron removal that 
prevented palladium encapsulation. On the other hand, using the commercial ferritin from 
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horse spleen resulted in the formation of the complex ferritin-PdNPs which led to full 
conversion of 5 mM of 32 within 4 h. However, the synthesis of the complex ferritin-
PdNPs requires several labour-intensive steps and an intermediated workup to remove 
CFE or whole cells before the hydrogenation reaction would be more convenient. Hence, 
Pd/C was chosen as the candidate catalyst for the last step of the cascade giving the 
commercial availability and high reactivity. 
4.5 Combination of the catalysts 
Using a non-terminal trans-alkene as a substrate for the synthesis of enantiopure amino 
alcohol presents several challenges. Most prominent is the control of stereoconfiguration 
of the chiral centres as well as regioselectivity during functionalization of the molecule 
as up to four isomers can be generated (Scheme 19). As mentioned previously, the 
strategy to control the formation of only one amino alcohol enantiomer was to combine 
an enantioselective epoxidation with a regioselective epoxide-ring opening. The 
combination of styrene monooxygenase with HheE or HheE5 and Pd/C should lead to 
the synthesis of (2R,3S)-2-amino-3-hydroxyhexane (41a) and (2R,3S)-2-amino-3-
hydroxyheptane (42a) starting from trans-2-hexene (1) and trans-2-heptene (2), 
respectively. In contrast, using the Shi epoxidation diketal catalyst in the epoxidation step 
should result in the formation of opposite product enantiomers, (2S,3R)-2-amino-3-
hydroxyhexane (41a) and (2S,3R)-2-amino-3-hydroxyheptane (42a), respectively. The 
validity of this strategy was carefully verified by testing different combinations of 
epoxidation catalyst with regio- or non-regioselective HHDHs (Figure 29 and Figure 30, 
Section 3.1.4). 
4.5.1 StyAB – HHDH – Pd/C cascade 
The combination of individual reaction steps, separately optimised before, in a cascade 
often requires further reaction optimization to achieve high overall productivities. As an 
example, reaction components required by one catalyst may negatively affect another 
catalyst in the cascade. Hence, identification of such cross-interactions and -inhibitions 
is important for cascade setup. 
The styrene monooxygenase and the halohydrin dehalogenase work under similar 
reaction conditions in terms of pH and temperature, and both could be used in the same 
50 mM potassium phosphate buffer. This would allow performing both cascade steps 
simultaneously or in two sequential stages. The presence of azide did not show any 
effect on the styrene monooxygenase (data not show), however probably at 
concentrations of azide >100 mM enzyme inactivation could occur as free azide can 
react with amino acids such as tryptophan cysteine or tyrosine.[207] In contrast, the 
presence of heptane, required in the epoxidation step to prevent substrate and product 
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inhibition of StyAB,[74,83] appeared to have a considerable negative effect on the HHDHs 
(Figure 39). For both enzymes, the conversions were significantly lower with heptane 
compared to epoxide ring opening reactions without heptane.   HheE appeared to be 
significantly more sensitive to the presence of this organic solvent as only 33% 
conversion was obtained within 24 hours. HheE may be more sensible to organic 
solvents and unfold more easily than HheE5. HheE5 was found to have a T50 46 degrees 
higher than HheE[167] and might explain the lower HheE’s stability as thermostability and 
solvent resistance are often correlated. On the other hand, HheC retained 90% of activity 
in presence of heptane but its T50 is only 9 °C higher than HheE.[167,208] 
Secondly, heptane, acting as a sink for hydrophobic compounds, efficiently extracted 
most of the epoxide from the aqueous phase and; this way, both HHDHs likely could not 
work at their maximal reaction velocities due to comparably high KM/K50 values and 
hence low affinity for the substrates (Table 22). Zou et al. observed a similar behaviour 
where higher substrate concentrations in the organic phase resulted in a higher initial 
rate as more substrate could diffuse in the aqueous phase.[209] Interestingly, epoxide 22 
seemed to be more soluble in aqueous phase compared to 21 (Figure 36) hence, a 
higher starting concentration of 21 in heptane may result in better activity of HheE as 
more could diffuse in the aqueous phase to react with the HHDH. 
Lastly, the influence of palladium on carbon on the first two enzymatic steps was 
evaluated, although in an ideal industrial process there would be active oxygen input for 
the first step and hydrogen input in the third step and hence mixing the two gasses (if 
step 1 and step 3 runs together) is not advisable or strictly forbidden due to potential 
explosions. 
On the other hand, the azidolysis and hydrogenation reactions could in principle work at 
the same time. According to the experimental data, it seems that the presence of Pd/C 
had a major negative effect on the epoxidation reaction, especially when StyAB was 
applied as whole-cell catalyst. Pd/C was shown to be toxic for E. coli cell that could not 
synthesise efficiently the required NADH necessary for the epoxidation;[210] lower 
conversions compared to control reactions were observed as a result (Figure 40). 
Epoxidations using StyA as cell-free extract showed a higher product yield and probably 
only adsorption on Pd/C occurred, but enough reduced cofactor was granted by the 
presence of BNAH. The epoxide ring opening catalysed by HheE5 seems to be less 
affected by the presence of the nanoparticles as the cellular adsorption on the Pd 
nanoparticles may only reduce the available surface for substrate diffusion into the cell. 
Afterwards, the influence of reagents of steps 1 and 2 on the hydrogenation reaction was 
also investigated. Pd/C showed lower tolerance to the presence of whole cells (green 
line, Figure 41) compared to cell-free extract (orange line, Figure 41). As mentioned 
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before, enzymes and/or whole cells combined with Pd/C can mutually inactivate each 
other due to adsorption. The mutual inactivation is concentration dependent and possibly 
doubling the concentration of cell-free extract would increase the negative effect on the 
hydrogenation. Nevertheless, based on the cross-interaction between the different 
catalysts, the best way to run the cascade would be to perform the reaction in three 
sequential steps in one-pot. The enzymatic catalysts should be supplemented as cell-
free extract to minimize their negative influence on the hydrogenation step. The HHDH 
could be added from the beginning although it is more important to limit the contact with 
heptane and start the epoxide ring opening reaction after the styrene monooxygenase 
produces enough epoxide. Finally, the palladium on carbon should be added at the end 
to complete the cascade.  
The combination of the three catalysts in one-pot-three-steps led to a very low isolated 
yield (2.4%) starting from trans-2-heptene (2) as none of the three catalysts could reach 
full conversion. For this cascade run the main bottleneck seems to be epoxide ring 
opening step as only 5 mM of 2-azido-3-hydroxyheptane were reached in 48h. 
Furthermore, only a part of this was further reduced by the Pd/C. Here, the inefficient in 
situ H2 formation may have contributed to the low yield obtained, Schrittwieser et al. used 
10 bar H2 in an autoclave reactor to reach optimal results in the hydrogenation of azides 
in cascade with an ADH.[211]  
Regioisomeric ratios and eeP determined for the azido alcohol product were in 
agreement with previous data and this value should correspond to the amino alcohol 
product enantiomeric excess, as the hydrogenation step does not involve any 
racemization.   
Besides the low conversion achieved in all steps, an inefficient workup might have further 
lowered the isolated yield as most of the amino alcohol could not be efficiently extracted 
from the aqueous phase. To overcome this limitation, the hydrogenation reaction was 
separated from the first two steps and performed in methanol. This way, free proteins 
from the first two steps could be removed in the intermediate work up and the obtained 
crude azido alcohols could be dissolved in an organic solvent (methanol in this case), 
which led to improved work up efficiency. Separating the last step from the first two 
resulted in a fourfold increase in isolated yields with no negative influence on the product 
enantiomeric excess, but slightly lower regioisomeric ratio for HheE-catalysed reactions. 
This is possibly explained by the presence of heptane resulting in reduced HheE activity. 
Hence, the impact of the unselective chemical azidolysis is higher resulting in a slight 
increase in regioisomer b formation. 
Apart from the improvements discussed for the StyAB-catalysed epoxidation step 
(section 4.2.1), different strategies could be implemented to further improve the final 
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product yields. The low solvent resistance of the HHDHs appears to be the limiting factor. 
Heavy enzyme engineering (29 mutations) could significantly improve the solvent 
resistance of HheC which was active even at 50% acetonitrile.[212] Alternatively, 
crosslinking HheC using the CLEA technology resulted only in a 2% loss of activity in 
presence of heptane.[208] Additionally, physical separation of the catalysts through PDMS 
was used to prevent enzyme inactivation caused by Cu ions. Sato et al. demonstrated 
that the PDMS membrane acted as a barrier between the chemical and enzymatic 
catalyst whereas the substrate and product could freely diffuse through it.[213]  
4.5.2 Shi epoxidation diketal catalyst – HHDH – Pd/C cascade 
The reaction conditions required by the Shi epoxidation diketal catalyst are extremely 
different from the conditions required in the HHDH-catalysed epoxide ring opening. 
Hence, both steps in a cascade can only be performed sequentially. As for cascade 1, 
cross-interactions and –inhibitions between reagents and the catalysts were determined 
prior to the combination of reaction steps.  
As observed for heptane in cascade 1, acetonitrile had a strong negative effect on the 
halohydrin dehalogenases as well. Overall, both HHDHs were significantly more 
sensitive to acetonitrile compared to heptane (logP 4.5), probably due to its higher 
solubility in water and higher polarity (logP -0334). Both enzymes seem to lose activity 
completely within four hours, as no further conversion was observed after this time point. 
In a previous study, HheC showed a residual activity around 30% after incubation with 
12.5% acetonitrile for 4 h[212] whereas incubation with more apolar organic solvents such 
as heptane or hexane showed less inactivation,[208] in agreement with the findings in this 
work. The HHDHs’ sensitivity to organic solvents indirectly interfered with the epoxidation 
step as lower acetonitrile concentrations (5%) led to the formation of only low epoxide 
concentrations with also low product enantiomeric excess (section 3.2.1).  
An Oxone© concentration of 10 mM did not affect the epoxide ring opening reaction, 
whereas 50 mM resulted in lower final conversion (green line, Figure 45, B). This is very 
likely an indirect effect due to Oxone© rapidly reacting with N3 generating N2 and N2O 
explaining the observed intense foaming.[188] As a result, only a limited amount of 
nucleophile was actually available for the azidolysis reaction. Therefore, it was important 
to decompose all residual Oxone© from the epoxidation reaction before the addition of 
azide as nucleophile for epoxide ring opening in the second step. 
The attempt to run cascade 2 as a sequential one-pot-three-steps cascade resulted in a 
slightly higher isolated yield of the final amino alcohol compared to cascade 1 (3% vs 
2.4%). The product enantiomeric excess, however, was significantly worse (eeP = 34%) 
due to the low acetonitrile concentration used in the first step. This time, the 
hydrogenation catalyst seemed to have been active for a longer reaction time, and 
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compared to cascade 1 there is only one enzymatic step. In cascade 1, the final total 
protein content reached was about 18 g/L which is four times higher than the amount 
used in the cross-interaction study. Whereas in cascade 2, the same amount of cells (60 
g/L) was used as in the cross-interaction study, hence Pd/C inactivation may have 
occurred at a slower rate. 
Again, separating the hydrogenation step from the first two cascade steps (= 2-pots-3-
steps cascade) could improve the isolated yields significantly. In general, the isolated 
yields were roughly two-fold higher than the ones in cascade 1, however poor eeP (40-
50%) was observed in the Shi epoxidation. These values could be slightly improved in 
the epoxide ring opening step, reaching final eeP of around 60%. Regioselective HHDHs, 
like HheE and HheE5 may be stereoselective for epoxides in (R,R)-conformation as 
observed for HheC in the epoxide ring opening of styrene oxide,[185] whereas more of the 
epoxide in (S,S)-conformation was opened unselectively by the chemical reaction with 
higher probability. The observed regioisomeric ratio of formed azido alcohols was slightly 
lower compared to the one measured in the HheE and HheE5-catalysed epoxide ring 
opening of racemic epoxides trans-2,3-epoxyhexane (21) and trans-2,3-epoxyheptane 
(22), respectively. This may be due to the presence of some residual Oxone© which was 
shown to catalyse epoxide ring opening in presence of acetonitrile and azide.[214] Luckily, 
the regioisomers could be separated by column chromatography; however, this resulted 
in approximately 12% product loss. In conclusion, the combination of Shi epoxidation, 
HHDH-catalysed epoxide ring opening and chemical hydrogenation of the formed azido 
alcohols resulted in higher yields, however, at the expense of selectivity. The latter is 
mainly caused by the low amounts (5%) of acetonitrile used in the Shi epoxidation to 
ensure compatibility with the subsequent HHDH-catalysed step. In situ removal of 
epoxide product (ISPR) or acetonitrile prior starting the epoxide ring opening reaction 
would be beneficial to improve isolated yields as the HHDHs would not be inactivated 
and eeP as the Shi diketal catalyst could produce the (R,R)-epoxide with 93% eeP in 
presence of >20% acetonitrile. A detailed study of the major differences between 
acetonitrile and epoxide products would determine the optimal ISPR strategy to use, 
example, a specific membrane where either acetonitrile or the epoxide (21 or 22) would 
adsorb allowing an easy separation.[215] Alternatively, the HHDHs could be engineered 
to improve their solvent tolerance towards acetonitrile, as mentioned before, HheC after 
protein engineering (27 mutations) could retain its activity after incubation for 4h in 50% 
acetonitrile.[212] 
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4.6 Cascade starting from cyclic alkenes 
4.6.1 MsAct-catalysed epoxidation of cyclohexene 
Unlike for cascade 1 and 2, the strategy for this cascade was slightly different as 
epoxidation of cyclohexene leads to an achiral epoxide. Hence, cascade 3 would only 
require a stereoselective epoxide ring opening whereas the epoxidation can be 
unselective. Lipases, like CAL-B, are known to mediate the epoxidation of alkenes by 
forming a peracid via perhydrolysis of an acyl donor such as ethyl acetate.[216] The 
peracid can then perform a chemical epoxidation of the alkene substrate. Generally, this 
is performed in organic solvents as CAL-B’s perhydrolysis/hydrolysis ratio is low and the 
presence of water results mostly in the hydrolysis of the acyl donor and no 
epoxidation.[216]  
MsAct, in contrast, has a high perhydrolysis/hydrolysis ratio, thanks to its highly 
hydrophobic active site.[161] Hence, an enzyme that can mediate the epoxidation in a 
buffer solution would be desirable giving the low solvent tolerance shown by HHDHs in 
the previous sections. 
Overall, the maximum conversion reached in the epoxidation of cyclohexene performed 
by MsAct was 50% and concentrations of ethyl acetate, as acyl donor, higher than 10% 
significantly hampered the product yield. Possibly an acyl donor with higher logP such 
as octyl acetate (logP 3.2) could limit protein damage caused by ethyl acetate (logP 
0.73). MsAct optimal pH was shown to be around 8,[161] however acetic acid is being 
formed during the reaction as a result of the peracetic acid reacting and by ethyl acetate 
hydrolysis to some minor extent. A shift of the pH during the reaction could have resulted 
in non-optimal enzyme activity and low product yield. Shifting to saturated NaHCO3 
buffer at pH 8, which has approximatively 1M buffering capacity, yielded no product 
formation. In these reactions, however, high CO2 formation was observed as a result of 
the buffering activity. Cycloalkenes and derivatives (e.g. cyclohexene and cyclohexene 
oxide) are known volatile compounds[217] and CO2 bubbling out might have caused 
intense product and substrate evaporation as none could be detected in GC analysis. 
Running the reaction with tight pH control would likely improve the conversion as the 
optimal pH for the enzyme can be maintained throughout the course of the reaction.  
4.6.2 HheG engineering using the Rosetta software suite 
There are several ways to improve proteins towards a certain desired characteristic.[5,126] 
Random approaches (e.g. directed evolution) are still powerful tools in protein 
engineering to identify mutations improving enzyme stability, activity or selectivity if a 
high throughput assay is available.[5]  
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It is not rare that a mutation far from the active site could improve either the stability or 
the activity of a certain enzyme.[218–220] For dihydrofolate reductase (DHFR) from E. coli, 
for instance, several mutations located away from the active site influenced catalytic 
properties and the interaction with the ligand.[218] Unfortunately, current algorithms cannot 
predict such second shell mutations yet. However, when the reaction mechanism is 
elucidated, a rational approach to improve enzyme activity or selectivity may work better 
than directed evolution as only a restricted number of mutants is generated that need to 
be tested.[136]  
Before this work, it was known that HheG preferentially produces (1R,2S)-2-
cyanocyclohexanol and (1S,2S)-2-azidocyclohexanol in the epoxide ring opening of 
cyclohexene oxide using cyanide or azide, respectively. Both reactions resulted in a 
product enantiomeric excess of 40% and the hypothesis was that cyclohexene oxide 
could bind in two different orientations with different probabilities in the active site of 
HheG resulting in the observed eeP.[105] Hence, stabilising one of the two orientations 
should result in an increased product enantiomeric excess. Consequently, substrate-
bound HheG structures were produced using HheC’s substrate-bound crystal structures 
to correctly place the epoxide ring or the cyano- and hydroxyl group with superimposition. 
Using HheC’s substrate-bound crystal structure was necessary to superimpose the 
catalytic triad and nucleophile binding pocket residues of the two structures as a 
substrate-bound structure of HheG is not available. A ligand-bound structure is needed 
as input for the coupled moves algorithm of Rosetta to select residues around the ligand 
that would improve protein-ligand interactions. 
The coupled moves results highlighted that only a few positions, showing high variability, 
might be relevant to stabilise the ligand in the starting position. This means that mutations 
at these positions often had a better energy score than the wild type residue and 
therefore were accepted more often. For other positions, the wild type residue showed 
100% frequency meaning that no other amino acid was accepted during in silico 
mutagenesis. Most likely, these positions do not interact with the ligand or no other amino 
acid had a better score than the wild-type residue.  
As described before, most of the mutants did not improve activity or selectivity and in 
some cases, a single mutation deleted the activity completely (Figure 50, A). Overall, 
what emerged was that one position had a significant influence on both activity and 
selectivity. Most of the mutations at this position had a considerably lower activity and 
most importantly, the enantioselectivity was reversed in few cases compared to the wild 
type. Surprisingly, different enantioselectivities were found using cyanide as a 
nucleophile. Possibly, the mutation at this position modified the nucleophile binding 
pocket resulting in reverse enantioselectivity in the synthesis of the azido alcohol. At the 
 4. Discussion 
 
145 
 
same time, it may have had a negative effect on cyanide binding causing lower activity 
and selectivity. According to the elucidated epoxide ring opening mechanism, a 
preferential synthesis of (1R,2R)-2-azidocyclohexanol should correspond to a 
preferential synthesis of (1R,2S)-2-cyanocyclohexanol having the same 
stereoconfiguration. In contrast, all the active mutants showed equal or lower 
enantiomeric excess compared to the wild type in the cyanolysis of cyclohexene oxide 
(Figure 51). For HheC, various engineering experiments highlighted that residues in the 
external part of the catalytic tunnel are responsible for the enzyme’s activity and 
stereoselectivity.[106,107,206] HheG’s active site, however, may undergo major 
rearrangements upon substrate binding.[105] Thus, it is difficult to speculate on the 
reasons for the observed different product enantiomeric excesses obtained in reactions 
with different nucleophiles. 
To conclude, it was possible to correctly identify a few mutations with a strong influence 
on enantioselectivity and activity using the coupled moves application in Rosetta. It could 
be interesting, however, to dock the ligands in opposite poses to see if different mutants 
would be suggested by the coupled moves. Furthermore, site-saturation mutagenesis of 
the position that showed the highest influence on HheG’s enantioselectivity could result 
in the identification of additional mutations to further improve the selectivity. 
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5. Conclusions and future prospects 
The aim of this work was to set up a novel synthetic pathway for the synthesis of 
enantiopure 2,3-amino alcohols through the combination of several chemical and 
enzymatic steps. Amino- and azido alcohols are important compounds and they can be 
used either as building blocks or as chiral auxiliaries in the synthesis of complex 
molecules. Our strategy for the synthesis of enantiopure azido alcohols from non-
terminal trans-alkenes was to combine a stereoselective epoxidation with a 
regioselective epoxide ring opening that would allow control of the stereoconfiguration of 
the two newly formed chiral centres. Finally, palladium nanoparticles were used to 
catalyse the hydrogenation of the azido group to an amino group without changing the 
stereoconfiguration.  
The most interesting achievement in this work, thus, was the setup and development of 
the synthetic strategy postulated starting from catalyst identification leading to 
preparative scale reactions for the production of enantiopure amino alcohols. 
Here, the asymmetric epoxidation catalysed by the styrene monooxygenase or the Shi 
epoxidation diketal catalyst is the key step to control the chiral centres in the 2,3-amino 
alcohol product, whereas the regioselective epoxide ring opening catalysed by the HHDH 
is essential to determine which of the two chiral centre will be reversed following the due 
to the SN2-type mechanism. The prepared enantiopure amino alcohols are relevant 
molecules often used as chiral building blocks in the pharmaceutical industry, for 
example in the synthesis of anti-inflammatory, antiviral, or antitumour agents. 
This approach compares favourably with existing synthetic routes for the production of 
enantiopure amino alcohols, as the number of steps required in the synthesis could be 
reduced compared to known methods (for examples see Section 1.2). Using a one-pot 
concept, however, only low isolated yields (2-3%) could be achieved, whereas an 
intermediate work up before the hydrogenation step could significantly improve isolated 
yields. The combination of the styrene monooxygenase, HHDH and Pd/C resulted in the 
production of (2R,3S)-2-amino/azido-3-hydroxyhexane and (2R,3S)-2-amino/azido-3-
hydroxyheptane with an eeP>99%. In contrast, the cascade combining the Shi 
epoxidation diketal catalyst, HHDH and Pd/C afforded (2S,3R)-2-amino/azido-3-
hydroxyhexane and (2S,3R)-2-amino/azido-3-hydroxyheptane only with a low eeP (40-
50%), due to incompatibility of the HHDHs with acetonitrile. Overall, the main challenge 
identified in combining a chemical and enzyme catalysts in this cascade was the 
incompatibility of reaction conditions. In particular, the presence of acetonitrile from the 
epoxidation step significantly hampered the epoxide ring opening reaction due to 
inactivation of the HHDHs. Decreasing the acetonitrile concentration resulted in low 
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yields in the Shi epoxidation reaction as the epoxide was obtained with only low eeP. The 
most promising approach to improve the overall reaction yields would be the laboratory 
evolution of HheE and HheE5 towards higher solvent resistance. Alternatively, 
immobilization of the HHDHs might also improve epoxide ring opening efficiency in the 
presence of 20% acetonitrile concentration. Additionally, the strategy chosen in this 
cascade reactions is highly versatile as changing epoxidation catalysts, HHDH’s type 
and/or nucleophile used in the epoxide ring opening could allow the conversion of a 
broader array of alkenes for the synthesis of different enantiopure β-substituted alcohols. 
The styrene monooxygenase from Rhodococcus sp. ST-10 is the first example of a 
styrene monooxygenase with significant activity on aliphatic alkenes.[85] In this work, the 
epoxidation of trans-2-heptene could be scaled up to a volume of 200 mL reaching 69 
mM epoxide product (69% conversion) after careful optimisation of reaction conditions. 
Hence, the work performed in this project highlights the importance of correctly 
identifying all parameters with major influence on the epoxidation yield (e.g. cofactor 
regeneration and oxygen availability, substrate and product inhibition) and their careful 
optimisation for successful upscaling of this monooxygenase-catalysed reaction. 
Additional reaction engineering would further increase the final epoxide concentration. 
For example, performing a reaction in a bioreactor allows to precisely control several 
parameters (e.g. dissolved oxygen, substrate and enzyme feed) and it would likely 
increase product yields and reproducibility. 
As mentioned previously, the epoxidation step is a key reaction step to control the 
chirality of one of the stereocenters in the amino-alcohols produced. In the Shi 
epoxidation, the opposite epoxide enantiomer is obtained compared to the styrene 
monooxygenase-catalysed reaction facilitating the formation of opposite amino alcohol 
enantiomers. Identifying a complementary catalyst to selectively access opposite 
product enantiomers confirmed the potential and versatility of this new synthetic route. A 
possible alternative solution could be to engineer or discover a styrene monooxygenase 
to synthesis the epoxide in (R,R)-conformation as so far, all known styrene 
monooxygenases show selectivity towards the opposite epoxide enantiomer.  
Another important aspect of this thesis is the detailed investigation of the azidolysis of 
five vicinally di-substituted epoxides catalysed by HHDHs. For the first time, this study 
highlighted the ability of HHDHs to accept also non-terminal epoxides (trans-2,3-
epoxyhexane, trans-2,3-epoxyheptane, trans-2,3-epoxyhexan-1-ol, trans-3,4-
epoxyheptane and trans-β-methyl styrene oxide) as substrates. Before this work, it was 
state of the art that HHDHs convert only terminal epoxides with almost exclusive 
nucleophilic attack on the terminal carbon of the epoxide ring. HheG from Ilumatobacter 
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coccineus displayed the broadest substrate scope as it was the only HHDH able to 
convert all five substrates with good to high activity. Interestingly, many other tested 
HHDHs converted at least the methyl-substituted epoxides trans-2,3-epoxyhexane and 
trans-2,3-epoxyheptane with different regio- and stereoselectivity. 
Furthermore, docking studies based on an epoxide-bound structure of HheC as well as 
on substrate-free structures of HheD2 and HheG revealed first structural insights into the 
enzymes’ observed substrate specificity and regioselectivity. The shape and size of the 
active site may play an important role in the enzymes’ selectivity and substrate 
specificity. HHDHs with a broad active site such as HheG displayed low regioselectivity 
and broad substrate scope, whereas enzymes with a narrow tunnel shape-like active site 
were highly regioselective but fewer substrates were accepted. This further broadened 
the biocatalytic applicability of HHDHs, in particular HheG, as also sterically more 
demanding epoxides or vicinally disubstituted halo-alcohols can be used as substrate. 
Perhaps, this would lead to an even wider exploration of the HHDH’s substrate scope by 
testing epoxides and halo-alcohols with more or less demanding substituents.   
Lastly, using an in silico assisted rational design allowed the successful identification of 
HheG variants with increased or inverted enantioselectivity in the epoxide ring opening 
of cyclohexene oxide using azide as nucleophile. This method proved to be a viable 
option to identify important residues, especially when available protein engineering 
information from other HHDHs could only be partially transferred. Furthermore, HheG’s 
stereoselectivity was found to be dependent on the used nucleophile as HheG variants 
with improved selectivity in the azidolysis reaction displayed no selectivity in the 
cyanolysis of cyclohexene oxide. A more in-depth study on other HHDHs might give 
additional insights on HHDHs regio- and enantioselectivity. Moreover, starting from a 
substrate-bound crystal structure of HheG for rational protein design could yield more 
accurate predictions and hence, might lead to the identification of even more selective 
variants.  
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(WC, 60 g/L wet cell weight) or as cell-free extract (CFE, 9.6 g/L total protein content). 
FDH (0.5 U/mL) was used as cofactor regenerating enzyme coupled with CFE, while 
glucose was added for cofactor regeneration in the WC system. Oxygen was either 
supplied via the air in the headspace (“No O2”) or using pure oxygen (“O2”) provided in a 
balloon. .......................................................................................................................74 
Figure 17. Conversions obtained after 1h in reactions using different substrate, BNAH 
and FAD concentrations and cell-free extract harbouring StyA (9.5 g/L, total protein 
concentration). Trans-2-heptene was first used to find optimal conditions (5 mM 
substrate, 10 mM BNAH, 50 µM FAD) and then they were used in the conversion of 
trans-2-hexene where similar conversions could be achieved. ....................................75 
Figure 18. Activity measured for StyAB used as whole cell biocatalyst using glucose for 
cofactor regeneration. The highest activity in the conversion of 2.5 mM trans-2-heptene 
is reached with 15 g/L wet cell weight. .........................................................................76 
Figure 19. Residual activity of StyA after incubation at 30 °C for different time points. 
After 6h most of the activity is lost. ..............................................................................77 
Figure 20. Classic purification chromatogram of His-tagged HHDH, HheE2 in this case. 
All HHDHs started to elute around 300 mM of imidazole concentration. The gel only 
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shows the fractions containing the target protein. All fractions appear to be fairly pure.
 ................................................................................................................................... 78 
Figure 21. Conversions and ratios of regioisomeric products a and b obtained in 
biocatalytic reactions of substrates 21-25 with HHDHs using azide as the nucleophile. 
The ratios of regioisomeric products a and b are represented in different colours within 
the bar representing the conversion. .......................................................................... 81 
Figure 22. Docking results for HheC (PDB: 1ZMT) with substrates 21 (A), 22 (B), 23 (C), 
24 (D) and 25 (E). Substrates with R,R-configuration are shown in light blue, whereas 
substrates with S,S-configuration are shown in orange. Hydrogen bonds between 
epoxide oxygen and catalytic residues S132 and Y145 are represented as green dotted 
lines. The water molecule present in the nucleophile binding pocket is shown as a green 
sphere to indicate the position of the nucleophile. Taken from Calderini et al.[183] ....... 85 
Figure 23. Docking results for HheD2 (unpublished PDB) with substrates 21 (A), 22 (B), 
23 (C), 24 (D) and 25 (E). Substrates with R,R-configuration are shown in light blue, 
whereas substrates with S,S-configuration are shown in orange. Hydrogen bonds 
between epoxide oxygen and catalytic residues S117 and Y130 are represented as 
green dotted lines. The water molecule present in the nucleophile binding pocket is 
shown as a green sphere to indicate the position of the nucleophile. .......................... 86 
Figure 24. Docking results for HheG (PDB: 5O30) with substrates 21 (A), 22 (B), 23 (C), 
24 (D) and 25 (E). Substrates with R,R-configuration are shown in light blue, whereas 
substrates with S,S-configuration are shown in orange. Hydrogen bonds between 
epoxide oxygen and catalytic residues S152 and Y165 are represented as green dotted 
lines. The water molecule present in the nucleophile binding pocket is shown as a green 
sphere to indicate the position of the nucleophile. Adapted from Calderini et al.[183] .... 87 
Figure 25. Conversion of epoxide 21 (graph A) and epoxide 22 (graph B) using the 
regioselective HHDHs from the E-type as whole cells catalysts (60 g/L, wet cell weight). 
Each reaction was carried out in duplicate using 10 mM of each substrate, 50 mM of 
NaN3........................................................................................................................... 88 
Figure 26. Conversions of the racemic azido hydroxyheptane (32) by Pd on different 
supports. 1 Palladium on carbon, 10 wt. % loading, matrix activated carbon support. 2 
Palladium on calcium carbonate, 5 wt. % loading, poisoned with lead. 3 Palladium 
hydroxide on carbon, 20 wt. % loading (dry basis), matrix carbon, wet support. 4 
Palladium on barium sulphate, reduced, 5 wt. % loading. 5 Palladium on carbon, 10 wt. 
% loading (dry basis), matrix activated carbon, wet support, Degussa type E101 NE/W. 6 
Palladium on alumina, 10 wt. % loading, powder, reduced, dry. ................................. 90 
Figure 27. TEM images of Pd@AFHS nanoparticles stained with uranyl acetate at 
different scale (100 nm and 50 nm). The nanoparticles show a very narrow size 
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distribution of 5 ± 1 nm. The picture on the right clearly shows the nanoparticles with a 
white coating that represents the apoferritin from horse spleen (AFHS) and a black core 
composed of Pd. .........................................................................................................91 
Figure 28. Conversion of 5 mM racemic azido-hydroxyheptane (32) to amino-
hydroxyheptane (42) using Pd nanoparticles entrapped in apoferritin from horse spleen 
(AFHS). On the right, the photo shows the solution of Pd and AFHS before and after the 
reduction of Pd using H2 that causes the aggregation of Pd in nanoparticles that causes 
the solution to turn dark grey. ......................................................................................91 
Figure 29. Comparison of chiral chromatograms of the azidoalcohols chemically 
produced starting from racemic epoxides (blue) or synthesised in starting from (S,S)-21 
(A) or (S,S)-22 (B) synthesised by StyAB (orange). The epoxide-ring opening was 
catalysed by HheG for the production of (2R,3S)-2-azido-3-hydroxyhexane (31a) and of 
(2S,3R)-3-azido-2-hydroxyhexane (31b) (orange line in A) and by HheD5 for the 
production of (2R,3S)-2-azido-3-hydroxyheptane (32a) and of (2S,3R)-3-azido-2-
hydroxyheptane (32b) (orange line in B ). ...................................................................93 
Figure 30. Chiral chromatograms of 2-azido-3-hydroxyhexane (A) and 2-azido-3-
hydroxyheptane (B). The grey line represents 31a (A) and 32a (B) produced in cascades 
composed by the styrene monooxygenase and HheE (A) or HheE5 (B). These reactions 
preferentially produce (2R,3S)-31a (A) or (2R,3S)-32a (B). The orange line represents 
31a (A) and 32a (B) produced in cascades composed by the Shi epoxidation diketal 
catalyst and HheE (A) or HheE5 (B). These reactions preferentially produce (2S,3R)-31a 
(A) or (2S,3R)-32a (B). The blue line represents racemic azidoalcohols 31a (A) and 32a 
(B) for reference. .........................................................................................................94 
Figure 31. Main effects plot for the DOE for optimization of the StyAB-catalysed 
epoxidation of trans-2-heptene (5 mM). Two values for each of the four variables were 
taken into account. The concentration of the epoxide after 2 h was selected as response 
factor. All reactions were performed in duplicate. ........................................................97 
Figure 32. Different experimental conditions used for the epoxidation of trans-2-heptene 
(2) catalysed by StyAB. Reactions using StyAB as CFE and LkADH for cofactor 
regeneration added as CFE separately with or without substrate feed are given in 
(Orange). Reactions using StyAB coexpressed with LsADH as CFE with substrate feed 
and with or without enzyme feed are given in red. The same reaction (with enzyme feed) 
using 25% heptane as organic phase is shown in blue. ...............................................98 
Figure 33. Oxygen consumption in styrene monooxygenase-catalysed reactions using 
whole cells and cofactor regeneration by cell metabolism (orange) or cell-free extract 
harbouring StyAB and coexpressed LsADH for cofactor regeneration (blue). The curves 
show the oxygen concentration in solution after addition of the respective co-substrates 
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for cofactor regeneration (glucose and isopropanol, respectively). In A no compressed 
air was added, whereas in B compressed air was constantly introduced at a flow of 3 L/h 
and the oxygen concentration was measured for longer times. .................................. 99 
Figure 34. Apparent KM and Vmax measured for StyAB coexpressed with LsADH applied 
as cell-free extract using different O2 concentrations. Kinetic data were collected in 
duplicate. .................................................................................................................. 100 
Figure 35. Comparison of different organic solvents used as second phase for the 
production of trans-2,3-epoxyheptane (22). All reactions were performed using the best 
setup found (StyAB coexpressed with LsADH, enzyme and substrate feed and 
compressed air input and 25% organic phase). ........................................................ 101 
Figure 36. The graph shows the concentrations of the different compounds found in the 
aqueous phase when 50% (v/v) heptane was used. When the compounds were present 
at a concentration of 5, 50 or 100 mM in aqueous phase before extraction. ............. 102 
Figure 37. StyAB coexpressed with LsADH, enzyme and substrate feed and compressed 
air input and 25% organic phase were used for the production of trans-2,3-epoxyhexane 
(21) (Orange). The blue line shows the same reaction setup for the epoxidation of trans-
2-heptene (2) on 200 mL scale (blue line). ............................................................... 103 
Figure 38. Whole-cell bioconversions of epoxide 21 (graph A) and epoxide 22 (graph B) 
at different substrate concentrations using HheE and HheE5 (60 g/L, wet cell weight), 
respectively. Each reaction was carried out in duplicate using the stated substrate 
concentrations and 2 eq. of NaN3. Dashed lines represent negative control reactions 
using E. coli cells carrying an empty vector. ............................................................. 104 
Figure 39. HheE (A) and HheE5 (B) conversion of 10 mM of their respective substrates 
(12 for HheE and 22 for HheE5). The blue dashed lines represent control epoxide ring 
opening reactions without a second organic phase. The orange lines represent 
conversions in presence of 25% (v/v) heptane. All experiments were done in duplicate.
 ................................................................................................................................. 105 
Figure 40. Influence of Pd/C (1 mg/mL) on the different catalysts for step 1 and step 2. 
All reactions were carried out for 1h using the model substrate were trans-2-heptene (2) 
for StyA/StyAB and trans-2,3-epoxyheptane (22) for HheE5. StyA was used as cell-free 
extract (4.6 g/L total protein content), with BNAH for cofactor regeneration. StyAB was 
used as whole cells (30 g/L wet cell weight), with glucose as cofactor regeneration 
system. HheE5 was used as whole cells (60 g/L wet cell weight). ............................ 106 
Figure 41. Hydrogenation of 5 mM racemic 2-azido-3-hydroxyheptane (32a) using 1 
mg/mL Pd/C in aqueous buffer. H2 was supplied via a balloon connected with a needle. 
The hydrogenation reaction performed only with Pd/C and H2 is given as dashed line 
(control). Components from other cascade steps were added individually: CFE (Cell-free 
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extract 4.6 g/L total protein content, orange line). WC (whole cells 60 g/L wet cell weight, 
green line). BNAH (10 mM, yellow line) and FAD (200 µM, dark blue line) All reactions 
were performed in duplicate. ..................................................................................... 107 
Figure 42. Concentrations (mM) of 22 and 32 produced during the cascade composed 
of StyAB, HheE5 and Pd/C in 80 mL scale (60 mL + 20 mL heptane as second phase) 
in the conversion of 20 mM of trans-2-heptene. Each catalyst was added sequentially; 
grey bars show for how long each reaction was performed. ...................................... 108 
Figure 43. Conversion and product enantiomeric excess (eeP) obtained at different 
acetonitrile (ACN) concentrations. The epoxidations were carried out using 0.2 
equivalents of the Shi epoxidation catalyst and four equivalents of Oxone in the 
conversion of 50 mM of either 1 or 2. ........................................................................ 112 
Figure 44. Conversion (light blue), product enantiomeric excess (eeP, dark blue) and final 
epoxide concentration (grey) obtained for the epoxidation of 250 mM of alkene 
substrates (1) and (2). In all cases, 0.2 eq. of Shi diketal catalyst, acetone to a 
concentration of 20 % (v/v) and 4 eq. of Oxone added portion wise were used. Both 
reactions were carried out at -2 °C. ........................................................................... 112 
Figure 45. Epoxide ring opening catalysed by HheE (A, 10 mM of 12 as substrate) and 
HheE5 (B, 10 mM of 22 as substrate) using whole cells (60 g/L wet cell weight) or cell-
free extract (purple line in graph B, 9.2 g/L total protein content) and NaN3 (40 mM) in 
presence of different components of the Shi epoxidation reaction. All reactions were 
performed in duplicate. Control reactions without acetonitrile or Oxone© are given as 
dashed lines. ............................................................................................................. 114 
Figure 46. Conversion values of the sequential cascade composed of Shi epoxidation, 
HheE5-catalysed epoxide ring opening and hydrogenation using Pd/C in 50 mL scale 
(5% acetone concentration) starting from 50 mM trans-2-heptene. The epoxidation and 
epoxide ring opening reactions were monitored via GC, the hydrogenation was 
monitored via 32 consumption. .................................................................................. 115 
Figure 47. The upper picture shows the purification chromatogram of the His-tagged 
MsAct. UV signal representing the protein elution is given in blue, whereas the gradient 
progression is represented by the green line. In the SDS-PAGE gels, only the fractions 
containing the target protein are shown. .................................................................... 118 
Figure 48. Epoxidation of cyclohexene (5 mM) promoted by MsAct in the presence of 
ethyl acetate at different concentrations (% v/v) and using different amounts of H2O2 (1, 
2, 3, 4, 10, 4x2.5 equivalents). .................................................................................. 120 
Figure 49. Visualization using sequence logos of the two in silico mutagenesis with either 
cyclohexene oxide (A) or (1R, 2S)-2 cyanocyclohexanol (B) in the active site of HheG 
crystal structure (5O30). ............................................................................................ 121 
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Figure 50. (A) Conversions of cyclohexene oxide with NaN3 as nucleophile catalysed by 
the different HheG mutants and (B) ratio of the different enantiomers produced. The 
reactions were carried out using whole cells, 20 mM cyclohexene oxide and 40 mM 
NaN3. EV = negative control using E. coli BL21 (DE3) cells containing empty vector. 
Enantiomer ratios are shown for the 22h reaction sample. ....................................... 122 
Figure 51. (A) Conversions of cyclohexene oxide with NaCN as nucleophile catalysed 
by the different HheG mutants and (B) ratio of the different enantiomers produced. The 
reactions were carried out using whole cells, either 20 mM 2-chlorocyclohexanol 
(cascade) or 20 mM cyclohexene oxide (epoxide ring opening) and 40 mM NaN3. EV = 
negative control using E. coli BL21 (DE3) cells containing empty vector. Enantiomer 
ratios are shown for the 46 h reaction sample. ......................................................... 123 
Figure 52. Active sites highlighted in deep teal for HHDHs with available crystal structure 
[HheA2 (PDB-ID: 1ZMO[205]), HheB2 (PDB-ID: 4ZD6[206]), HheC (PDB-ID: 1PWZ[184]), 
HheG (PDB-ID: 5O30[105]) and HheD2 (unpublished data)]. The water molecule present 
in the nucleophile binding pocket is shown as a green sphere to indicate the position of 
the nucleophile. ........................................................................................................ 134 
  
List of abbreviations 
AFHS  Apoferritin from horse spleen 
Amp  ampicillin 
APS  Ammonium persulfate 
AIXC  Anion exchange chromatography 
BNAH   1-benzyl-1,4-dihydronicotinamide 
bp  Base pairs 
BVMO  Baeyer-Villiger monooxygenase 
CFE  Cell free extract 
Cm  chloramphenicol 
CV  Column volume 
CYP  Cytochrome P450 monooxygenase 
ddH2O  Double distilled water 
dO2  dissolved oxygen 
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DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxynucleotide triphosphate 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
e.g.  exempli gratia (for example) 
et al.  et alii (and others) 
EtOAc  Ethyl acetate 
EtOH   Ethanol 
EV  Empty vector, negative control 
F  Flow-through  
FID  Flame ionization detector 
FPLC  Fast protein liquid chromatography 
GC  Gas chromatography 
GC-MS Gas chromatography- mass spectroscopy 
HHDH  Halohydrin dehalogenase 
HIC  Hydrophobic interaction chromatography 
HR-MS High resolution - mass spectroscopy 
IMAC  Immobilized metal affinity chromatography 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
ISTD  Internal standard  
kan  Kanamycin 
kb  Kilobase 
kcat  Turnover number 
kDa  Kilodalton 
LB  Luria broth 
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M  Marker 
MsAct  Acyl transferase from Mycobacterium smegmatis 
Nu-  Nucleophile 
OD600   Optical density at λ = 600 nm 
PCR  Polymerase chain reaction 
Pd/C  Palladium on carbon 
PdR   Putidaredoxin reductase from Pseudomonas putida 
Pdx  Putidaredoxin from Pseudomonas putida 
PMS   Phenylmethylsulfonyl fluoride 
rpm  Revolutions per minute 
SDS  Sodium dodecyl sulphate  
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SOC  Super optimal broth with Catabolite repression 
Spec  Spectinomycin 
SSM  Site-saturation mutagenesis 
StyAB   Styrene monooxygenase 
TAE  Tris base, acetic acid and EDTA 
TB  Terrific broth 
TBME  Methyl tert-butyl ether 
TE  Tris base, EDTA 
TEM  Transmission electron microscopy 
TEMED Tetramethylethylenediamine  
TES  Triethylsilane 
TFAA  Trifluoroacetic anhydride 
TLC  Thin Layer Chromatography 
Tm   Melting temperature 
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Tris   Tris(hydroxymethyl)aminomethane 
UPO  Unspecific peroxygenase 
UV  Ultraviolet 
W  Wash fraction 
WT   Wild type 
X-   Halide 
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Abbreviations of amino acids: 
Alanine  Ala  A 
Arginine  Arg  R 
Asparagine  Asn  N 
Aspartic acid  Asp  D 
Cysteine  Cys  C 
Glutamic acid  Glu  E 
Glutamine  Gln  Q 
Glycine  Gly  G 
Histidine  His  H 
Isoleucine  Ile  I 
Leucine  Leu  L 
Lysine   Lys  K 
Methionine  Met  M 
Phenylalanine  Phe  F 
Proline   Pro  P 
Serine   Ser  S 
Threonine  Thr  T 
Tryptophan  Trp  W 
Tyrosine  Tyr  Y 
Valine   Val  V 
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Supplementary material 
Heterologous expression  
 
Supporting figure 1. Exemplary SDS-PAGE corresponding to fermentations for the production of HheE5 or 
HheE. P corresponds to the insoluble fraction and CFE corresponds to the soluble fraction. 
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Epoxide ring opening supporting tables 
Supporting table 1. Regiopreferences of active HHDHs in the azidolysis of (R,R)- and (S,S)-enantiomers of 
epoxide substrates 1, 2 and 5. Regiopreference is given as the ratio of nucleophilic attack at the -carbon 
(sterically less hindered) and the βcarbon (sterically more hindered). 
Regiopreference (α:β attack) 
HHDH  (R,R)-1  (S,S)-1  (R,R)-2  (S,S)-2  (R,R)-5  (S,S)-5  
HheA3 12:1  12:1  21:1  13:1  n.d.[a]  n.d.[a]  
HheB3  11:1  1:1  11:1  1:1  n.d.[a]  n.d.[a]  
HheB5  67:1  3:1  162:1  2:1  n.d.[a]  n.d.[a]  
HheB6  105:1  4:1  151:1  4:1  n.d.[a]  n.d.[a]  
HheB7  153:1  4:1  161:1  3:1  n.d.[a]  n.d.[a]  
HheC  60:1  18:1  332:1  26:1  n.d.[a]  n.d.[a]  
HheD  8:1  1:3  16:1  1:4  n.d.[a]  n.d.[a]  
HheD2  6:1  1:3  7:1  1:4  n.d.[a]  n.d.[a]  
HheD3  15:1  1:5  14:1  1:6  1:7  1:80  
HheD5  16:1  1:2  1:1  1:1  n.d.[a]  n.d.[a]  
HheE  97:1  40:1  217:1  36:1  n.d.[a]  n.d.[a]  
HheE2  9:1  5:1  55:1  20:1  n.d.[a]  n.d.[a]  
HheE3  8:1  8:1  62:1  27:1  n.d.[a]  n.d.[a]  
HheE4  n.d.[a]  n.d.[a]  6:1  11:1  n.d.[a]  n.d.[a]  
HheE5  83:1  30:1  327:1  60:1  n.d.[a]  n.d.[a]  
HheF  4:1  7:1  5:1  7:1  1:4  1:113  
HheG  1:1  1:1  21:1  1:4  1:118  1:1743  
HheG2  1:1  1:1  1:1  1:1  1:111  1:5702  
[a] not determined  
 
Supporting table 2. Conversions (C), enantiomeric excesses (eeP) and calculated apparent enantiomeric 
ratios (Eapp) of regiomeric azidoalcohols 10a and b formed in the HHDH-catalysed azidolysis of epoxide 5. 
The absolute configuration of the preferentially formed enantiomer of each regioisomer is given in 
parentheses. 
 
10a 10b 
HHDH  C [%]  eeP [%]  Eapp  C [%]  eeP [%]  Eapp  
HheD3  0.08  80  9.0 (R,S)  1.1  7.5  1.2 (R,S)  
HheF  0.17  95  39 (S,R)  1.2  17  1.4 (S,R)  
HheG  0.02  83  11 (R,S)  44  11  1.3 (R,S)  
HheG2  0.01  93  28 (R,S)  24  26  1.8 (R,S)  
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1H, DEPT, COSY and HSQC NMR spectra 
Epoxides 
 
Supporting figure 2. 1H NMR (300 MHz, CDCl3) of trans-2,3-epoxyhexane (21) (Spectrum analysed with 
MestReNova 6). 
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Supporting figure 3. 1H NMR (300 MHz, CDCl3) of trans-2,3-epoxyheptane (22) (Spectrum analysed with 
MestReNova 6). 
 
Supporting figure 4. 1H NMR (300 MHz, CDCl3) of trans-4,5-epoxyhexanol (23) (Spectrum analysed with 
MestReNova 6). 
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Supporting figure 5. 1H NMR (300 MHz, CDCl3) of trans-3,4-epoxyheptane (24) (Spectrum analysed with 
MestReNova 6). 
 
Supporting figure 61H NMR (300 MHz, CDCl3) of trans-1-phenylpropylene oxide (25) (Spectrum analysed 
with MestReNova 6). 
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Azido alcohols 
 
Supporting figure 7. 1H NMR (600 MHz, CDCl3) of the regioisomeric mixture of 2-azido-3-hydroxyhexane 
(31a) and 3-azido-2-hydroxyhexane (31b) (Spectrum analysed with MestReNova 6). 
 
Supporting figure 8. DEPT (151 MHz, CDCl3) of the regioisomeric mixture of 2-azido-3-hydroxyhexane (31a) 
and 3-azido-2-hydroxyhexane (31b) (Spectrum analysed with MestReNova 6). 
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Supporting figure 9. COSY spectrum with double quantum filter, applied for the identification of regioisomers 
of 2-azido-3-hydroxyhexane (31a) and 3-azido-2-hydroxyhexane (31b) (Spectrum analysed with 
MestReNova 6). 
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Supporting figure 10. HSQC spectrum, applied for the identification of regioisomers of 2-azido-3-
hydroxyhexane (31a) and 3-azido-2-hydroxyhexane (31b) (Spectrum analysed with MestReNova 6). 
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Supporting figure 11. 1H NMR (600 MHz, CDCl3) of the regioisomeric mixture of 2-azido-3-hydroxyheptane 
(32a) and 3-azido-2-hydroxyheptane (32b) (Spectrum analysed with MestReNova 6). 
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Supporting figure 12. 1H NMR (600 MHz, CDCl3) of the regioisomeric mixture of azidohexan-diol 33 
(Spectrum analysed with TopSpin 4.0). 
 
Supporting figure 13. DEPT (151 MHz, CDCl3) of regioisomeric mixture of azidohexan-diol 33 (Spectrum 
analysed with TopSpin 4.0). 
 Appendix 
 
179 
 
 
Supporting figure 14. COSY spectrum with double quantum filter, applied for the identification of 
regioisomers of 33 (Spectrum analysed with TopSpin 4.0). 
180 
 
 
Supporting figure 15. HSQC spectrum, applied for the identification of regioisomers of 33 (Spectrum 
analysed with TopSpin 4.0). 
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Supporting figure 16. 1H NMR (600 MHz, CDCl3) of the regioisomeric mixture of azidoheptanol 34 (Spectrum 
analysed with MestReNova 6). 
 
Supporting figure 17. DEPT (151 MHz, CDCl3) of the regioisomeric mixture of azidoheptanol 34 (Spectrum 
analysed with MestReNova 6). 
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Supporting figure 18. COSY spectrum with double quantum filter, applied for the identification of 
regioisomers of 34 (Spectrum analysed with MestReNova 6). 
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Supporting figure 19. HSQC spectrum, applied for the identification of regioisomers of 34 (Spectrum 
analysed with MestReNova 6). 
Amino alcohols 
 
Supporting figure 20. 1H NMR (600 MHz, CDCl3) of 2-amino-3-hydroxyhexane (41a) (Spectrum analysed 
with TopSpin 4.0). 
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Supporting figure 21. DEPT (151 MHz, CDCl3) of 2-amino-3-hydroxyhexane (41a) (Spectrum analysed with 
TopSpin 4.0). 
 
Supporting figure 22. 1H NMR (600 MHz, CDCl3) of 2-amino-3-hydroxyheptane (42a) (Spectrum analysed 
with TopSpin 4.0). 
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Supporting figure 23. DEPT (151 MHz, CDCl3) of 2-amino-3-hydroxyheptane (42a) (Spectra analysed with 
TopSpin 4.0). 
Thin Layer Chromatography 
 
Supporting figure 24. Exemplary TLCs where the specific stain for amino groups (ninhydrin, A) and the 
general potassium permanganate stain (B) were used to follow the hydrogenation reaction. In B 2-azido-3-
hydroxyheptane is not visible anymore in TLC. 
2-amino-3-hydroxyheptane 
2-azido-3-hydroxyheptane 
Hydrazine 
A B 
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Supporting figure 25. Exemplary column chromatography for the purification of 2-amino-3-hydroxyheptane. 
Most impurities eluted in the first fractions (F 1-22). 
 
 
3-amino-2-hydroxyheptane 
2-amino-3-hydroxyheptane 
F 2-10          F 12-20          F 22-30        F 32-40 
F 42-50          F 26, 29, 31,  
                         41 and 45 
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Chiral GC chromatograms 
 
Supporting figure 26. Chromatograms of trans-2,3-epoxyhexane (21) synthesized by chemical epoxidation 
(blue) or by the styrene monooxygenase from Rhodococcus sp. ST-10 (orange). 
 
Supporting figure 27. Chromatograms of 2-azido-hexan-3-ol (31a) and 3-azido-hexan-2-ol (31b) 
enantiomers synthesized by a regioselective HHDH (orange), by a non-regioselective HHDH (grey) and by 
a non-regioselective HHDH converting (S,S)-21 (blue). 
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Supporting figure 28. Chromatograms of trans-2,3-epoxyheptane (22) synthesized by chemical epoxidation 
(blue) or by the styrene monooxygenase from Rhodococcus sp. ST-10 (orange). 
 
Supporting figure 29. Chromatograms of 2-azido-heptan-3-ol (32a) and 3-azido-heptan-2-ol (32b) 
enantiomers synthesized by a regioselective HHDH (orange), by a non-regioselective HHDH (grey) and by 
a non-regioselective HHDH converting (S,S)-22 (blue). 
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Supporting figure 30. Chromatograms of the commercially available pure enantiomers of trans-β-methyl 
styrene oxide (25) [(S,S)-25 in blue and (R,R)-25 in orange] 
 
Supporting figure 31. Chromatograms of 2-azido-1-phenylpropan-1-ol (35a) and 1-azido-1-phenylpropan-2-
ol (35b) enantiomers synthesised using the commercially available (S,S)-25 (blue), (R,R)-25 (orange) and 
the racemic mixture of 25 (grey) as substrates. 
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Enzyme Kinetics 
Supporting figure 32. HheE Michaelis-Menten kinetics for trans-2,3-epoxyhexane (21) and 50 mM of NaN3 
 
Supporting figure 33. HheE Hill kinetics for trans-2,3-epoxyheptane (22) and 50 mM of NaN3. 
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Supporting figure 34. HheE Michaelis-Menten kinetics for NaN3 and 50 mM of trans-2,3-epoxyhexane (21). 
 
Supporting figure 35. HheE5 Hill kinetics for trans-2,3-epoxyheptane (22) and 50 mM of NaN3. 
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Supporting figure 36. HheE5 Hill kinetics for NaN3 and 50 mM of trans-2,3-epoxyheptane (22). 
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